<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration - Solomon, SD - 2019 | Cochrane Library</title> <meta content="Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration - Solomon, SD - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005139.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration - Solomon, SD - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005139.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005139.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration" name="citation_title"/> <meta content="Sharon D Solomon" name="citation_author"/> <meta content="Johns Hopkins University School of Medicine" name="citation_author_institution"/> <meta content="ssolomon1@jhmi.edu" name="citation_author_email"/> <meta content="Kristina Lindsley" name="citation_author"/> <meta content="Johns Hopkins Bloomberg School of Public Health" name="citation_author_institution"/> <meta content="Satyanarayana S Vedula" name="citation_author"/> <meta content="Johns Hopkins University" name="citation_author_institution"/> <meta content="Magdalena G Krzystolik" name="citation_author"/> <meta content="Mass Eye and Ear Infirmary" name="citation_author_institution"/> <meta content="Barbara S Hawkins" name="citation_author"/> <meta content="Johns Hopkins University School of Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD005139.pub4" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/03/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005139.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005139.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005139.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Angiogenesis Inhibitors [*therapeutic use]; Antibodies, Monoclonal [*therapeutic use]; Antibodies, Monoclonal, Humanized [*therapeutic use]; Aptamers, Nucleotide [*therapeutic use]; Bevacizumab [*therapeutic use]; Choroidal Neovascularization; Intravitreal Injections; Macular Degeneration [*drug therapy]; Randomized Controlled Trials as Topic; Ranibizumab [*therapeutic use]; Vascular Endothelial Growth Factor A [*antagonists &amp; inhibitors]; Visual Acuity [drug effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005139.pub4&amp;doi=10.1002/14651858.CD005139.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="Ko3zGe0H";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005139\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005139\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fr","fa","de"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005139.pub4",title:"Anti\\u2010vascular endothelial growth factor for neovascular age\\u2010related macular degeneration",firstPublishedDate:"Mar 4, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005139.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005139.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005139.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005139.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005139.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005139.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005139.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005139.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005139.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005139.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7723 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005139.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-sec-0038"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-sec-0039"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-sec-0124"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/appendices#CD005139-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/table_n/CD005139StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/table_n/CD005139StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information#CD005139-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sharon D Solomon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information#CD005139-cr-0003">Kristina Lindsley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information#CD005139-cr-0004">Satyanarayana S Vedula</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information#CD005139-cr-0005">Magdalena G Krzystolik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information#CD005139-cr-0006">Barbara S Hawkins</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information/en#CD005139-sec-0148">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 March 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005139.pub4">https://doi.org/10.1002/14651858.CD005139.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005139-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005139-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005139-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005139-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005139-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005139-abs-0001" lang="en"> <section id="CD005139-sec-0001"> <h3 class="title" id="CD005139-sec-0001">Background</h3> <p>Age‐related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to AMD accounts for most cases of AMD‐related severe vision loss. Intravitreous injection of anti‐vascular endothelial growth factor (anti‐VEGF) agents aims to block the growth of abnormal blood vessels in the eye to prevent vision loss and, in some instances, to improve vision. </p> </section> <section id="CD005139-sec-0002"> <h3 class="title" id="CD005139-sec-0002">Objectives</h3> <p>• To investigate ocular and systemic effects of, and quality of life associated with, intravitreous injection of three anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) versus no anti‐VEGF treatment for patients with neovascular AMD </p> <p>• To compare the relative effects of one of these anti‐VEGF agents versus another when administered in comparable dosages and regimens </p> </section> <section id="CD005139-sec-0003"> <h3 class="title" id="CD005139-sec-0003">Search methods</h3> <p>To identify eligible studies for this review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Eyes and Vision Trials Register (searched January 31, 2018); MEDLINE Ovid (1946 to January 31, 2018); Embase Ovid (1947 to January 31, 2018); the Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to January 31, 2018); the International Standard Randomized Controlled Trials Number (ISRCTN) Registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a> ‐ searched January 31, 2018); ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a> ‐ searched November 28, 2018); and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en" target="_blank">www.who.int/ictrp/search/en</a> ‐ searched January 31, 2018). We did not impose any date or language restrictions in electronic searches for trials. </p> </section> <section id="CD005139-sec-0004"> <h3 class="title" id="CD005139-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) that evaluated pegaptanib, ranibizumab, or bevacizumab versus each other or versus a control treatment (e.g. sham treatment, photodynamic therapy), in which participants were followed for at least one year. </p> </section> <section id="CD005139-sec-0005"> <h3 class="title" id="CD005139-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened records, extracted data, and assessed risks of bias. We contacted trial authors for additional data. We compared outcomes using risk ratios (RRs) or mean differences (MDs). We used the standard methodological procedures expected by Cochrane. </p> </section> <section id="CD005139-sec-0006"> <h3 class="title" id="CD005139-sec-0006">Main results</h3> <p>We included 16 RCTs that had enrolled a total of 6347 participants with neovascular AMD (the number of participants per trial ranged from 23 to 1208) and identified one potentially relevant ongoing trial. Six trials compared anti‐VEGF treatment (pegaptanib, ranibizumab, or bevacizumab) versus control, and 10 trials compared bevacizumab versus ranibizumab. Pharmaceutical companies conducted or sponsored four trials but funded none of the studies that evaluated bevacizumab. Researchers conducted these trials at various centers across five continents (North and South America, Europe, Asia, and Australia). The overall certainty of the evidence was moderate to high, and most trials had an overall low risk of bias. All but one trial had been registered prospectively. </p> <p>When compared with those who received control treatment, more participants who received intravitreous injection of any of the three anti‐VEGF agents had gained 15 letters or more of visual acuity (risk ratio [RR] 4.19, 95% confidence interval [CI] 2.32 to 7.55; moderate‐certainty evidence), had lost fewer than 15 letters of visual acuity (RR 1.40, 95% CI 1.27 to 1.55; high‐certainty evidence), and showed mean improvement in visual acuity (mean difference 6.7 letters, 95% CI 4.4 to 9.0 in one pegaptanib trial; mean difference 17.8 letters, 95% CI 16.0 to 19.7 in three ranibizumab trials; moderate‐certainty evidence) after one year of follow‐up. Participants treated with anti‐VEGF agents showed improvement in morphologic outcomes (e.g. size of CNV, central retinal thickness) compared with participants not treated with anti‐VEGF agents (moderate‐certainty evidence). No trial directly compared pegaptanib versus another anti‐VEGF agent and followed participants for one year; however, when compared with control treatments, ranibizumab and bevacizumab each yielded larger improvements in visual acuity outcomes than pegaptanib. </p> <p>Visual acuity outcomes after bevacizumab and ranibizumab were similar when the same RCTs compared the same regimens with respect to gain of 15 or more letters of visual acuity (RR 0.95, 95% CI 0.81 to 1.12; high‐certainty evidence) and loss of fewer than 15 letters of visual acuity (RR 1.00, 95% CI 0.98 to 1.02; high‐certainty evidence); results showed similar mean improvement in visual acuity (mean difference [MD] ‐0.5 letters, 95% CI ‐1.5 to 0.5; high‐certainty evidence) after one year of follow‐up, despite the substantially lower cost of bevacizumab compared with ranibizumab. Reduction in central retinal thickness was less among bevacizumab‐treated participants than among ranibizumab‐treated participants after one year (MD ‐11.6 μm, 95% CI ‐21.6 to ‐1.7; high‐certainty evidence); however, this difference is within the range of measurement error, and we did not interpret it to be clinically meaningful. </p> <p>Ocular inflammation and increased intraocular pressure (IOP) after intravitreal injection were the most frequently reported serious ocular adverse events. Researchers reported endophthalmitis in less than 1% of anti‐VEGF‐treated participants and in no cases among control groups. The occurrence of serious systemic adverse events was comparable across anti‐VEGF‐treated groups and control groups; however, the numbers of events and trial participants may have been insufficient to show a meaningful difference between groups (evidence of low‐ to moderate‐certainty). Investigators rarely measured and reported data on visual function, quality of life, or economic outcomes. </p> </section> <section id="CD005139-sec-0007"> <h3 class="title" id="CD005139-sec-0007">Authors' conclusions</h3> <p>Results of this review show the effectiveness of anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) in terms of maintaining visual acuity; studies show that ranibizumab and bevacizumab improved visual acuity in some eyes that received these agents and were equally effective. Available information on the adverse effects of each medication does not suggest a higher incidence of potentially vision‐threatening complications with intravitreous injection of anti‐VEGF agents compared with control interventions; however, clinical trial sample sizes were not sufficient to estimate differences in rare safety outcomes. Future Cochrane Reviews should incorporate research evaluating variable dosing regimens of anti‐VEGF agents, effects of long‐term use, use of combination therapies (e.g. anti‐VEGF treatment plus photodynamic therapy), and other methods of delivering these agents. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005139-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005139-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005139-abs-0010">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005139-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005139-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005139-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005139-abs-0004">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005139-abs-0003" lang="en"> <h3>Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration</h3> <p><b>What is the aim of this review?</b><br/> The aim of this Cochrane review was to compare treatment with anti‐vascular endothelial growth factor (anti‐VEGF) agents for neovascular age‐related macular degeneration (wet AMD). This review focuses on two questions: (1) whether using anti‐VEGF agents is better than not using them, and (2) which anti‐VEGF agent works best. </p> <p><b>Key messages</b><br/> Anti‐VEGF agents were better than no anti‐VEGF agents or other types of treatment for patients with wet AMD. When studies compared anti‐VEGF agents, researchers found that ranibizumab and bevacizumab were similar in terms of vision‐related outcomes and numbers of adverse events among participants followed for at least one year. The major difference was cost, as bevacizumab was cheaper. </p> <p><b>What was studied in this review?</b><br/> Wet AMD is a common cause of severe vision loss among people 55 years of age and older. The macula, located in the central retina in the back of the eye, is important for vision. Wet AMD occurs when abnormal growth of blood vessels in the back of the eye damages the macula. Wet AMD causes blurriness, darkness, or distortion in the center of the field of vision, thus reducing the individual's ability to read, drive, and see faces. </p> <p>Injection into the eye of medicines like pegaptanib, ranibizumab, and bevacizumab can help block abnormal growth of blood vessels in the back of the eye. These drugs are known as anti‐VEGF agents. We conducted this review to compare benefits and risks of treatment with anti‐VEGF agents versus treatment without anti‐VEGF agents and to compare different types of anti‐VEGF agents. </p> <p><b>What are the main results of the review?</b><br/> We found 16 studies that enrolled a total of 6347 people with wet AMD. Six studies compared anti‐VEGF agents against no anti‐VEGF agent, and ten studies compared bevacizumab versus ranibizumab. Drug companies conducted or sponsored four of the studies. Investigators conducted the 16 studies at various centers on five continents (North and South America, Europe, Asia, and Australia); they treated people and provided follow‐up for at least one year. </p> <p>After one year, more people treated with any of the three anti‐VEGF agents (pegaptanib, ranibizumab, or bevacizumab) had improved vision, fewer had vision loss, and fewer were legally blind in the study eye when compared with people who did not receive anti‐VEGF agents. People treated with anti‐VEGF agents also showed structural improvements in the eye, which doctors use to monitor the disease and determine the need for more treatment. People who did not receive anti‐VEGF agents did not show the same kind of improvement. </p> <p>Treatment with ranibizumab or bevacizumab yielded larger improvements in vision compared with treatment with pegaptanib in trials comparing anti‐VEGF treatment against treatment not using anti‐VEGF agents. Comparison of bevacizumab versus ranibizumab revealed no major differences with respect to any vision‐related outcomes. The major difference between the two agents was cost; bevacizumab was cheaper. </p> <p>Inflammation and increased pressure in the eye were the most common unwanted effects caused by anti‐VEGF agents. Investigators reported endophthalmitis (infection in the inner part of the eye, which can cause blindness) in less than 1% of anti‐VEGF‐treated eyes and observed no cases among those not treated with anti‐VEGF agents. The occurrence of serious side effects, such as high blood pressure and internal bleeding, was low and was similar between anti‐VEGF‐treated groups and groups that did not receive anti‐VEGFs. The number of total side effects was very small, so it is impossible to tell which drug may have caused the most harmful effects. </p> <p><b>How up‐to‐date is this review?</b><br/> Cochrane researchers searched for studies that had been published up to January 31, 2018. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005139-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005139-sec-0130"></div> <h3 class="title" id="CD005139-sec-0131">Implications for practice</h3> <section id="CD005139-sec-0131"> <p>The results of this review indicate the effectiveness of three anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) in terms of stability or improvement in visual acuity after one year and two years of treatment. Ranibizumab and bevacizumab have resulted in improved visual acuity in a sizable fraction of treated eyes. The beneficial effects of these anti‐VEGF agents with respect to visual acuity are consistent with their effects on changes in lesion size as evaluated on fluorescein angiography and by OCT. Available information on adverse effects of each medication does not suggest a substantially higher incidence of potentially vision‐threatening complications with intravitreal injection compared with control interventions; however, this review may not be sufficiently powered to detect rare safety outcomes. We found no trials that had compared pegaptanib directly with either ranibizumab or bevacizumab for 12 months or longer. </p> <p>Since anti‐VEGF agents were introduced into clinical practice, ophthalmologists have observed among their patients with neovascular AMD that individual patients respond differently to different agents, and that tolerance for individual anti‐VEGF agents develops in some patients with prolonged use. Thus, access to multiple agents may offer the patient the best chance for a good visual acuity outcome. However, we did not address these issues in this review and, thus, cannot make an evidence‐based recommendation. </p> <p>At the time of preparation of this review, bevacizumab remains an off‐label therapy for patients with neovascular AMD. The manufacturer (Genentech) that produces both bevacizumab and ranibizumab has not submitted bevacizumab for approval as treatment for AMD. Bevacizumab is a significantly less expensive treatment option, so perhaps it would compete with the company's more costly and FDA‐approved ophthalmic anti‐VEGF agent, ranibizumab. Thus, trials comparing functional, anatomic, vision‐specific quality of life, as well as cost utility outcomes, between bevacizumab and ranibizumab ultimately may have no effect on the treatment of individuals with neovascular AMD if off‐label therapy with bevacizumab were proscribed. The US Centers for Medicare and Medicaid (CMS) and other national health agencies currently cover the cost of bevacizumab for ophthalmic use in hospital outpatient settings; however, other national health agencies do not include off‐label use of bevacizumab in their coverage (<a href="./references#CD005139-bbs2-0091" title="Centers for Medicare and Medicaid Services. Billing and coding information regarding uses, including off‐label uses, of bevacizumab and ranibizumab, for the treatment of ophthalmological diseases. Document ID A49034. www.cms.gov/medicare‐coverage‐database (accessed 9 April 2014). ">CMS 2014</a>; <a href="./references#CD005139-bbs2-0092" title="CohenD . Roche and Novartis colluded over wet AMD drugs, says Italian regulator. BMJ2014;348:g2006. ">Cohen 2014</a>). </p> </section> <h3 class="title" id="CD005139-sec-0132">Implications for research</h3> <section id="CD005139-sec-0132"> <p>Use of anti‐VEGF agents for treatment of AMD has become part of standard clinical practice; however, certain issues regarding their use remain. Several factors encourage evaluation of the efficacy of alternative and less‐frequent dosing regimens with anti‐VEGF compounds. These include lingering concerns about ocular and systemic toxicity, convenience for individuals with AMD and their physicians associated with fewer intravitreal injections, and costs of treatment. Research to evaluate long‐term use of anti‐VEGF agents should consider both effects of the drugs on vision and long‐term effects of multiple injections over time. It remains unclear how one can best evaluate these effects, as RCTs to identify rare events during long follow‐up periods are difficult to conduct and finance. Some of the RCTs included in this review have provided data for up to seven years of follow‐up (<a href="./references#CD005139-bbs2-0122" title="RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. ">Rofagha 2013</a>); however, these follow‐up data are observational, were not included in the trial protocols, and include only a subset of originally enrolled participants. <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> received funding from the US National Eye Institute to continue follow‐up of participants enrolled in that trial so investigators could document long‐term positive and negative effects of intravitreous injections of ranibizumab and bevacizumab; five year outcomes have been reported for the trial cohort. </p> <p>Use of anti‐VEGF agents in combination with other neovascular AMD treatments, such as verteporfin photodynamic therapy (PDT) or intravitreal steroids, is an important and active area of research because acceptance of anti‐VEGF therapy may make it unethical to conduct trials without providing this treatment to all participants with neovascular AMD. The goal of combination treatments would be to improve vision and quality of life even further than is achievable with anti‐VEGF agents alone, and perhaps to reduce the number of intravitreal injections needed. Research also is needed to evaluate methods of delivering these agents other than intravitreally. Vehicles already under development include implants and refillable reservoirs (<a href="./references#CD005139-bbs2-0094" title="deJuanE , LaganovskaG , LoewensteinA , AlsterY , EricksonS . First in‐human results of a refillable drug delivery implant providing sustained release of ranibizumab in patients with neovascular AMD. Macula Society. 2013:136‐7. ">de Juan 2013</a>). </p> <p>Based on our review, only one or more very large randomized trials with findings that differ substantially from those reported by trials already completed would be required to modify or reverse our conclusions that (1) intravitreous injection of pegaptanib, ranibizumab, and bevacizumab has beneficial effects on best‐corrected visual acuity in eyes with neovascular age‐related macular degeneration, and (2) ranibizumab and bevacizumab have equivalent safety and effectiveness in such eyes. Thus, we do not anticipate a need for future updates to this systematic review. Future reviews are expected to address the effects of newer agents and other approaches for treating eyes with neovascular age‐related macular degeneration. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005139-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005139-sec-0029"></div> <div class="table" id="CD005139-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: anti‐VEGF treatment versus control</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anti‐VEGF treatment versus control for neovascular age‐related macular degeneration</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> people with neovascular age‐related macular degeneration </p> <p><b>Settings:</b> clinical centers </p> <p><b>Intervention:</b> intravitreal injections of anti‐VEGF agents (pegaptanib, ranibizumab, or bevacizumab) </p> <p><b>Control:</b> standard therapy at the time of the trial (sham injections, verteporfin photodynamic therapy with or without triamcinolone acetonide, or intravitreal injections of pegaptanib) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gain of 15 or more letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b><br/> (99 to 322) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.19</b><br/> (2.32 to 7.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2667<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Loss of fewer than 15 letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>599 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>838 per 1000</b><br/> (760 to 928) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> </p> <p>(1.27 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2667<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year (number of letters)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change across control groups ranged from a <b>loss of 10 to 16</b> letters </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2508<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Owing to substantial statistical heterogeneity between pegaptanib and ranibizumab subgroups, we did not combine data across subgroups </p> <p>Mean change in visual acuity in pegaptanib groups was on average <b>6.72 more letters gained</b> (95% CI 4.43 letters to 9.01 letters); <b>MD 6.72</b> (95% CI 4.43 to 9.01) </p> <p>Mean change in visual acuity in ranibizumab groups was on average <b>17.80 more letters gained</b> (95% CI 15.95 letters to 19.65 letters); <b>MD 17.80</b> (95% CI 15.95 to 19.65) </p> <p>Mean change from baseline in visual acuity was 7.0 letters in bevacizumab group and ‐9.4 letters in control group in 1 study. The second study reported that participants in bevacizumab group gained 8 letters on average and participants in control group lost 3 letters on average </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in central retinal thickness at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to find data on central retinal thickness in reports from the only trial comparing pegaptanib with control and from any of the 3 included trials comparing ranibizumab with control </p> <p>Mean change was ‐91 μm in bevacizumab group and ‐55 μm in control group in one study, and ‐113 μm in bevacizumab group and ‐72 μm in control group in the other study </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in vision‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change across control groups in vision‐related quality of life scores ranged from <b>‐3 to 2 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change across control groups in vision‐related quality of life scores ranged from <b>5 to 7 points</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 6.69</b> (3.38 to 9.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1134<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of the NEI‐VFQ questionnaire with a 10‐point difference considered clinically meaningful </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious systemic adverse events at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>5 to 83 per 1000</b> for various systemic adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>0 to 55 per 1000</b> for various systemic adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of <b>RR 0.17</b> (0.01 to 4.24) to <b>2.08</b> (0.23 to 18.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2667<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious ocular adverse events at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>0 to 68 per 1000</b> for various ocular adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>3 to 118 per 1000</b> for various ocular adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of <b>RR 0.52</b> (0.03 to 8.25) to <b>2.71</b> (1.36 to 5.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2667<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is estimated by the proportion with the event in the control group. The <b>corresponding risk</b> (and its 95% CI) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> Anti‐VEGF: anti‐vascular endothelial growth factor; CI: confidence interval; MD: mean difference; NEI‐VFQ: National Eye Institute‐Visual Functioning Questionnaire; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence.<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded (‐1) owing to imprecision in the confidence interval.<br/> <sup>b</sup>Downgraded (‐1) owing to inconsistency in effect between types of anti‐VEGF agents.<br/> <sup>c</sup>Adverse events downgraded to moderate quality as not all eligible trials reported all types of adverse events, and numbers were small (&lt; 1%) for many specific adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005139-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: bevacizumab versus ranibizumab</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bevacizumab versus ranibizumab for neovascular age‐related macular degeneration</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> people with neovascular age‐related macular degeneration </p> <p><b>Settings:</b> clinical centers </p> <p><b>Intervention:</b> intravitreal injections of bevacizumab </p> <p><b>Comparison:</b> intravitreal injections of ranibizumab </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gain of 15 or more letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b><br/> (204 to 282) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/> (0.81 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3144<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Loss of fewer than 15 letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>944 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>944 per 1000</b><br/> (926 to 963) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.98 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3144<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year (number of letters)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change across ranibizumab groups ranged from <b>gains of 3 to 8 letters</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in visual acuity in bevacizumab groups was on average <b>0.58 fewer letters gained</b> (95% CI 1.55 fewer letters to 0.40 more letters) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐0.6</b><br/> (‐1.6 to 0.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in central retinal thickness at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean reduction in central retinal thickness across ranibizumab groups ranged from <b>30 to 182 μm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean reduction in central retinal thickness in bevacizumab groups was on average <b>11.61 μm less</b> (95% CI 21.55 less to 1.66 less) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐11.6</b><br/> (‐21.6 to ‐1.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2693<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three additional trials reported no differences between groups for this outcome; however, these data were not reported in formats that could be included in meta‐analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No problems in quality of life domains at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>591 per 1000</b> to <b>861 per 1000</b> across 5 quality of life domains </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>608 per 1000</b> to <b>828 per 1000</b> across<br/> 5 quality of life domains </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of <b>RR 0.96</b> (0.90 to 1.04) to <b>1.02</b><br/> (0.89 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life domains included mobility, self‐care, usual activities, pain/discomfort, anxiety/depression </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious systemic adverse events at</b> <br/> <b>1 year<sup>b</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b> with at least 1 serious systemic adverse event </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b><br/> (154 to 209) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b><br/> (0.99 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3365<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious ocular adverse events at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 5 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of <b>RR 0.51</b> (0.05 to 5.62) to <b>7.05</b> (0.36 to 136.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 1670 to 2280<br/> (2 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies reported different ocular adverse events. One study reported only that there was no difference between treatment arms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is estimated by the proportion with the event in the ranibizumab group. The <b>corresponding risk</b> (and its 95% CI) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; MD: mean difference; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence.<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Quality of life and adverse event outcomes downgraded to moderate quality as not all eligible trials reported these outcomes, and numbers of some adverse events were small (&lt; 1%).<br/> <sup>b</sup>A Cochrane review on systemic safety of bevacizumab versus ranibizumab includes more complete data for this finding (<a href="./references#CD005139-bbs2-0117" title="MojaL , LucenteforteE , KwagKH , BerteleV , CampomoriA , ChakravarthyU , et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2] ">Moja 2014</a>). Please refer to <a href="./references#CD005139-bbs2-0117" title="MojaL , LucenteforteE , KwagKH , BerteleV , CampomoriA , ChakravarthyU , et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2] ">Moja 2014</a> for the most complete information on systemic safety for bevacizumab versus ranibizumab. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005139-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005139-sec-0030"></div> <section id="CD005139-sec-0031"> <h3 class="title" id="CD005139-sec-0031">Description of the condition</h3> <section id="CD005139-sec-0032"> <h4 class="title">Introduction</h4> <p>Age‐related macular degeneration (AMD) is a progressive, degenerative disease of the retina that occurs with increasing frequency with advancing age. Two major types of AMD are known; these are commonly referred to as non‐neovascular ("dry") and neovascular ("wet") AMD. The non‐neovascular type is characterized by drusen (yellow spots under the retina), pigmentary changes (redistribution of melanin within the retinal pigment epithelium [RPE] under the retina and migration of melanin into the retina), and geographic atrophy (loss of the RPE and choriocapillaris). </p> <p>This review is concerned with neovascular AMD and its treatment. The hallmark of neovascular AMD is choroidal neovascularization (CNV). Breaks in the RPE and in Bruch’s membrane allow naturally occurring vessels in the choroid to grow aberrantly into the subretinal space. These choroidal neovascular vessels typically leak and bleed, causing exudative or hemorrhagic retinal detachments. Without treatment, the process usually evolves into a fibrous scar, which replaces the outer layers of the retina, the RPE, and the choriocapillaris. The scarred retina has greatly diminished visual capacity. </p> </section> <section id="CD005139-sec-0033"> <h4 class="title">Epidemiology</h4> <p>AMD is a leading cause of irreversible vision loss among the elderly in developed countries (<a href="./references#CD005139-bbs2-0087" title="BourneRR , JonasJB , FlaxmanSR , KeeffeJ , LeasherJ , NaidooK , et al. Prevalence and causes of vision loss in high‐income countries and in Eastern and Central Europe: 1990‐2010. British Journal of Ophthalmology2014;98(5):629‐38. ">Bourne 2014</a>; <a href="./references#CD005139-bbs2-0089" title="BunceC , WormaldR . Leading causes of certification for blindness and partial sight in England &amp; Wales. BMC Public Health2006;6:58. ">Bunce 2006</a>; <a href="./references#CD005139-bbs2-0093" title="CongdonN , O'ColmainB , KlaverCC , KleinR , MuñozB , FriedmanDS , et al. Causes and prevalence of visual impairment among adults in the United States. Archives of Ophthalmology2004;122(4):477‐85. ">Congdon 2004</a>; <a href="./references#CD005139-bbs2-0100" title="GhafourIM , AllanD , FouldsWS . Common causes of blindness and visual handicap in the west of Scotland. British Journal of Ophthalmology1983;67(4):209‐13. ">Ghafour 1983</a>; <a href="./references#CD005139-bbs2-0108" title="HymanL . Epidemiology of eye disease in the elderly. Eye1987;1(Pt 2):330‐41. ">Hyman 1987</a>; <a href="./references#CD005139-bbs2-0112" title="LeibowitzHM , KruegerDE , MaunderLR , MiltonRC , KiniMM , KahnHA , et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973‐1975. Survey of Ophthalmology1980;24(Suppl):335‐610. ">Leibowitz 1980</a>; <a href="./references#CD005139-bbs2-0131" title="TielschJA . Vision problems in the US: a report on blindness and vision impairment in adults age 40 and older. Prevent Blindness. Illinois: Schaumberg, 1994. ">Tielsch 1994</a>). Although the non‐neovascular type is much more common, the neovascular form of AMD is responsible for most cases of severe vision loss. The incidence of progression from non‐neovascular AMD to neovascular AMD is increased by the presence of numerous large and confluent drusen in the macula, as well as by the presence of pigment in the macula. Neovascular AMD occurs in only 10% of people with AMD, yet 80% of those with severe visual loss (worse than 20/200 Snellen acuity) have the neovascular form (<a href="./references#CD005139-bbs2-0112" title="LeibowitzHM , KruegerDE , MaunderLR , MiltonRC , KiniMM , KahnHA , et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973‐1975. Survey of Ophthalmology1980;24(Suppl):335‐610. ">Leibowitz 1980</a>). Once neovascular disease develops in one eye, the risk of developing neovascular disease in the other eye of the same person is approximately 40% by five years (<a href="./references#CD005139-bbs2-0084" title="Age‐Related Eye Disease Study Research Group. A randomized, placebo‐controlled, clinical trial of high‐dose supplementation with vitamins C and E, beta carotene, and zinc for age‐related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1414‐36. ">AREDS 2001</a>; <a href="./references#CD005139-bbs2-0129" title="Submacular Surgery Trials Research Group, SolomonSD , JefferysJL , HawkinsBS , BresslerNM . Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age‐related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. Archives of Ophthalmology2007;125(10):1323‐30. ">SST 20</a>). </p> <p>The overall prevalence of AMD, estimated in a meta‐analysis of studies from Australia, Europe, and the United States, was 1.47% (95% confidence interval [CI] 1.38% to 1.55%) (<a href="./references#CD005139-bbs2-0099" title="FriedmanDS , O'ColmainBJ , MuñozB , TomanySC , McCartyC , deJongPT , et al. Prevalence of age‐related macular degeneration in the United States. Archives of Ophthalmology2004;122(4):564‐72. ">Friedman 2004</a>); however, AMD increases in prevalence with advancing age, and incidence is low among individuals younger than 50 years of age. Thus, the burden of disease is greatest in regions where life expectancy is highest. Among those aged 80 years or older, the prevalence of neovascular AMD has been estimated to be 5.79% (95% CI 4.72% to 7.01%) in the UK (<a href="./references#CD005139-bbs2-0119" title="OwenCG , FletcherAE , DonoghueM , RudnickaAR . How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?. British Journal of Ophthalmology2003;87(3):312‐7. ">Owen 2003</a>), and 8.18% (95% CI 7.07% to 9.29%) in the United States (<a href="./references#CD005139-bbs2-0099" title="FriedmanDS , O'ColmainBJ , MuñozB , TomanySC , McCartyC , deJongPT , et al. Prevalence of age‐related macular degeneration in the United States. Archives of Ophthalmology2004;122(4):564‐72. ">Friedman 2004</a>). </p> <p>No consistent evidence indicates that modifiable factors such as lipid levels, blood pressure, light exposure, or alcohol intake put people at greater risk of AMD. One notable exception is smoking (<a href="./references#CD005139-bbs2-0110" title="KleinR , KnudtsonMD , CruickshanksKJ , KleinBE . Further observations on the association between smoking and the long‐term incidence and progression of age‐related macular degeneration. Archives of Ophthalmology2008;126(1):115‐21. ">Klein 2008</a>; <a href="./references#CD005139-bbs2-0115" title="MitchellP , WangJJ , SmithW , LeederSR . Smoking and the 5‐year incidence of age‐related maculopathy: the Blue Mountains Eye Study. Archives of Ophthalmology2002;120(10):1357‐63. ">Mitchell 2002</a>; <a href="./references#CD005139-bbs2-0128" title="SmithW , MitchellP , LeederSR . Smoking and age‐related maculopathy. The Blue Mountains Eye Study. Archives of Ophthalmology1996;114(12):1518‐23. ">Smith 1996</a>). Elevated baseline levels of inflammatory biomarkers such as C‐reactive protein have been found to be associated with the development of early and late AMD in a large population‐based cohort (<a href="./references#CD005139-bbs2-0086" title="BoekhoornSS , VingerlingJR , WittemanJCM , HofmanA , deJongPT . C‐reactive protein level and risk of aging macula disorder: the Rotterdam study. Archives of Ophthalmology2007;125(10):1396‐401. ">Boekhoorn 2007</a>). Furthermore, several studies have shown gene‐environment interactions of complement factor H with smoking and C‐reactive protein (<a href="./references#CD005139-bbs2-0095" title="DeangelisMM , JiF , KimIK , AdamsS , CaponeAJr , OttJ , et al. Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age‐related macular degeneration. Archives of Ophthalmology2007;125(1):49‐54. ">Deangelis 2007</a>; <a href="./references#CD005139-bbs2-0105" title="HaddadS , ChenCA , SantangeloSL , SeddonJM . The genetics of age‐related macular degeneration: a review of progress to date. Survey of Ophthalmology2006;51(4):316‐63. ">Haddad 2006</a>; <a href="./references#CD005139-bbs2-0124" title="SchaumbergDA , HankinsonSE , GuoQ , RimmE , HunterDJ . A prospective study of 2 major age‐related macular degeneration susceptibility alleles and interactions with modifiable risk factors. Archives of Ophthalmology2007;125(1):55‐62. ">Schaumberg 2007</a>; <a href="./references#CD005139-bbs2-0127" title="SeddonJM , GeorgeS , RosnerB , KleinML . CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age‐related macular degeneration. Human Heredity2006;61(3):157‐65. ">Seddon 2006</a>). High doses of vitamins C and E, beta‐carotene, and zinc provide a modest protective effect against progression to advanced AMD among individuals with extensive drusen or in initially unaffected fellow eyes with neovascular AMD (<a href="./references#CD005139-bbs2-0084" title="Age‐Related Eye Disease Study Research Group. A randomized, placebo‐controlled, clinical trial of high‐dose supplementation with vitamins C and E, beta carotene, and zinc for age‐related macular degeneration and vision loss: AREDS report no. 8. Archives of Ophthalmology2001;119(10):1414‐36. ">AREDS 2001</a>; <a href="./references#CD005139-bbs2-0085" title="Age‐Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. ">AREDS2 2013</a>). </p> <p>As the population continues to age, a higher prevalence of this disease is expected in the future, at least in certain populations. A population‐based survey estimated that AMD, as a contributing cause of blindness, had increased worldwide from 4.4% (95% CI 4.0 to 5.1) in 1990 to 6.6% (95% CI 5.9 to 7.9) in 2010 (<a href="./references#CD005139-bbs2-0087" title="BourneRR , JonasJB , FlaxmanSR , KeeffeJ , LeasherJ , NaidooK , et al. Prevalence and causes of vision loss in high‐income countries and in Eastern and Central Europe: 1990‐2010. British Journal of Ophthalmology2014;98(5):629‐38. ">Bourne 2014</a>). </p> </section> <section id="CD005139-sec-0034"> <h4 class="title">Presentation and diagnosis</h4> <p>Neovascular AMD may affect one eye or both eyes at the same time or sequentially. Symptoms of neovascular AMD include metamorphopsia (distortions while looking at objects), scotomata (black or gray spots), and blurry vision. Depending upon the location of the CNV and the quality of vision in the fellow eye, individuals with AMD may be unaware of a change in visual acuity or may note difficulty when performing normal activities that require good central vision, such as reading and writing, watching television, driving, and recognizing faces. When AMD affects only one eye, visual loss may go undetected until monocular testing is performed at a routine eye examination, or until chance occlusion of the better eye is noted. Frequently, people are unaware that their disturbed binocular vision is caused by changes in only one eye. </p> <p>Neovascular AMD is diagnosed clinically with the help of imaging such as optical coherence tomography (OCT) and fluorescein angiography, which may be necessary to detect subtle exudation in some individuals who have experienced a recent change in visual acuity. At the onset of symptoms, fundus examination often reveals subretinal exudation of fluid, lipid, or blood. OCT, a non‐invasive imaging modality, shows cross‐sectional images of the retina, RPE, and choroid. Some studies have defined the characteristic appearance of different stages of the disease process on OCT (<a href="./references#CD005139-bbs2-0132" title="TingTD , OhM , CoxTA , MeyerCH , TothCA . Decreased visual acuity associated with cystoid macular edema in neovascular age‐related macular degeneration. Archives of Ophthalmology2002;120(6):731‐7. ">Ting 2002</a>; <a href="./references#CD005139-bbs2-0133" title="VanKerckhovenW , LafautB , FollensI , DeLaeyJJ . Features of age‐related macular degeneration on optical coherence tomography. Bulletin de la Societe Belge d'Ophtalmologie2001;281:75‐84. ">Van Kerckhoven 2001</a>). The most characteristic findings on OCT corresponding to a CNV lesion include areas of hyporeflectivity under the retina that, in turn, correspond to subretinal fluid, cystic hyporeflective changes consistent with macular edema, and attenuation of the photoreceptor/choriocapillaris layer. CNV can be seen in several characteristic patterns on fluorescein angiography. Classic CNV is defined as an area of early hyperfluorescence with increasing fluorescein leakage on late frames of the angiogram (<a href="./references#CD005139-bbs2-0118" title="Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five‐year results from randomized clinical trials. Archives of Ophthalmology1991;109(8):1109‐14. ">MPSG 1991</a>). Occult CNV occurs in two different patterns: fibrovascular pigment epithelial detachment and late fluorescein leakage from an undetermined source. Classic CNV typically has well‐demarcated borders, in contrast to the poorly demarcated borders usually seen in occult CNV. </p> <p>Another test ‐ indocyanine green (ICG) angiography ‐ may facilitate evaluation of individuals with neovascular AMD, as it images the choroidal circulation better than fluorescein angiography and may show "hot" spots under the RPE that are amenable to treatment. ICG angiography is particularly useful in the diagnosis of polypoidal choroidal vasculopathy, a form of AMD that is most common among Asian populations. </p> </section> </section> <section id="CD005139-sec-0035"> <h3 class="title" id="CD005139-sec-0035">Description of the intervention</h3> <p>Until the advent of anti‐vascular endothelial growth factor (VEGF) agents, treatments most frequently used for neovascular AMD included thermal laser photocoagulation and verteporfin photodynamic therapy (PDT). A Cochrane systematic review concluded that laser photocoagulation effectively slowed the progression of neovascularization in non‐subfoveal lesions compared with observation alone (<a href="./references#CD005139-bbs2-0134" title="VirgiliG , BiniA . Laser photocoagulation for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD004763.pub2] ">Virgili 2007</a>). A Cochrane review of verteporfin PDT concluded that PDT was effective in preventing clinically significant vision loss (<a href="./references#CD005139-bbs2-0135" title="WormaldR , EvansJ , SmeethL , HenshawK . Photodynamic therapy for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2007, Issue 3. [DOI: 10.1002/14651858.CD002030.pub2] ">Wormald 2007</a>). However, neither laser photocoagulation nor PDT offered any significant chance for vision improvement. </p> <p>Over the past two decades, researchers have developed new drugs for the treatment of patients with neovascular AMD. These drugs target a protein in the body known as vascular endothelial growth factor (VEGF), which stimulates the growth of abnormal blood vessels in neovascular AMD through a process called angiogenesis; the drugs block VEGF, leading to regression of abnormal blood vessels. Antiangiogenic therapy currently is the most commonly used treatment for neovascular AMD, particularly of subfoveal neovascular lesions. </p> <p>An example of an anti‐VEGF antagonist is pegaptanib (Macugen, a trademark of Eyetech/Pfizer, Inc.). Pegaptanib is a chemically synthesized 28‐base ribonucleic acid molecule. It is an aptamer (foldable single‐strand nucleic acid) that has the ability to change its three‐dimensional structure to fit a target protein, in this case VEGF. By binding to VEGF, pegaptanib blocks and inactivates VEGF, thus halting the process of neovascularization. The US Food and Drug Administration (FDA) approved pegaptanib in December 2004 for the treatment of patients with neovascular AMD. </p> <p>Ranibizumab, previously known as rhuFab‐VEGF (Lucentis, a trademark of Genentech, Inc.), is another example of an anti‐VEGF medication developed for ocular administration. It is a humanised antibody fragment capable of binding to the VEGF protein to prevent it from binding to its receptor, thus inhibiting angiogenic activity. Ranibizumab was the first treatment for neovascular AMD that offered a realistic hope for vision improvement; it was approved by the FDA in 2007. </p> <p>Bevacizumab (Avastin, a trademark of Genentech, Inc.) is a humanized monoclonal antibody against VEGF. It is the larger parent molecule from which ranibizumab was derived. Bevacizumab currently is approved for the treatment of patients with conditions such as colorectal cancer, but it is widely used off‐label by ophthalmologists to treat neovascular AMD. </p> <p>Aflibercept, previously known as VEGF Trap (Eylea, a trademark of Regeneron Pharmaceuticals, Inc.), is another anti‐VEGF agent; the molecule serves as a VEGF decoy to inhibit the growth of new blood vessels. The FDA approved aflibercept in 2011 for treatment of neovascular AMD. Conbercept, a drug similar to aflibercept, has been developed in China. Because the mechanism of action of these types of drugs is slightly different from that of the drugs listed above (pegaptanib, ranibizumab, and bevacizumab), and because they were introduced after the protocol for this review was developed, we have not evaluated aflibercept or conbercept in this review. </p> </section> <section id="CD005139-sec-0036"> <h3 class="title" id="CD005139-sec-0036">How the intervention might work</h3> <p>Angiogenesis is a complex process whereby interactions between stimulatory and inhibitory factors result in new blood vessel formation. These factors have been identified in CNV formation in animal models and human tissue (<a href="./references#CD005139-bbs2-0083" title="AielloLP , AveryRL , ArriggPG , KeytBA , JampelHD , ShahST , et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine1994;331(22):1480‐7. ">Aiello 1994</a>; <a href="./references#CD005139-bbs2-0111" title="KvantaA , AlgverePV , BerglinL , SeregardS . Subfoveal fibrovascular membranes in age‐related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology and Visual Science1996;37(9):1929‐34. ">Kvanta 1996</a>; <a href="./references#CD005139-bbs2-0114" title="LopezPF , SippyBD , LambertHM , ThachAB , HintonDR . Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age‐related macular degeneration‐related choroidal neovascular membranes. Investigative Ophthalmology and Visual Science1996;37(5):855‐68. ">Lopez 1996</a>). Antiangiogenic therapies work by blocking stimulatory factors or by promoting inhibitory factors, thus disrupting the formation of new vessels. Agents that block the activity of VEGF (anti‐VEGFs), a polypeptide with mitogenic effects on endothelial blood vessels, form one type of anti‐angiogenic therapy. VEGF antagonists have been shown to inhibit CNV in animal models. </p> <p>In the past, the primary goal of both laser photocoagulation and PDT was to prevent or delay further loss of visual acuity in the treated eye. With the development of agents to counteract VEGF, together known as anti‐VEGF agents, the primary goal of intravitreal injection of these agents is to retain or improve visual acuity. Currently, anti‐VEGF agents are administered most commonly via monthly intravitreous injections or as needed after three consecutive monthly injections. </p> </section> <section id="CD005139-sec-0037"> <h3 class="title" id="CD005139-sec-0037">Why it is important to do this review</h3> <p>Previous versions of this Cochrane review have documented the effectiveness of anti‐VEGF agents in halting the loss of visual acuity in a substantial fraction of treated eyes (<a href="./references#CD005139-bbs2-0137" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3] ">Solomon 2014</a>; <a href="./references#CD005139-bbs2-0139" title="VedulaSS , KrzystolikM . Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2] ">Vedula 2008</a>). Further, intravitreal injections with ranibizumab led to improved vision in about one‐third of eyes ‐ an improvement not previously observed with other AMD treatments (<a href="./references#CD005139-bbs2-0137" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3] ">Solomon 2014</a>; <a href="./references#CD005139-bbs2-0138" title="SolomonSD , LindsleyKB , KrzystolikMG , VedulaSS , HawkinsBS . Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age‐related macular degeneration: findings from a Cochrane systematic review. Ophthalmology2016;123(1):70‐7. ">Solomon 2016</a>). Since this Cochrane review was first published in 2008, numerous studies have been conducted to evaluate the safety and effectiveness of various anti‐VEGF agents, treatment regimens, and combination therapies for treatment of patients with neovascular AMD (<a href="#CD005139-tbl-0003">Table 1</a>). This review is restricted to primary randomized controlled trials (RCTs) of anti‐VEGF agents versus no anti‐VEGF treatment; and head‐to‐head (comparative effectiveness) RCTs of one anti‐VEGF agent versus another. Studies on dosage, different treatment strategies, and anti‐VEGF agents combined with other treatments are outside the scope of this review. The emphasis of this updated review is improvement in visual acuity with treatment. </p> <div class="table" id="CD005139-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of study acronyms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acronym</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Details</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b><i>Included studies</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Avastin<sup>®</sup> (Bevacizumab) in Choroidal Neovascularization Trial </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ANCHOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐related Macular Degeneration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BRAMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison of Bevacizumab (Avastin<sup>®</sup>) and Ranibizumab (Lucentis<sup>®</sup>) in Exudative Age‐related Macular Degeneration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CATT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison of Age‐related Macular Degeneration Treatment Trials</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GEFAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>French Evaluation Group Avastin<sup>®</sup> Versus Lucentis<sup>®</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVAN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A Randomized Controlled Trial of Alternative Treatments to Inhibit VEGF in Age‐related Choroidal Neovascularisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LUCAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lucentis<sup>®</sup> Compared to Avastin<sup>®</sup> Study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MANTA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age‐related Macular Degeneration Multicenter Anti‐VEGF Trial in Austria </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MARINA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PIER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A Phase IIIb, Multicenter, Randomized, Double‐Masked, Sham Injection‐Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization With or Without Classic CNV Secondary to Age‐related Macular Degeneration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAVE‐AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of VEGF Inhibitors in Age‐Related Macular Degeneration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VISION</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF Inhibition Study in Ocular Neovascularization</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b><i>Ongoing study</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIBERA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevention of Vision Loss in Patients With Age‐Related Macular Degeneration by Intravitreal Injection of Bevacizumab and Ranibizumab </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005139-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005139-sec-0038"></div> <p> <ul id="CD005139-list-0001"> <li> <p>To investigate ocular and systemic effects of, and quality of life associated with, intravitreous injection of anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) versus no anti‐VEGF treatment for patients with neovascular AMD </p> </li> <li> <p>To compare the relative effects of one of these anti‐VEGF agents versus another when administered in comparable dosages and regimens </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005139-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005139-sec-0039"></div> <section id="CD005139-sec-0040"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005139-sec-0041"> <h4 class="title">Types of studies</h4> <p>We included only RCTs in this review.</p> </section> <section id="CD005139-sec-0042"> <h4 class="title">Types of participants</h4> <p>We included trials in which participants had neovascular AMD as defined by study investigators.</p> </section> <section id="CD005139-sec-0043"> <h4 class="title">Types of interventions</h4> <p>We included studies that compared anti‐VEGF treatment versus another treatment, sham treatment, or no treatment. We did not include studies that compared different doses of one anti‐VEGF treatment against another, studies that included no control or comparator group, or studies that used anti‐VEGF agents in combination with other treatments. We did not include studies of aflibercept (VEGF Trap‐Eye/EYLEA solution) or studies that compared different treatment schedules (e.g. monthly vs as needed dosing), because other Cochrane reviews have evaluated these interventions (<a href="./references#CD005139-bbs2-0113" title="LiE , DonatiS , VirgiliG , KrzystolikMG . Treatment schedules for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2016, Issue 5. [DOI: 10.1002/14651858.CD012208] ">Li 2016</a>; <a href="./references#CD005139-bbs2-0123" title="SarwarS , ClearfieldE , SolimanMK , SadiqMA , BaldwinAJ , HanoutM , et al. Aflibercept for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD011346.pub2] ">Sarwar 2016</a>). </p> </section> <section id="CD005139-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD005139-sec-0045"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome for this review was based on best‐corrected visual acuity (BCVA) at one‐year follow‐up. All included RCTs randomized only one eye per participant (i.e. the study eye); therefore we defined the primary outcome for the comparison of treatments as the proportion of participants who gained 15 or more letters (three lines) of BCVA in the study eye when BCVA was measured on a visual acuity chart with a LogMAR scale. </p> </section> <section id="CD005139-sec-0046"> <h5 class="title">Secondary outcomes</h5> <section id="CD005139-sec-0047"> <h6 class="title">Visual acuity outcomes</h6> <p> <ul id="CD005139-list-0002"> <li> <p>Proportion of participants who gained 15 or more letters of BCVA in the study eye as measured at two‐year follow‐up </p> </li> <li> <p>Proportion of participants who lost fewer than 15 letters of visual acuity at one year and at two years </p> </li> <li> <p>Proportion of participants who lost fewer than 30 letters of visual acuity at one year and at two years </p> </li> <li> <p>Proportion of participants for whom blindness was avoided in the study eye, defined as eyes with visual acuity better than 20/200 at one year and at two years </p> </li> <li> <p>Proportion of participants maintaining visual acuity, defined as a gain of zero or more letters (i.e. no loss of BCVA from baseline) at one year and at two years </p> </li> <li> <p>Mean change in visual acuity from baseline to one year and to two years</p> </li> </ul> </p> </section> <section id="CD005139-sec-0048"> <h6 class="title">Other secondary outcomes</h6> <p> <ul id="CD005139-list-0003"> <li> <p>Contrast sensitivity, reading speed, or any other validated measure of visual function as measured in the included studies </p> </li> <li> <p>Assessment of morphologic characteristics by fluorescein angiography or OCT, including mean change in size of CNV, mean change in size of total lesion, and mean change in central retinal thickness (CRT) </p> </li> <li> <p>Quality of life measures, as assessed with any validated measurement scale</p> </li> <li> <p>Economic data, such as comparative cost analyses</p> </li> <li> <p>Ocular or systemic adverse outcomes</p> </li> </ul> </p> </section> <section id="CD005139-sec-0049"> <h6 class="title">Follow‐up</h6> <p>We included only trials in which participants were followed for at least one year. We also included outcomes at two‐year follow‐up when these data were available. </p> </section> </section> </section> </section> <section id="CD005139-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005139-sec-0051"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Eyes and Vision Information Specialist conducted systematic searches in the following databases for randomized controlled trials and controlled clinical trials. This search included no language or publication year restrictions. The date of the most recent search was January 31, 2018. </p> <p> <ul id="CD005139-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched January 31, 2018) (<a href="./appendices#CD005139-sec-0136">Appendix 1</a>). </p> </li> <li> <p>MEDLINE Ovid (1946 to January 31, 2018) (<a href="./appendices#CD005139-sec-0137">Appendix 2</a>). </p> </li> <li> <p>Embase Ovid (1980 to January 31, 2018) (<a href="./appendices#CD005139-sec-0138">Appendix 3</a>). </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature (LILACS) information database (1982 to January 31, 2018) (<a href="./appendices#CD005139-sec-0139">Appendix 4</a>). </p> </li> <li> <p>International Standard Randomized Controlled Trials Number (ISRCTN) registry (<a href="http://www.isrctn.com/editAdvancedSearch" target="_blank">www.isrctn.com/editAdvancedSearch</a>; searched January 31, 2018) (<a href="./appendices#CD005139-sec-0140">Appendix 5</a>). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched January 31, 2018) (<a href="./appendices#CD005139-sec-0141">Appendix 6</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched January 31, 2018) (<a href="./appendices#CD005139-sec-0142">Appendix 7</a>). </p> </li> </ul> </p> </section> <section id="CD005139-sec-0052"> <h4 class="title">Searching other resources</h4> <p>We reviewed the reference lists of included trial reports and related systematic reviews to identify additional potentially relevant trials. </p> <p>We contacted pharmaceutical companies conducting or sponsoring studies of anti‐VEGF drugs to ask for information about any ongoing or completed clinical trials not published. One review author (SSV) handsearched abstracts from annual meetings of the Association for Research in Vision &amp; Ophthalmology (ARVO) for the years 2006 and 2007 for ongoing trials (http://files.abstractsonline.com/SUPT/163/1807/PresentationTitle.htm; http://files.abstractsonline.com/SUPT/163/1601/Presentation_Title_PDF_wlinks.htm; accessed November 24, 2007). After 2007, Cochrane Eyes and Vision personnel handsearched conference abstracts reporting clinical trials; the trial records identified are included in CENTRAL. Another review author (KL) handsearched abstracts from the 2006 annual meeting of the European VitreoRetinal Society (http://www.evrs.eu/2006‐evrs‐congress‐cannes/; accessed November 27, 2012). If future updates of this review are performed, we will consider handsearching abstracts for the following conferences when they have not been searched by Cochrane Eyes and Vision: ARVO; Macula Society; Retina Society; subspecialty meetings at the American Academy of Ophthalmology meeting; American Society of Retinal Surgeons; and European VitreoRetinal Society. </p> </section> </section> <section id="CD005139-sec-0053"> <h3 class="title" id="CD005139-sec-0053">Data collection and analysis</h3> <section id="CD005139-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently evaluated the titles and abstracts obtained through electronic searches. We classified each record as "definitely relevant," "possibly relevant," or "definitely not relevant"; a third review author resolved discrepancies. We obtained full‐text reports for all records assessed as "definitely relevant" or "possibly relevant." Two review authors independently assessed the full‐text reports and classified each study as "include," "exclude," "awaiting classification," or "ongoing"; a third review author resolved discrepancies. For trials identified by handsearching of conference abstracts, a second review author verified eligibility based on the stated criteria. We contacted study authors to clarify any details necessary for a complete assessment of relevance of the study. We documented studies excluded after review of the full‐text report and noted the reasons for exclusion. </p> </section> <section id="CD005139-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted study characteristics, including details of study methods, participants, interventions, outcomes, and funding sources, using data collection forms developed specifically for this purpose. We contacted trial authors for data on primary and secondary outcomes of individual trials when this information was not clearly available from published reports. We extracted data regarding visual acuity, adverse events, and other outcomes for the two trials forming part of the <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> study from documents available on the FDA website. We also extracted data from figures published in trial reports and communicated with study authors to verify extracted data. One review author entered data into Review Manager (<a href="./references#CD005139-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 5 2014</a>), and a second review author verified the data entered. </p> </section> <section id="CD005139-sec-0056"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors assessed potential sources of bias in trials according to methods set out in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005139-bbs2-0106" title="HigginsJP , AltmanDG , SterneJAC , editor(s) . Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We considered the following parameters: random sequence generation and method of allocation concealment before randomization (selection bias), masking of participants and researchers (performance bias), masking of outcome assessors (detection bias), rates of loss to follow‐up and non‐compliance as well as failure to include in analyses all randomized participants (attrition bias), reporting bias, and other potential sources of bias. We judged each potential source of bias as conferring low risk, unclear risk, or high risk of bias in each trial and contacted authors of trial reports for additional information when study methods needed to assess bias domains were described unclearly or were not reported. </p> </section> <section id="CD005139-sec-0057"> <h4 class="title">Measures of treatment effect</h4> <p>Data analysis was guided by Chapter 9 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD005139-bbs2-0096" title="DeeksJJ , HigginsJP , AltmanDG , editor(s) . Chapter 9. Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). The primary outcome and many secondary outcomes for this review relied on measurements of best‐corrected visual acuity (BCVA) of the study eye. We analyzed BCVA, measured on LogMAR charts, as both dichotomous and continuous outcomes. We calculated risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes. Dichotomous visual acuity outcomes included proportion of participants who gained 15 or more letters (same as a gain of three or more lines) of visual acuity; proportion of participants who lost fewer than 15 letters (fewer than three lines) of visual acuity; proportion of participants who lost fewer than 30 letters (fewer than six lines) of visual acuity; proportion of participants not blind in the study eye (defined as visual acuity better than 20/200); and proportion of participants who maintained baseline visual acuity (gain of zero or more letters) in the study eye. We calculated the mean difference (MD) between treatment groups for mean change in BCVA from baseline to follow‐up time as a continuous visual acuity outcome. </p> <p>Secondary outcomes related to visual function and morphology of CNV also included both dichotomous and continuous outcomes. We calculated risk ratios with 95% confidence intervals for dichotomous outcomes, and mean differences with 95% confidence intervals for continuous outcomes. We reported contrast sensitivity outcomes, measured by Pelli‐Robson charts, both dichotomously (proportion of participants with a gain of nine or more letters, three levels of contrast, on the chart) and continuously (mean number of letters read correctly on the chart) depending on available data. We calculated mean differences with 95% confidence intervals for near visual acuity and reading speed outcomes when sufficient data were available. </p> <p>Continuous morphologic outcomes included mean change in size of CNV, mean change in total size of the neovascular lesion, and mean change in CRT. We sought data for only one dichotomous morphologic outcome: resolution of subretinal or intraretinal fluid based on OCT evaluation. </p> <p>We analyzed quality of life scores as continuous data. Because trials that reported quality of life outcomes included in meta‐analyses used the same scale, we did not calculate standardized mean differences. </p> <p>We reported adverse events as risk ratios with 95% confidence intervals when sufficient data were available. Otherwise, we reported the numbers of participants who experienced adverse events in both narrative and tabular form. </p> </section> <section id="CD005139-sec-0058"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual (one study eye per participant).</p> </section> <section id="CD005139-sec-0059"> <h4 class="title">Dealing with missing data</h4> <p>We used multiple sources to identify relevant data for this review, such as journal publications, conference abstracts, FDA documents, and clinical trial registries. When data were unclear (e.g. numbers were extracted from graphs or were derived from percentages), we contacted study investigators for verification. When data were missing, we contacted study investigators for additional information. If we received no response within two weeks, we attempted to contact them again. When we received no response by six weeks after the first attempt, we used data as available. </p> <p>For outcome data, we used data provided in trial reports or supplied by primary investigators. We noted the number of participants with missing data and statistical methods used in individual studies to analyze data (e.g. available case analysis, last observation carried forward). We did not impute missing outcome data for our analyses. </p> </section> <section id="CD005139-sec-0060"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity based on the Chi² test, the I² statistic, and the overlap of confidence intervals in forest plots. We considered a Chi² P value &lt; 0.10 to represent significant statistical heterogeneity, and an I² statistic of 60% or more to represent substantial statistical heterogeneity. We assessed clinical and methodological heterogeneity among studies by comparing study populations, interventions, and study methods. </p> </section> <section id="CD005139-sec-0061"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed selective outcome reporting for each study by comparing outcomes specified in a protocol, research plan, or clinical trial registry with reported results. When protocols, research plans, or clinical trial registry records were not available, we assessed selective outcome reporting based on outcomes specified in the methods section of the study reports and on data collected as specified in the study design. In future updates of this review, when outcome data from 10 or more studies are included in a meta‐analysis, we will use a funnel plot to judge potential publication bias. </p> </section> <section id="CD005139-sec-0062"> <h4 class="title">Data synthesis</h4> <p>We performed statistical analyses using <a href="./references#CD005139-bbs2-0121" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 5 2014</a>. We did not combine studies in meta‐analysis when we identified clinical or methodological heterogeneity (e.g. different anti‐VEGF agents, different outcome time points); instead we analyzed data by type of anti‐VEGF agent and time point, or, when data were not sufficient for meta‐analysis, we provided a narrative summary. We used a random‐effects model for all analyses. When the I² statistic was 60% or greater, suggesting substantial statistical heterogeneity, we assessed the direction of treatment effects across studies and the overlap of confidence intervals to determine whether meta‐analysis was appropriate. We did not adjust estimates of treatment effects to account for the multiplicity of outcomes considered in this review. </p> </section> <section id="CD005139-sec-0063"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In the first published version of this review, we conducted subgroup analyses of the primary outcome, as specified in the protocol, by stratifying data according to the angiographic subtype of CNV, using definitions adopted in the included trials (<a href="./references#CD005139-bbs2-0139" title="VedulaSS , KrzystolikM . Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2] ">Vedula 2008</a>). Because we changed the primary outcome to a gain of 15 or more letters of visual acuity for later versions of the review, and because available data were insufficient, we did not conduct these subgroup analyses; if data by angiographic subtype of CNV become available for inclusion in any future update to this review, we will include these subgroup analyses. For this review update, we combined in meta‐analysis outcome data from trials that had compared any anti‐VEGF agent versus a control other than an anti‐VEGF agent; we presented the effect estimates for individual anti‐VEGF agents (pegaptanib, ranibizumab, and bevacizumab) in subgroups. </p> </section> <section id="CD005139-sec-0064"> <h4 class="title">Sensitivity analysis</h4> <p>In the first published version of this review, we conducted sensitivity analyses to examine potential bias caused by missing data for participants excluded after randomization or lost to follow‐up in analyses of the primary outcome. We analyzed the primary outcome while assuming that (1) participants lost to follow‐up had lost 15 or more letters of visual acuity (worst‐case analysis); and (2) participants lost to follow‐up did not lose 15 or more letters of visual acuity at one‐year follow‐up (best‐case analysis) (<a href="./references#CD005139-bbs2-0139" title="VedulaSS , KrzystolikM . Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2] ">Vedula 2008</a>). Because these analyses did not alter the conclusions of this review, and because studies added in subsequent updates were too small to affect estimates of effectiveness and safety, we did not conduct sensitivity analyses for this version of the review and do not believe they would be needed in a future update. </p> <p>We planned to conduct sensitivity analyses to assess the impact of studies graded as having high risk of bias on any parameter, unpublished data only, or industry funding. After assessing the studies included and the data collected, we determined that these analyses were not needed because studies within each meta‐analysis did not differ on the basis of these factors. </p> <section id="CD005139-sec-0065"> <h5 class="title">"Summary of findings"</h5> <p>We prepared "Summary of findings" tables for each comparison assessed in this review. These tables include relative and absolute effects for the following outcomes of interest at one‐year follow‐up: (1) visual acuity gain of 15 or more letters, (2) visual acuity loss of fewer than 15 letters, (3) mean change in visual acuity (number of letters), (4) reduction in central retinal thickness, (5) quality of life scores, (6) serious systemic adverse events, and (7) serious ocular adverse events. We assessed the certainty of evidence for all outcomes by using the GRADE classification system (<a href="./references#CD005139-bbs2-0103" title="GRADE Working Group, McMaster University. GRADEpro. Version accessed 11 December 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014. ">GRADEpro 2014</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005139-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005139-sec-0066"></div> <section id="CD005139-sec-0067"> <h3 class="title">Description of studies</h3> <section id="CD005139-sec-0068"> <h4 class="title">Results of the search</h4> <p>Electronic searches for the first published version of this review (conducted in August 2005, October 2006, June 2007, and February 2008) yielded a total of 1407 titles and abstracts (<a href="./references#CD005139-bbs2-0139" title="VedulaSS , KrzystolikM . Antiangiogenic therapy with anti‐vascular endothelial growth factor modalities for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005139.pub2] ">Vedula 2008</a>). We selected 36 records for full‐text review and identified five trials described in 10 reports for inclusion in the review (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0097" title="EyetechPharmaceuticals , Inc , Pfizer , Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). ">EOP 1003</a>; <a href="./references#CD005139-bbs2-0098" title="EyetechPharmaceuticals , Inc , Pfizer , Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). ">EOP 1004</a>; <a href="./references#CD005139-bbs2-0036" title="AntoszykAN , TuomiL , ChungCY , SinghA , FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age‐related macular degeneration (FOCUS): year 2 results. American Journal of Ophthalmology2008;145(5):862‐74. HeierJS , BoyerDS , CiullaTA , FerronePJ , JumberMJ , GentileRC , et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age‐related macular degeneration: year 1 results of the FOCUS study. Archives of Ophthalmology2006;124(11):1532‐42. HeierJS , FOCUS Study Group. Intravitreal ranibizumab with verteporfin photodynamic therapy for neovascular age‐related macular degeneration: year one results. Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting; 2005 July 16‐20; Montreal. 2005. ">FOCUS 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>). We excluded 16 studies (24 reports) and added two studies identified by handsearching of abstracts as awaiting classification. <a href="#CD005139-tbl-0003">Table 1</a> lists acronyms used to refer to many studies in this review. </p> <p>We identified two concurrent randomized trials that used individual participant data meta‐analyses under the acronym VISION (<a href="./references#CD005139-bbs2-0104" title="GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR , the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. ">Gragoudas 2004</a>) ‐ <a href="./references#CD005139-bbs2-0097" title="EyetechPharmaceuticals , Inc , Pfizer , Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). ">EOP 1003</a> (an international trial) and <a href="./references#CD005139-bbs2-0098" title="EyetechPharmaceuticals , Inc , Pfizer , Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). ">EOP 1004</a> (a North American trial). In the first published version of this review, we assessed the data from these two trials separately and analyzed them according to the original protocol of the review. We obtained data for primary and secondary outcomes for the two trials by accessing information available on the FDA website and by contacting study authors. For the 2014 update of this review (<a href="./references#CD005139-bbs2-0137" title="SolomonSD , LindsleyK , VedulaSS , KrzystolikMG , HawkinsBS . Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 8. [DOI: 10.1002/14651858.CD005139.pub3] ">Solomon 2014</a>), we considered the two trials as one study (<a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004)</a>, and we collected new data from published articles as available. We have summarized characteristics of the two individual trials in <a href="./appendices#CD005139-sec-0143">Appendix 8</a> and <a href="./appendices#CD005139-sec-0144">Appendix 9</a>. </p> <p>For the 2014 update, we refined the eligibility criteria to exclude studies in which researchers gave anti‐VEGF treatment in combination with other AMD treatments, and to include trials that compared two anti‐VEGF agents (i.e. head‐to‐head trials). A separate Cochrane review will cover combination therapies for AMD. Thus, in subsequent updates of the review, we did not include <a href="./references#CD005139-bbs2-0036" title="AntoszykAN , TuomiL , ChungCY , SinghA , FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age‐related macular degeneration (FOCUS): year 2 results. American Journal of Ophthalmology2008;145(5):862‐74. HeierJS , BoyerDS , CiullaTA , FerronePJ , JumberMJ , GentileRC , et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age‐related macular degeneration: year 1 results of the FOCUS study. Archives of Ophthalmology2006;124(11):1532‐42. HeierJS , FOCUS Study Group. Intravitreal ranibizumab with verteporfin photodynamic therapy for neovascular age‐related macular degeneration: year one results. Program and abstracts of the American Society of Retina Specialists 23rd Annual Meeting; 2005 July 16‐20; Montreal. 2005. ">FOCUS 2006</a>, which compared ranibizumab plus PDT versus PDT alone and was included in the first version of this review. Electronic searches in September 2008, April 2011, February 2013, and March 2014 yielded 4827 unique records from bibliographic databases, 403 clinical trial registrations, and 19 additional records identified by handsearching of conference abstracts. Of 153 reports from potentially relevant records, we included 12 RCTs (reported in 108 records) and excluded 39 studies (reported in 45 records). We excluded two additional studies from three records identified by handsearching and included the remaining 16 records identified by handsearching as additional reports on the included studies. We identified seven additional studies from the search of clinical trial registries ‐ one that was awaiting classification owing to insufficient information to determine eligibility, and six assessed as ongoing or completed with results not yet published. </p> <p>We updated the electronic searches on January 31, 2018, and identified 2737 unique records (<a href="#CD005139-fig-0001">Figure 1</a>). We excluded 2702 records after screening titles and abstracts, and 21 records after reviewing full‐text reports. Of the 35 records not excluded, four pertained to four newly included studies (<a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>), 14 were reports from studies already included, and three were from studies excluded earlier. We had classified one newly included study as ongoing in the 2014 version of this review. Two excluded studies had been labeled as ongoing in an earlier version but were terminated before enrollment (<a href="./references#CD005139-bbs2-0037" title="NCT02036723 . Multicentre double blind randomized clinical study evaluating the efficacy and safety of BCD‐021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in patients with neovascular wet age‐related macular degeneration (GALATIR). clinicaltrials.gov/show/NCT02036723 (accessed 5 February 2017). ">GALATIR 2014</a>; <a href="./references#CD005139-bbs2-0067" title="NCT01319188 . Ranibizumab for age‐related macular degeneration and the risk of arterial thromboembolic events (RATE). clinicaltrials.gov/show/NCT01319188 (accessed 5 February 2017). ">RATE 2011</a>). Overall, we identified and included 16 eligible studies and one ongoing study and excluded 65 studies after review of the full‐text reports. We have listed reasons for exclusion of each of the 65 studies in the <a href="./references#CD005139-sec-0155" title="">Characteristics of excluded studies</a> table and described the ongoing study in the <a href="./references#CD005139-sec-0156" title="">Characteristics of ongoing studies</a> section. All but one included study had been documented in a clinical trial register. </p> <div class="figure" id="CD005139-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD005139-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD005139-sec-0069"> <h4 class="title">Included studies</h4> <section id="CD005139-sec-0070"> <h5 class="title">Types of participants</h5> <p>This review included a total of 6347 participants from 16 RCTs; the number of participants per trial ranged from 23 to 1208. In 14 of 16 trials, investigators reported that they had randomized one eye per participant; this was unclear in 2 of 16 trials (<a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>). Countries in which the trials were conducted spanned the globe: two studies were international (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>); four were conducted in the United States only (<a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>), three in Austria (<a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>), two in the United Kingdom (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>), and one each in France (<a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>), India (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>), the Netherlands (<a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>), Norway (<a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>), and Switzerland (<a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>). The 16 trials were similar in that all enrolled both men and women 50 years of age or older who had subfoveal CNV secondary to AMD; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a> also enrolled participants with juxtafoveal or extrafoveal CNV. The goal of <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> was to compare the effects of anti‐VEGF agents on neovascular and non‐neovascular AMD, with random assignment of participants in each cohort to ranibizumab or bevacizumab. Among the included trials, reports describe variation in types of eligible neovascular lesions (e.g. predominantly classic CNV, minimally classic CNV, occult CNV), lesion sizes, and baseline visual acuities of participants. A majority of participants in most trials were women, but one trial enrolled a greater number of men than women (<a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>). </p> <p>All trials predefined visual acuity eligibility criteria for the study eye of each participant. Six studies specified the most common criterion: study eye BCVA of 20/40 to 20/320 (Snellen equivalent) in the study eye (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). BCVA eligibility ranges included somewhat better visual acuity in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> (20/25 to 20/320), <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> (20/32 to 20/320), <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> (20/320 or better), and <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> (20/40 to 20/320), but potentially worse visual acuity in <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> (20/40 to 20/800) and <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> (20/400 or better). In <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, participants with a BCVA between 35 and 70 Early Treatment Diabetic Retinopathy Study (ETDRS) letters were eligible, but study authors did not report the test distance. In <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>, participants with a BCVA between 20 and 78 ETDRS letters were eligible. </p> <p>Eight trials included only participants who had received no previous treatment for CNV or AMD (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>). The remaining trials included participants who had received previous therapy for AMD, with certain restrictions as to type of treatment (e.g. verteporfin PDT, intravitreal injections, surgery), location of treatment, and time interval since last treatment. Six trials enrolled participants with primary or recurrent CNV in the study eye (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>), and one enrolled only participants with primary CNV (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>). </p> <p>Among seven studies that reported the type of neovascular lesion, <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> had the highest proportion of participants with predominantly classic CNV (410/423; 97%). In <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>, 25% of 131 participants had predominantly classic CNV; the remaining 75% had minimally classic or occult CNV. In <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>, 26% of 1208 participants had predominantly classic CNV, 36% had minimally classic CNV, and 38% had occult CNV. <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> reported proportions similar to <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>, with 19% of 184 participants having predominantly classic CNV, 38% having minimally classic CNV, and 43% having occult CNV at baseline. In BRAMD 2016, 27% had predominantly classic CNV, 16% had minimally classic CNV, and 57% of 327 participants had occult CNV. Forty‐four per cent of 120 participants had occult CNV in <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>. <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> was limited to participants with minimally classic or occult CNV and, thus, included the greatest proportion of participants with occult CNV (451/716; 63%). </p> <p>Three studies that did not report neovascular lesion type described the subfoveal component of the CNV lesion in the study population. In <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> (1208 participants), 58% had CNV in the foveal center, 27% had fluid in the foveal center, 8% had hemorrhage in the foveal center, and 6% had other foveal center involvement. The distribution was similar in <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> (628 participants), in which 54% of participants had CNV in the foveal center, 29% had hemorrhage in the foveal center, and 13% had other foveal center involvement. In <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> (431 participants with data), 69% had CNV in the foveal center, 80% had fluid in the foveal center, and 20% had hemorrhage in the foveal center. The three smallest studies (<a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>), with 28, 23, and 28 participants, as well as <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> (501 participants) and <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> (321 participants), did not describe the type of neovascularization nor the subfoveal component of the CNV lesion in the study population. </p> <p>Six trials specified lesion size as an inclusion criterion. Five trials included participants with lesions of 12 disc areas (DAs) or smaller (1 DA = 2.54 mm², i.e. standard DA) (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>), and one study set four DAs as the maximum lesion size (<a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>). </p> <p>We have summarized in the <a href="./references#CD005139-sec-0154" title="">Characteristics of included studies</a> table additional details about each trial included in this review. </p> </section> <section id="CD005139-sec-0071"> <h5 class="title">Types of interventions</h5> <p>We have listed in <a href="#CD005139-tbl-0004">Table 2</a> comparisons of interventions evaluated by trials included in this review, and we summarize them here. Among the 16 included trials, we focused on two main comparisons of interventions: (1) anti‐VEGF monotherapy versus control, and (2) one anti‐VEGF monotherapy versus a different anti‐VEGF monotherapy. Of six studies that compared anti‐VEGF monotherapy versus control, one study evaluated three doses of pegaptanib versus sham injection (<a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>), three studies compared two doses of ranibizumab versus sham injections or PDT (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>), and two studies compared bevacizumab with other treatments for AMD (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>). The remaining ten studies were head‐to‐head trials of bevacizumab versus ranibizumab (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>). </p> <div class="table" id="CD005139-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Treatment groups in included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>Treatment period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention 4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pegaptanib vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> </p> <p>2 years; re‐randomized at end of first year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3 mg pegaptanib every 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0 mg pegaptanib every 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0 mg pegaptanib every 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham every 6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Ranibizumab vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> </p> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3 mg ranibizumab monthly plus sham verteporfin PDT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly plus sham verteporfin PDT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham intravitreal injection plus verteporfin PDT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> </p> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3 mg ranibizumab monthly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham intravitreal injection monthly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> </p> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3 mg ranibizumab monthly for 3 months, then every 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 3 months, then every 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham intravitreal injection monthly for 3 months, then every 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Bevacizumab vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab given first 3 injections every 6 weeks, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard therapy (0.3 mg pegaptanib every 6 weeks, verteporfin PDT, or sham injection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0 mg bevacizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verteporfin PDT plus same day 4 mg triamcinolone acetonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> </p> <p>2 years; re‐randomized at end of first year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 1 year; at 1 year, re‐randomization to ranibizumab monthly or variable dosing </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 1 year; at 1 year, re‐randomization to ranibizumab monthly or variable dosing </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab as needed after first injection for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab as needed after first injection for 2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> </p> <p>2 years; ongoing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 3 months, then as needed in 3‐month cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 3 months, then as needed in 3‐month cycles</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a><br/> 18 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a><br/> 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab; maximum of 1 injection per month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab; maximum of 1 injection per month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab; treat and extend protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab; treat and extend protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a><br/> 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab at day 1 and at week 4, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab at day 1 and at week 4, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab for 3 months, at 30‐day intervals, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab for 3 months, at 30‐day intervals, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 mL bevacizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 mL ranibizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PDT: photodynamic therapy.</p> </div> </div> <section id="CD005139-sec-0072"> <h6 class="title">Anti‐VEGF monotherapy versus control</h6> <p><a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> investigators compared sham injections versus intravitreous injections of pegaptanib at dosages of 0.3 mg, 1.0 mg, and 3.0 mg given every six weeks over a 48‐week period. </p> <p>Three trials evaluated two different doses of ranibizumab (0.3 mg and 0.5 mg) (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>). Control groups and the injection schedule for ranibizumab differed among the three trials. <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> compared monthly intravitreal injection of ranibizumab (for 12 months) with sham intravitreal injections. Participants assigned to receive sham intravitreal injections in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> were allowed verteporfin PDT whenever the CNV lesions in the eyes became predominantly classic CNV. <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> compared monthly injections of ranibizumab combined with sham PDT (for 24 months) versus verteporfin PDT and sham intravitreal ranibizumab injections. <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> compared a regimen of monthly injection of ranibizumab for three months followed by an injection every three months versus sham intravitreal injections. </p> <p>Two trials evaluated bevacizumab versus control. <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> compared a 1.25 mg dose of bevacizumab versus standard therapy, which was determined by clinical evaluation and included 0.3 mg pegaptanib, verteporfin PDT, or sham injection. <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> (a small trial) compared a 1 mg dose of bevacizumab versus verteporfin PDT combined with intravitreal triamcinolone. </p> </section> <section id="CD005139-sec-0073"> <h6 class="title">Bevacizumab versus ranibizumab</h6> <p>Ten trials compared bevacizumab for non‐inferiority versus ranibizumab. In addition to the primary comparison of the two agents, <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> compared monthly injections of anti‐VEGF agents with an "as‐needed" regimen after three initial injections of the assigned agent. <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>, <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>, and <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> used the latter treatment regimen (a 0.5 mg dose of ranibizumab and a 1.25 mg dose of bevacizumab) to compare the two anti‐VEGF agents. <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a> used a monthly injection schedule, and <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> used a "treat‐and‐extend" protocol for both drugs. In <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>, investigators did not specify the hypothesis and treated participants with an "as‐needed" regimen after three initial injections of the assigned agent. In <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>, researchers gave intravitreous injections after the initial two injections PRN for the remainder of the one‐year follow‐up period. </p> </section> </section> <section id="CD005139-sec-0074"> <h5 class="title">Types of outcome measures</h5> <section id="CD005139-sec-0075"> <h6 class="title">Visual acuity</h6> <p>BCVA formed the basis of the primary outcome for all included studies except <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>. The primary outcome for this review ‐ the proportion of participants who gained 15 or more letters of BCVA at one‐year follow‐up ‐ was the primary outcome for the <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> included study and a secondary outcome for the remaining 15 studies. The proportion of participants losing fewer than 15 letters at one year was the primary outcome for the three earliest studies (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>), and it was a secondary outcome for 11 of the remaining 13 studies. The primary outcome was mean change in visual acuity at one year for eight studies (<a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>), and the primary outcome was mean change in visual acuity at 18 months for one study (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>). Five of the remaining studies reported mean change in visual acuity as a secondary outcome. The primary outcome for <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> was best‐corrected distance visual acuity at two‐year follow‐up; we did not analyze mean BCVA (as opposed to mean change from baseline) as an outcome for this review. </p> <p>Some included studies reported other visual acuity outcomes relevant to this review. Five studies reported loss of fewer than 30 letters of visual acuity (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>); eight studies reported BCVA better than 20/200 (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>); and four studies reported maintenance of visual acuity (defined as a gain of zero or more letters) (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). Investigators in included studies reported several other visual acuity outcomes that we did not consider in this review. </p> <p>All studies measured visual acuity on a LogMAR scale, typically using ETDRS charts. Each line on the ETDRS chart consists of five letters; thus, a change of 15 letters approximates a three‐line change (0.3 LogMAR change) in visual acuity. Researchers reported the outcome for visual acuity of 20/200 or better as the Snellen equivalent. </p> </section> <section id="CD005139-sec-0076"> <h6 class="title">Visual function</h6> <p>Five studies assessed visual function outcomes. <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> specified contrast sensitivity and reading ability as secondary outcomes. <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> specified contrast sensitivity, near visual acuity, and reading index outcomes as secondary outcomes. We identified one conference abstract that reported contrast sensitivity outcomes for <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>, <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>, and <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>. </p> <p>Eleven studies did not report visual function outcomes (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). </p> </section> <section id="CD005139-sec-0077"> <h6 class="title">Morphologic outcomes</h6> <p>All studies included at least one measure related to morphologic characteristics of neovascular lesions in study eyes. In many cases, publications or conference abstracts did not provide sufficient data for informative analysis of these outcomes. When possible, we used data provided by primary investigators, or we asked primary investigators to confirm data extracted from graphs in study reports. We have not reported data derived from graphs included in study reports unless we received confirmation of the data from study investigators. </p> <p>All studies except <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> used fluorescein angiography to monitor lesion activity; that study used OCT to monitor lesion status. Six studies also used fundus photography (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>), and two studies used ICG angiography (<a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>). Six studies evaluated mean change in CNV size by fluorescein angiography (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>), and eight studies used fluorescein angiography to evaluate mean change in the size of neovascular lesions (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). </p> <p>The earliest study included in the review did not use OCT for assessment of subretinal characteristics of eyes with neovascular AMD (<a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). The next three studies, which were conducted chronologically (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>), used OCT to assess a subset of study participants. The 12 most recently reported studies used OCT for all study participants and specified at least one OCT measure as a primary or secondary outcome (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>). All studies that used OCT assessed mean change in central retinal thickness (CRT) from baseline. We considered central macular thickness, central foveal thickness, and center point thickness as interchangeable terms for CRT. </p> <p>Individual studies reported other morphologic outcomes, such as area of CNV leakage and subretinal fluid, but we did not include these outcomes in this review. </p> </section> <section id="CD005139-sec-0078"> <h6 class="title">Quality of life outcomes</h6> <p>Four studies evaluated vision‐specific quality of life using the 25‐item National Eye Institute‐Visual Functioning Questionnaire (NEI‐VFQ) (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). The NEI‐VFQ, which was administered by an interviewer, relies on patient‐reported responses to specific visual function questions to calculate overall and subscale scores, which can range from 0 to 100, with higher values representing better visual function. </p> <p>In one study (<a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>), participants completed the EuroQoL Group health‐related quality of life assessment (EQ‐5D). The EQ‐5D converts participant responses to specific health questions using scales of 1 to 3, on which 1 represents no health problems, 2 represents moderate health problems, and 3 represents extreme health problems. Investigators then summarize scores for each of the five subscale domains (mobility, self‐care, usual activities, pain/discomfort, and anxiety/depression) into a single index score ranging from ‐0.59 to 1.00, with 1.00 representing no health problems. Both the NEI‐VFQ and the EQ‐5D are validated tools that can be used to assess quality of life outcomes. </p> <p>The remaining studies either did not measure or have not reported quality of life outcomes (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>). </p> </section> <section id="CD005139-sec-0079"> <h6 class="title">Economic outcomes</h6> <p>Two studies included economic‐related outcomes as prespecified secondary outcomes. <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> evaluated annual costs associated with each treatment group. <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> evaluated cumulative resource use and costs for each treatment group. </p> </section> <section id="CD005139-sec-0080"> <h6 class="title">Adverse events</h6> <p>Seven studies reported individual ocular and non‐ocular adverse events up to one‐year follow‐up (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>), one study up to 18‐month follow‐up (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>), five studies up to five‐year follow‐up (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>), and one study up to seven‐year follow‐up (<a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a> investigators did not report ocular adverse events but reported major systemic adverse events. <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> investigators reported that there was "no serious ocular adverse event (e.g. endophthalmitis, retina detachment, and lens damage)" during the 12‐month follow‐up period. </p> </section> </section> </section> <section id="CD005139-sec-0081"> <h4 class="title">Excluded studies</h4> <p>We excluded 65 studies after completing full‐text assessments: 23 studies were not RCTs; 13 followed participants for less than one year; nine were dose‐response studies that included no control or comparator arm; six compared combination therapies in which treatment groups received the same anti‐VEGF therapy; two did not administer anti‐VEGF agents via intravitreous injection; one did not include participants with neovascular AMD; ten evaluated agents that were not eligible for this review (aflibercept, brolucizumab, and pazopanib eye drops); one did not report any outcome targeted for this review; and two potentially relevant studies were terminated before enrollment. </p> <p>See <a href="./references#CD005139-sec-0155" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD005139-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>We have provided assessments of risks of bias for each included study at the end of each respective <a href="./references#CD005139-sec-0154" title="">Characteristics of included studies</a> table. When we needed unpublished information to assess the risk of bias for any given parameter, we contacted primary investigators for additional information. We have documented these instances together with investigators' responses in the <a href="./references#CD005139-sec-0154" title="">Characteristics of included studies</a> table. <a href="#CD005139-fig-0002">Figure 2</a> summarizes "Risk of bias" assessments for all 16 studies. </p> <div class="figure" id="CD005139-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005139-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD005139-sec-0083"> <h4 class="title">Allocation</h4> <p>Overall, the included studies were at low risk of selection bias. Reports from 14 of the 16 studies described methods of random sequence generation that we judged to confer low risk of bias; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> investigators and <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> did not describe the methods used in sufficient detail for us to assess risk of bias in this domain. Six studies used dynamic randomization, the method used most commonly for random sequence generation (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). Four studies used permuted block randomization designs (<a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>), three used random number tables or lists (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>), and one reported only use of a computer‐randomized schema (<a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>). </p> <p>Investigators in 12 of the 16 trials reported adequate allocation concealment. For <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, the report was unclear as to whether the randomization sequence, determined by random numbers tables generated before study enrollment, was concealed or was made available to study investigators. <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> did not describe how assignments were allocated, and we were unable to make an assessment by using only available information. Eight studies employed a third party or a central co‐ordinating center (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>), and four studies used a computer‐based portal for allocation concealment (<a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). </p> <p>Communication with investigators from <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008,</a><a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>, and <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> yielded no additional information about methods used to assess risks of selection bias (email communication). </p> <section id="CD005139-sec-0084"> <h5 class="title">Masking (performance bias and detection bias)</h5> <p>We judged most of the included studies to be at low risk of performance bias and detection bias. Only one study was an open‐label study that employed no form of masking (<a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>). <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> initially masked participants to the drug (not to the injection protocol), but participants may have become aware of treatment assignments through billing records. <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017,</a> and <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> did not report whether study participants were masked. <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a> and <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> masked personnel and outcome assessors. The remaining 11 studies masked study participants, personnel (other than personnel directly administering treatment), and outcome assessors; thus, we assessed these studies as being at low risk of performance bias and detection bias. Investigators in studies that compared intravitreous injections versus no injections most commonly used sham injections when participants were not assigned or did not require an injection. In head‐to‐head studies of ranibizumab versus bevacizumab, researchers masked participants to their assigned treatment group. To minimize detection bias, study investigators who were involved in assessing outcomes were separate from treating physicians and were masked to treatment groups, with the exception of <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>, which provided no masking. <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> and <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> provided no information on masking of study participants, study personnel, or outcome assessors. </p> </section> </section> <section id="CD005139-sec-0085"> <h4 class="title">Incomplete outcome data</h4> <p>In all 16 trials, few participants missed the follow‐up examination specified as the primary time for assessing the study's primary outcome or were not treated in accord with the randomized treatment assignment. In nine trials, rates of loss to follow‐up at primary follow‐up visits were less than 15%; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>, <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>, <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>, <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>, <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>, and <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> had 16% to 25% of participants with missing outcome data. Losses to follow‐up were evenly balanced between treatment groups in the included studies. </p> <p>Eight trials included in this review analyzed the data using methods designed to overcome, in part, loss of information due to missed follow‐up examinations. Seven of these eight trials used the last observation carried forward method to impute missing data (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>), and the eighth trial did not report the method used to impute data for one participant with missing data (<a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>). The remaining eight trials reported available case data and included in the analysis only participants with data: 87% in <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, 91.5% in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>, 81% in <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>, 89% in <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>, 84% in <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>, 81% in <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>, 83% in <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014,</a> and 79% in <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>. Investigators in all trials reported that they had analyzed data for participants by assigned treatment arms. Analyses using simple imputation methods or available case data assume that participants are lost to follow‐up at random; bias may be introduced when this assumption is not true, with greater risk of bias associated with higher rates of missing data. </p> </section> <section id="CD005139-sec-0086"> <h4 class="title">Selective reporting</h4> <p>With the exception of <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, we identified design articles, protocols, or clinical trial registrations for 15 of the included studies. We judged 11 of these 15 trials to be free of reporting bias on the basis of consistency between study outcomes defined in protocols and clinical trial registrations and those reported in study results papers. Researchers did not specify quality of life outcomes, and we identified no report on quality of life findings from <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>. We found no data on reading ability outcomes, which <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> specified as secondary outcomes. Published articles on one‐year and two‐year results did not report findings for three outcomes specified in the protocol for <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>: treatment satisfaction, survival free from treatment failure, and exploratory (serum) analysis. Differences in outcomes between trial registration and published one‐year results of <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> included the following: differences in details of outcome specifications (e.g. efficacy of treatments vs proportion of participants with a gain of 15 or more letters of visual acuity); outcomes specified in the trial register but not reported in publications; and an outcome that was not mentioned in the trial registration document. </p> </section> <section id="CD005139-sec-0087"> <h4 class="title">Other potential sources of bias</h4> <p>We considered various other aspects of trial design and reporting, trial sponsorship, and financial interests of investigators as other potential sources of bias. </p> <p>Pharmaceutical companies marketing the study drugs under investigation sponsored <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>, <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>, <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>, and <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>, and submitted data from these trials to the FDA to obtain approval for ranibizumab and pegaptanib. In addition, pharmaceutical company sponsors had important roles in trial design, analysis, and reporting. Some investigators from other trials reported that they received trial agents or financial support from pharmaceutical companies; however, because the companies did not directly sponsor these trials, we did not judge them to be at risk of bias for this domain (<a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>). We observed no other potential sources of bias for the remaining eight studies. </p> </section> </section> <section id="CD005139-sec-0088"> <h3 class="title" id="CD005139-sec-0088">Effects of interventions</h3> <p>See: <a href="./full#CD005139-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: anti‐VEGF treatment versus control</a>; <a href="./full#CD005139-tbl-0002"><b>Summary of findings 2</b> Summary of findings: bevacizumab versus ranibizumab</a> </p> <p>We conducted meta‐analyses of results through comparisons of treatments by combining different doses and regimens of the same drug evaluated in individual trials (<a href="#CD005139-tbl-0004">Table 2</a>). Forest plots presented in this review for visual acuity outcomes show that effect estimates to the right of the vertical line of the forest plots (i.e. risk ratios &gt; 1 and mean differences &gt; 0) favor the test treatment defined for the comparison. </p> <section id="CD005139-sec-0089"> <h4 class="title">Anti‐VEGF monotherapy versus control</h4> <p>Six studies that had enrolled 2690 participants compared an anti‐VEGF monotherapy versus no anti‐VEGF treatment. Overall, we rated the risk of bias as low among the six studies. Pharmaceutical companies funded four studies (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). All six studies followed participants for at least one year after enrollment. </p> <p>One study, comprising two individual RCTs, compared three doses of intravitreal pegaptanib (0.3 mg, 1.0 mg, and 3.0 mg) versus a sham injection control (<a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). The study, which was conducted at 117 international centers, enrolled 1208 adult participants (50 years of age or older) with subfoveal CNV lesions secondary to AMD. The pegaptanib groups included 904 participants, and the sham injection group included 304. At one‐year follow‐up, follow‐up analyses included 1186 (98%) participants, and investigators re‐randomized according to their original treatment assignment 1053 (87%) who remained in the study. Researchers re‐randomized participants in the pegaptanib groups to continue current treatment or to discontinue treatment and participants in the sham group to continue with sham injections, discontinue sham injections, or receive one of the three study doses of pegaptanib. Study follow‐up continued for one year after re‐randomization, and study authors analyzed participants in three cohorts: those who continued with their original assignments, those who discontinued treatment, and those who received sham injections during the first year then pegaptanib during the second year. In total, two‐year analysis included 1053 (87%) participants; however, we could not analyze the two‐year data because they reflect changes from year 1 to year 2 rather than from baseline to year 2. </p> <p>Three studies comprising a total of 1323 participants compared two doses of intravitreal ranibizumab (0.3 mg and 0.5 mg) versus sham or control treatment. In <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>, 280 participants received ranibizumab and 143 received verteporfin PDT therapy. Study personnel administered injections monthly and administered verteporfin PDT therapy on day 0 and as needed at visits at months 3, 6, 9, and 12. In <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>, 478 participants received ranibizumab and 238 received sham injections, all of which were administered on a monthly basis. In <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>, 121 participants received ranibizumab and 63 received sham injections monthly for the first three months, then every three months. During the second year of <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>, participants in the 0.3 mg ranibizumab and sham‐treated groups crossed over to receive 0.5 mg ranibizumab. At one‐year follow up, investigators excluded from analyses two participants ‐ one in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> and one in <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>. Analysis included remaining study participants, and researchers imputed missing data by using the last observation carried forward method. </p> <p>Two studies of 159 total participants compared intravitreal bevacizumab injections with control treatment. In <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>, 131 participants received 1.25 mg intravitreal bevacizumab (65 participants) or standard therapy consisting of pegaptanib injections (38 participants), verteporfin PDT (16 participants), or sham injections (12 participants). In <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>, 28 participants received 1.0 mg intravitreal bevacizumab (14 participants) or verteporfin PDT with 4 mg intravitreal triamcinolone acetonide (14 participants). In both studies, investigators administered intravitreal bevacizumab as needed after the first three scheduled injections. </p> <section id="CD005139-sec-0090"> <h5 class="title">(1) Visual acuity</h5> <section id="CD005139-sec-0091"> <h6 class="title">(a) Gain of 15 or more letters of visual acuity</h6> <p>At one year, more participants in the anti‐VEGF group than in the control group had a gain of 15 or more letters of visual acuity. The risk ratio for combined anti‐VEGF versus control groups was 4.19 (95% CI 2.32 to 7.55), that is, eyes treated with an anti‐VEGF agent 4 times as often gained 15 or more letters of vision than control eyes. Assessment of effect by type of anti‐VEGF agent revealed that the direction of effect consistently favored anti‐VEGF treatment (<a href="./references#CD005139-fig-0007" title="">Analysis 1.1</a>; <a href="#CD005139-fig-0003">Figure 3</a>). We graded the certainty of evidence for the outcome as moderate, after downgrading for imprecision (‐1). </p> <div class="figure" id="CD005139-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.1 Gain of 15 or more letters visual acuity at 1 year." data-id="CD005139-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.1 Gain of 15 or more letters visual acuity at 1 year. </p> </div> </div> </div> <p>At two years, data were available from only the three ranibizumab trials. The proportion of participants who were treated with ranibizumab and had gained 15 or more letters at two years was nearly six times the proportion of those treated with control who gained 15 or more letters (RR 5.77, 95% CI 3.38 to 9.84; <a href="./references#CD005139-fig-0008" title="">Analysis 1.2</a>; <a href="#CD005139-fig-0004">Figure 4</a>). We graded the certainty of evidence for the two‐year outcome also as moderate, again downgrading for imprecision (‐1). </p> <div class="figure" id="CD005139-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.2 Gain of 15 or more letters visual acuity at 2 years." data-id="CD005139-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.2 Gain of 15 or more letters visual acuity at 2 years. </p> </div> </div> </div> </section> <section id="CD005139-sec-0092"> <h6 class="title">(b) Loss of fewer than 15 letters of visual acuity</h6> <p>At one year, a greater proportion of participants treated with an anti‐VEGF agent lost fewer than 15 letters of visual acuity in the study eye compared with those treated with control. Participants were estimated to be 1.40 times more likely not to lose 15 or more letters of visual acuity when treated with an anti‐VEGF agent than with sham or control therapy (RR 1.40, 95% CI 1.27 to 1.55; <a href="./references#CD005139-fig-0009" title="">Analysis 1.3</a>). Although we observed statistical heterogeneity among the trials (I² = 62%), effect estimates of individual trials were in the same direction, and confidence intervals of individual trials overlapped one another. We graded the certainty of evidence for this outcome as high, upon finding no reason to downgrade. </p> <p>At two years, data were available for only the three ranibizumab trials. The beneficial effect of ranibizumab for this outcome persisted at a similar magnitude when compared with control therapy. Sixty per cent more participants treated with ranibizumab lost fewer than 15 letters of visual acuity at two‐year follow‐up as participants in control groups (RR 1.62, 95% CI 1.32 to 1.98; <a href="./references#CD005139-fig-0010" title="">Analysis 1.4</a>). We observed substantial statistical heterogeneity in the analysis comparing ranibizumab with control (I² = 78%; P value for Chi² test of homogeneity = 0.01); however, confidence intervals among individual studies overlapped, and effect estimates were in the same direction. Heterogeneity may have been attributable to the fact that the control group in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> received an active treatment (verteporfin PDT therapy) but control eyes in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> and <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> received sham injections. We graded the certainty of evidence for this outcome as high, as we found no reason to downgrade. </p> </section> <section id="CD005139-sec-0093"> <h6 class="title">(c) Loss of fewer than 30 letters of visual acuity</h6> <p>At one year, four trials reported this outcome (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>), and two trials did not report this outcome (<a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>). The risk ratio for combined anti‐VEGF groups versus the control group was 1.12 (95% CI 1.06 to 1.19), indicating that 12% (95% CI 6% to 19%) fewer eyes treated with an anti‐VEGF agent than eyes treated with control lost 30 or more letters of visual acuity (<a href="./references#CD005139-fig-0011" title="">Analysis 1.5</a>). Estimates from the included studies revealed statistical heterogeneity (I² = 73%); however, effect estimates of individual trials showed the same direction, and confidence intervals of individual trials overlapped one another, except for <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>. We graded the certainty of evidence for this outcome as high, with no reason to downgrade. </p> <p>The ranibizumab treatment effect for this outcome persisted through two years, and fewer participants treated with ranibizumab in two trials lost 30 or more letters (16/757; 2%) than participants given control treatment (77/381; 20%). When comparing ranibizumab groups versus controls, we estimated a 22% benefit of ranibizumab with respect to loss of fewer than 30 letters of visual acuity after two years (RR 1.22, 95% CI 1.15 to 1.29; <a href="./references#CD005139-fig-0012" title="">Analysis 1.6</a>). We graded the certainty of evidence for this outcome as high, upon finding no reason to downgrade. No study reported this outcome for two years for bevacizumab or pegaptanib. </p> </section> <section id="CD005139-sec-0094"> <h6 class="title">(d) Prevention of blindness in the study eye (visual acuity better than 20/200)</h6> <p>At one year, four trials reported this outcome (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). Treatment with pegaptanib or ranibizumab resulted in fewer blind study eyes at one‐year follow‐up; the summary effect estimate (risk ratio) for visual acuity better than 20/200 was 1.58 (95% CI 1.34 to 1.86) for the two anti‐VEGF agents compared with control (<a href="./references#CD005139-fig-0013" title="">Analysis 1.7</a>). Although point estimates and confidence intervals of individual studies showed some degree of overlap, we noted a substantial amount of statistical heterogeneity for this outcome (I² = 73%). Neither bevacizumab trial reported data sufficient for analysis; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> did not report blindness, and authors of the <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> trial reports noted that more participants in the bevacizumab group than in the control group had visual acuity of 20/200 or better at one year. At two years, based on comparison of the combined ranibizumab groups with control intervention groups, we again estimated that a substantially greater proportion of study eyes of participants in the ranibizumab groups had visual acuity better than 20/200 than those in the control group (RR 1.73, 95% CI 1.52 to 1.98; <a href="./references#CD005139-fig-0014" title="">Analysis 1.8</a>). We graded the certainty of evidence for this outcome as high both at one year and at two years, finding no reason to downgrade. </p> </section> <section id="CD005139-sec-0095"> <h6 class="title">(e) Maintenance of visual acuity</h6> <p>At one year, data on maintenance of visual acuity were available from only three trials that had compared anti‐VEGF treatment with a control intervention (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>); three trials did not report this outcome (<a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>). Twice as many participants treated with an anti‐VEGF agent maintained visual acuity in the study eye (i.e. visual acuity at follow‐up was the same as or better than at baseline) compared with participants in the control group; the risk ratio was 1.98 (95% CI 1.31 to 3.00; <a href="./references#CD005139-fig-0015" title="">Analysis 1.9</a>). At two years, the corresponding effect estimate from <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> was 2.71 (95% CI 2.08 to 3.54; <a href="./references#CD005139-fig-0016" title="">Analysis 1.10</a>). We graded the certainty of evidence for this outcome at both time points as high, upon finding no reason to downgrade. </p> </section> <section id="CD005139-sec-0096"> <h6 class="title">(f) Mean change in visual acuity</h6> <p>At one year, data for mean change in visual acuity from baseline were available for analysis from four trials that had compared anti‐VEGF treatment with a control intervention (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>; <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>). Owing to significant heterogeneity (I² = 98%), we did not pool data from pegaptanib and ranibizumab trials. The mean difference in mean change in visual acuity from baseline between the pegaptanib group and the sham group was 6.7 letters (95% CI 4.4 to 9.0) when measured on an ETDRS chart placed at 2 meters; thus, eyes treated with pegaptanib lost on average 6.7 letters fewer than sham‐treated eyes (<a href="./references#CD005139-fig-0017" title="">Analysis 1.11</a>). On the logMAR scale, 0.10 logMAR unit corresponds to one line (five letters) on the visual acuity chart. Thus, the mean difference between pegaptanib and sham groups was equivalent to 0.13 logMAR units, that is, the mean change in visual acuity was better in the pegaptanib groups than in the sham group by 0.13 logMAR unit. At one year, participants treated with ranibizumab also read more letters on ETDRS charts placed at 4 m than participants treated with control. Participants treated with ranibizumab were able to read 18 more letters at one‐year follow‐up (mean difference [MD] 17.8, 95% CI 16.0 to 19.6; <a href="./references#CD005139-fig-0017" title="">Analysis 1.11</a>). Available data from the bevacizumab studies were insufficient for analysis of the difference in mean changes in visual acuity between treatment groups. In <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>, the mean change from baseline in visual acuity was 7.0 letters in the bevacizumab group and ‐9.4 letters in the control group at one‐year follow‐up. This equates to a mean difference of 16.4 letters (more than three lines of visual acuity); however, we were unable to compute the standard error (SE) of the mean using the information available. <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> reported a statistically significant difference between groups at one year, when participants in the bevacizumab group had gained eight letters on average and participants in the control group had lost three letters on average. We graded the certainty of evidence for this outcome as moderate, after downgrading for inconsistency (‐1). </p> <p>At two years, participants treated with ranibizumab were able to read 20 more letters (0.4 logMAR unit) compared with participants given control treatment (MD 20.1, 95% CI 18.1 to 22.2; <a href="./references#CD005139-fig-0018" title="">Analysis 1.12</a>). We graded the certainty of evidence for this outcome as high, finding no reason to downgrade. </p> </section> </section> <section id="CD005139-sec-0097"> <h5 class="title">(2) Visual function</h5> <p><a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> and <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> did not report visual function outcomes. The ranibizumab trials did not specify visual function outcomes as outcomes of interest (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>); however, we identified one conference abstract that discussed contrast sensitivity outcomes among participants from these trials (see Korobelnik 2006 under <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>). Investigators reported no between‐group comparisons for contrast sensitivity as measured by Pelli‐Robson charts, but the abstract author reported that participants in the ranibizumab groups had statistically significant increases of two to four letters (i.e. approximately one contrast level) after one year. Participants in the control groups lost an average of three letters (i.e. one contrast level) at one year. The mean difference when ranibizumab was compared with control was six letters (i.e. two contrast levels on the Pelli‐Robson chart), as determined on the basis of data extracted from the abstract. </p> <p><a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> reported outcomes for contrast sensitivity measured with Pelli‐Robson charts. At one year, the difference observed between bevacizumab and control groups in terms of a gain of 15 or more letters (i.e. five levels of contrast) of contrast sensitivity was uncertain (RR 2.03, 95% CI 0.39 to 10.71); however, a greater proportion of participants in the bevacizumab group (23/65) compared with the control group (10/66) gained six or more letters (i.e. two levels of contrast) of contrast sensitivity (RR 2.34, 95% CI 1.21 to 4.51). Also, five times as many participants in the control group lost six or more letters (two contrast levels) of contrast sensitivity compared with participants in the bevacizumab group (RR 0.22, 95% CI 0.07 to 0.72). We graded the certainty of evidence for visual function as low, after downgrading for imprecision (‐1) and inconsistency (‐1). Although the published protocol for <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> also listed reading ability (including maximum reading speed, critical print size, and reading acuity) measured with Minnesota Reading Charts as a secondary outcome for the study, we found no report of results for this outcome. </p> </section> <section id="CD005139-sec-0098"> <h5 class="title">(3) Morphologic outcomes</h5> <section id="CD005139-sec-0099"> <h6 class="title">(a) Mean change in size of CNV</h6> <p>Available information was insufficient for analysis of the mean change in size of CNV in <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>; however, study investigators provided data that allowed us to evaluate mean CNV size at one‐year follow‐up. Given that baseline CNV sizes were comparable among all study participants, the difference in mean size of CNV between study groups at one year was used to estimate the treatment effect. Researchers measured total CNV sizes as numbers of standard disc areas (DAs). Pegaptanib treatment, across all doses studied, resulted in a lower final mean CNV size compared with that of the sham group at the one‐year follow‐up examination (MD 0.92 DAs, 95% CI 0.42 to 1.42; <a href="./references#CD005139-fig-0019" title="">Analysis 1.13</a>). We considered a difference in the size of CNV of one or more DAs as a clinically meaningful difference. We graded the certainty of evidence for this outcome as moderate, after downgrading for imprecision (‐1). </p> <p><a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> reported the median change in the size of CNV. At 54 weeks, the size of CNV regressed by 0.88 mm² (interquartile range [IQR], reduction of 4.08 mm² to increase of 0.40 mm²) in the bevacizumab‐treated group compared with 0.27 mm² (IQR, reduction of 2.58 mm² to increase of 1.24 mm²) in the control group. </p> <p>We were unable to identify and extract any data on mean change in size of the CNV from any of the three included trials comparing ranibizumab with control interventions (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006,</a><a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006,</a><a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>), and from one of the trials comparing bevacizumab with control interventions (<a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>). </p> </section> <section id="CD005139-sec-0100"> <h6 class="title">(b) Mean change in size of lesion</h6> <p>Available information was insufficient to estimate mean change in size of the total subfoveal lesion with pegaptanib; however, study investigators provided data that allowed us to analyze mean size of the lesion at one‐year follow‐up. Pegaptanib treatment resulted in smaller mean lesion size at one‐year follow‐up compared with sham treatment (MD 0.86 DAs, 95% CI 0.35 to 1.37; <a href="./references#CD005139-fig-0020" title="">Analysis 1.14</a>). We graded the certainty of evidence for this outcome as moderate, after downgrading for imprecision (‐1). </p> <p>Data for the mean change in size of the total subfoveal lesion were available from two of the three included trials that had compared ranibizumab with control interventions (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>). The mean reduction in lesion size was greater by 2.34 DAs (95% CI 1.88 to 2.81) among participants treated with ranibizumab compared with participants treated with control interventions after one year (<a href="./references#CD005139-fig-0021" title="">Analysis 1.15</a>). At two years, this effect persisted in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> (MD 2.44, 95% CI 1.87 to 3.00) but not in <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> (MD 0.59, 95% CI ‐0.55 to 1.73; <a href="./references#CD005139-fig-0022" title="">Analysis 1.16</a>). Owing to substantial statistical heterogeneity (I² = 88%) and differences between control groups in the two trials during the second year of follow‐up, we did not combine these study findings in a meta‐analysis. We graded the certainty of evidence for the outcome as moderate, after downgrading for inconsistency (‐1). </p> <p><a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> reported median change in subfoveal lesion size. At 54 weeks, the size of the total subfoveal lesion regressed by 0.03 mm² (IQR, reduction of 1.88 mm² to increase of 2.63 mm²) in the bevacizumab‐treated group and increased by 2.33 mm² (IQR, reduction of 0.06 mm² to increase of 6.44 mm²) in the control group. </p> <p><a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> and <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> did not report this outcome. </p> </section> <section id="CD005139-sec-0101"> <h6 class="title">(c) Mean change in CRT</h6> <p><a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> did not use OCT and did not measure CRT outcomes. We were unable to find data on CRT in reports from any of the three included trials that had compared ranibizumab with control interventions (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>). </p> <p>In <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>, the mean change in CRT after 54 weeks was ‐91 μm in the bevacizumab group and ‐55 μm in the control group (P = 0.08). In <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>, the mean change in CRT by 12 months was ‐113 μm in the bevacizumab group and ‐72 μm in the control group (P = 0.8; analysis of variance [ANOVA]). Investigators reported no measures of variability for these outcomes, precluding meta‐analysis. </p> </section> </section> <section id="CD005139-sec-0102"> <h5 class="title">(4) Quality of life outcomes</h5> <p>One of the two trials from <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> (<a href="./references#CD005139-bbs2-0098" title="EyetechPharmaceuticals , Inc , Pfizer , Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration; and FDA. Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). ">EOP 1004</a>) and the three ranibizumab trials measured vision‐related quality of life using the NEI‐VFQ questionnaire (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>). Two trials provided sufficient data for inclusion in a meta‐analysis (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>). Investigators in both studies considered a 10‐point change in scores as clinically meaningful. We did not extract the limited data available from <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> because investigators presented data in the full‐text articles only as graphs, and information provided in the conference abstracts was insufficient for inclusion in our analysis. Correspondence with trial investigators yielded no additional data. <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> reported that treatment with pegaptanib was associated with better scores on the NEI‐VFQ questionnaire, specifically for distance vision and role limitation domains. However, investigators did not report standard deviations for scores; thus we could not include these data in our meta‐analysis. </p> <p>At one year, overall vision‐related quality of life improved more often among participants in ranibizumab groups than among those in control groups (MD 6.7, 95% CI 3.4 to 10.0). The mean difference was greater in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> (MD 8.2, 95% CI 6.0 to 10.4) than in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> (MD 4.8, 95% CI 1.7 to 7.9). This difference between the two trials may have occurred because participants in the control group in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> received an active treatment (verteporfin PDT therapy). Three subscale domains of the NEI‐VFQ questionnaire in which participants in ranibizumab groups showed approximately a 10‐point greater improvement at one‐year follow‐up compared with participants in control groups were distance vision activities, vision‐related dependency, and driving ability (<a href="./references#CD005139-fig-0023" title="">Analysis 1.17</a>). The I² statistic for subscale analyses ranged from 0 to 91%, possibly due to different effects among control groups. We graded the certainty of evidence for quality of life outcomes at one year as moderate, after downgrading for imprecision (‐1). </p> <p>At two years, overall vision‐related quality of life improved more often among participants in ranibizumab groups than among those in control groups (MD 8.6, 95% CI 3.3 to 14.0). Similar to one‐year results, the mean difference was greater in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> (MD 11.2, 95% CI 8.8 to 13.5) than in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> (MD 5.7, 95% CI 2.0 to 9.4). Subscale domains of the NEI‐VFQ questionnaire in which participants in ranibizumab groups showed greater improvement at two‐year follow‐up compared with those in control groups were consistent with those identified at one year (<a href="./references#CD005139-fig-0024" title="">Analysis 1.18</a>). The I² statistic for subscale analyses ranged from 0 to 87%, reflecting greater comparative differences between treatment and sham control groups in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> than between treatment and active control groups in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>. For six subscales, mean differences differed by approximately 10 or more points between ranibizumab and control groups: near vision activities, distance vision activities, vision‐related dependency, driving ability, mental health, and general vision (<a href="./references#CD005139-fig-0024" title="">Analysis 1.18</a>). We graded the certainty of evidence for quality of life outcomes at two years as moderate, after downgrading for imprecision (‐1). </p> <p><a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> and <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> did not assess quality of life outcomes. </p> </section> <section id="CD005139-sec-0103"> <h5 class="title">(5) Economic outcomes</h5> <p>We found no report of economic outcomes from <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a>, <a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a>, or <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a>. We found no data on economic outcomes when <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>, <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>, and <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> directly compared ranibizumab with controls. Data from <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> yielded estimates of the cost of treatment with ranibizumab at USD 27,004 for the first year and USD 26,417 for the second year; investigators did not report data for the control group (<a href="./references#CD005139-bbs2-0088" title="BrownMM , BrownGC , BrownHC , PeetJ . A value‐based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology2008;115(6):1039‐45. ">Brown 2008</a>). </p> </section> <section id="CD005139-sec-0104"> <h5 class="title">(6) Adverse events</h5> <p>We have reported adverse events separately by type of anti‐VEGF agent because investigators of different trials reported different types of adverse events. </p> <section id="CD005139-sec-0105"> <h6 class="title">(a) Pegaptanib versus control</h6> <p><a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> reported ocular and systemic adverse events. Participants in the pegaptanib groups experienced an ocular adverse event nearly four times as often (RR 3.84, 95% CI 0.91 to 16.20) and were estimated to be 1.25 times as likely to have a serious systemic adverse event (RR 1.25, 95% CI 0.93 to 1.70) as participants in the control group. We have presented results for the most frequent adverse events in <a href="#CD005139-tbl-0005">Table 3</a>. Although uncommon, 12 eyes treated with pegaptanib injections for one year developed endophthalmitis compared with no cases in control eyes. Because of the small number of events, risk estimates for individual adverse events are imprecise. We graded the certainty of evidence for ocular and systemic adverse events as moderate, after downgrading for imprecision (‐1). </p> <div class="table" id="CD005139-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events up to 1 year: pegaptanib versus control</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg pegaptanib<br/> n = 295</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.0 mg pegaptanib<br/> n = 301</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.0 mg pegaptanib<br/> n = 296</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses pegaptanib<br/> n = 892</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 298</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any eye disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.84 [0.91 to 16.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.37 [0.50 to 140.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.68 [0.20 to 66.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.68 [0.20 to 66.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 [0.08 to 34.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitreous hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.04 to 24.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.04 to 24.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated intraocular pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.04 to 24.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Papilledema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 [0.00 to 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg pegaptanib<br/> n = 295</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.0 mg pegaptanib<br/> n = 301</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.0 mg pegaptanib<br/> n = 296</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses pegaptanib<br/> n = 892</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 298</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 1 serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 (22%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 [0.93 to 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 [0.31 to 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoplasms (benign, malignant, unspecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 [0.37 to 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Injury and procedural complications, such as fractures (also includes traumatic cataracts)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.01 [0.92 to 9.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 [0.52 to 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infections and infestations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 [0.51 to 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 [0.39 to 3.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory, thoracic, mediastinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.33 to 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Musculoskeletal and connective tissue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 [0.33 to 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal and urinary disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 [0.20 to 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 [0.20 to 3.00]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> <p>RR: risk ratio.</p> <p><sup>a</sup>Most frequent serious adverse events experienced by 1190 participants in the <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> study. </p> </div> </div> </section> <section id="CD005139-sec-0106"> <h6 class="title">(b) Ranibizumab versus control</h6> <p>Of the three ranibizumab trials (<a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>), <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> and <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> reported ocular and systemic adverse events at one‐year follow‐up (<a href="#CD005139-tbl-0006">Table 4</a>), and all three studies at two‐year follow up (<a href="#CD005139-tbl-0007">Table 5</a>). At both one‐year and two‐year follow‐up, small numbers of participants had experienced ocular adverse events, such as endophthalmitis, uveitis, retinal detachment, and retinal or vitreous hemorrhage, and non‐ocular adverse events, such as myocardial infarction, stroke or cerebral infarction, ischemic cardiomyopathy, and death (&lt; 1% of total participants). Because of the small number of events, risk estimates for these adverse events are imprecise. </p> <div class="table" id="CD005139-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events up to 1 year: ranibizumab versus control</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg ranibizumab<br/> n = 196</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.5 mg ranibizumab<br/> n = 201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses ranibizumab<br/> n = 397</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 206</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.60 [0.13 to 53.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 [0.03 to 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 [0.83 to 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 [0.07 to 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitreous hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 [0.06 to 38.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 [0.06 to 38.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated intraocular pressure (≥ 30 mmHg increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22 [0.99 to 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ocular inflammation (trace to 4+)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.71 [1.36 to 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg ranibizumab<br/> n = 196</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.5 mg ranibizumab<br/> n = 201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses ranibizumab<br/> n = 397</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 206</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 [0.25 to 6.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.08 [0.23 to 18.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke or cerebral infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 [0.09 to 11.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ischemic cardiomyopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 [0.01 to 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment‐emergent hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 [0.36 to 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐ocular hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.90 [0.78 to 4.62]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> <p>RR: risk ratio.</p> <p><sup>a</sup>Adverse events experienced by 420 participants in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> and by 183 participants in <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>. Adverse events at 1‐year follow‐up not reported in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>. </p> </div> </div> <div class="table" id="CD005139-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events up to 2 years: ranibizumab versus control</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg ranibizumab<br/> n = 434</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.5 mg ranibizumab<br/> n = 440</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses ranibizumab<br/> n = 874</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 441</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.59 [0.50 to 148.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 [0.07 to 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 [0.94 to 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 [0.03 to 8.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitreous hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 [0.19 to 5.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.58 [0.43 to 132.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated intraocular pressure (≥ 30 mmHg increase)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106 (18%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.81 [2.63 to 8.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ocular inflammation (1+ to 4+)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.91 [1.89 to 8.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg ranibizumab<br/> n = 434</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.5 mg ranibizumab<br/> n = 440</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses ranibizumab<br/> n = 874</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 441</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 [0.41 to 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 [0.44 to 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke or cerebral infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 [0.43 to 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ischemic cardiomyopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 [0.01 to 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment‐emergent hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (14%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 [0.73 to 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐ocular hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 [1.05 to 2.55]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> <p>RR: risk ratio.</p> <p><sup>a</sup>Adverse events experienced by 420 participants in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; 713 participants in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; and 182 participants in <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>.<br/> <sup>b</sup>Adverse events for elevated intraocular pressure not reported in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> at 2‐year follow‐up (n = 297 in 0.3 mg ranibizumab group, n = 300 in 0.5 mg ranibizumab group, and n = 298 in 0.3 mg control group). </p> </div> </div> <p>With respect to ocular adverse events, cataract developed in study eyes treated with ranibizumab more often than in eyes treated with control at both one‐year (RR 1.48, 95% CI 0.83 to 2.66) and two‐year follow‐up (RR 1.25, 95% CI 0.94 to 1.66). Elevated intraocular pressure (IOP), defined as an increase of 30 mmHg or more, was observed more often in eyes in the ranibizumab groups than in eyes in the control groups by both one‐year (RR 2.22, 95% CI 0.99 to 4.98) and two‐year follow‐up (RR 4.81, 95% CI 2.63 to 8.81). Ocular inflammation, graded from trace (1+) to 4+, also occurred more often in eyes in the ranibizumab groups than in eyes in the control groups at both one‐year (RR 2.71, 95% CI 1.36 to 5.42) and two‐year follow‐up (RR 3.91, 95% CI 1.89 to 8.09). Two eyes during the first year of ranibizumab injections and six more eyes during the second year developed endophthalmitis compared with no cases in control eyes. We graded the certainty of evidence for ocular adverse events as moderate, after downgrading, because not all eligible trials reported all types of adverse events and because numbers were small (&lt; 1%) for many specific adverse events (‐1). </p> <p>With respect to non‐ocular adverse events, participants in ranibizumab groups less often experienced treatment‐emergent hypertension than participants in control groups at one‐year follow‐up (RR 0.67, 95% CI 0.36 to 1.24); however, at two‐year follow‐up, risk was similar in the ranibizumab and control groups (RR 0.96, 95% CI 0.73 to 1.25). Non‐ocular hemorrhage occurred more often among participants in ranibizumab groups than among those in control groups at both one‐year (RR 1.90, 95% CI 0.78 to 4.62) and two‐year follow‐up (RR 1.64, 95% CI 1.05 to 2.55). We graded the certainty of evidence for systemic adverse events as moderate, after downgrading, because not all eligible trials reported all types of adverse events and because numbers were small (&lt; 1%) for many specific adverse events (‐1). </p> </section> <section id="CD005139-sec-0107"> <h6 class="title">(c) Bevacizumab versus control</h6> <p><a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> reported serious ocular and non‐ocular adverse events among 65 bevacizumab‐treated participants and 66 control participants. Serious ocular events that affected at least one study participant included uveitis (two bevacizumab participants; one control participant), rhegmatogenous retinal detachment (no bevacizumab participant; one control participant), vitreous hemorrhage (one bevacizumab participant; no control participant), and ocular inflammation (eight bevacizumab participants; four control participants). Investigators reported no instances of presumed endophthalmitis, retinal tear, or lens damage in either group. Three participants experienced a non‐ocular adverse event: myocardial infarction (bevacizumab group), death due to vascular cause (bevacizumab group), or non‐ocular hemorrhage reported as serious (control group). </p> <p><a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> reported no occurrence of severe ocular or systemic events during the study period. We graded the certainty of evidence for ocular and systemic adverse events for bevacizumab as low; we downgraded for imprecision (‐2). </p> </section> </section> </section> <section id="CD005139-sec-0108"> <h4 class="title">Bevacizumab versus ranibizumab</h4> <p>Ten trials directly compared intravitreous injections of bevacizumab with ranibizumab. These studies included a total of 3657 participants. The largest study randomized 1208 participants in a 2 × 2 factorial design (two drugs administered in two injection schedules) to receive 1.25 mg intravitreal bevacizumab or 0.5 mg intravitreal ranibizumab on a monthly or as‐needed basis (<a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>). Participants in the as‐needed injection groups received the first three injections monthly, followed by an injection whenever treatment was needed, as determined by monthly examinations. After one year of treatment, participants in the groups treated monthly were re‐randomized to continue treatment on a monthly basis or to change to treatment as needed. Participants in the as‐needed groups remained on their original assignments, and all participants were followed for another year. <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>, with 628 participants, included four treatment groups similar to those in the CATT study: 1.25 mg intravitreously injected bevacizumab monthly, 0.5 mg intravitreously injected ranibizumab monthly, 1.25 mg intravitreously injected bevacizumab as needed, and 0.5 mg intravitreously injected ranibizumab as needed. Participants in as‐needed dosing groups received the first three injections monthly, followed by three consecutive monthly treatments whenever treatment was needed. The treatment period lasted two years. Six of the eight smaller studies randomized participants to receive 1.25 mg intravitreal bevacizumab or 0.5 mg intravitreal ranibizumab on a monthly basis (<a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>), or on an as‐needed basis (<a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>), for one year or 18 months (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>). We combined 18‐month data from <a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a> with 12‐month data from the other trials. Two small studies randomized participants to an as‐needed treatment regimen following two and three injections, respectively, given at monthly intervals (<a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>). </p> <p>For data analyses in this section, we combined groups given the same drug type regardless of injection regimen. Thus the bevacizumab and ranibizumab groups included both monthly and as‐needed injection schedules. Risk of bias in most domains was low among these studies, and none were funded by pharmaceutical companies. At one‐year follow‐up, investigators provided data for the primary outcome for 3164 (88%) of 3657 participants. </p> <section id="CD005139-sec-0109"> <h5 class="title">(1) Visual acuity</h5> <section id="CD005139-sec-0110"> <h6 class="title">(a) Gain of 15 or more letters of visual acuity</h6> <p>At one‐year follow‐up, investigators provided analyzable data for the primary outcome of this review for 3144 (86%) of 3657 participants. Overall, the proportion of participants who gained 15 or more letters of visual acuity at one year was not statistically significantly different between bevacizumab‐ and ranibizumab‐treated groups (RR 0.95, 95% CI 0.81 to 1.12; <a href="./references#CD005139-fig-0025" title="">Analysis 2.1</a>; <a href="#CD005139-fig-0005">Figure 5</a>). Individual confidence intervals for seven of the eight trials crossed unity, and all confidence intervals overlapped. We graded the certainty of evidence for this outcome as high, with no reason to downgrade. </p> <div class="figure" id="CD005139-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.1 Gain of 15 or more letters visual acuity at 1 year." data-id="CD005139-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.1 Gain of 15 or more letters visual acuity at 1 year. </p> </div> </div> </div> <p>At two years, data were available for 1030 (85%) of 1208 participants in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>, and for 517 (82%) of 628 participants in <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>. Results were consistent with one‐year outcomes in terms of the effect estimate and confidence intervals when we compared the proportion of participants who gained 15 or more letters of visual acuity between ranibizumab‐ and bevacizumab‐treated groups (RR 0.84, 95% CI 0.64 to 1.11; <a href="./references#CD005139-fig-0026" title="">Analysis 2.2</a>; <a href="#CD005139-fig-0006">Figure 6</a>). When we analyzed only the 778 participants who remained in their originally randomized groups in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> (i.e. excluding participants who were switched to a different treatment regimen after one year), summary results were unchanged (RR 0.84, 95% CI 0.64 to 1.11). The I² statistics for these analyses were at or about 50%, indicating a difference in magnitude but not in direction of the treatment effect estimated based on data from <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>. We graded the certainty of evidence for this outcome as high, finding no reason to downgrade. </p> <div class="figure" id="CD005139-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.2 Gain of 15 or more letters visual acuity at 2 years." data-id="CD005139-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.2 Gain of 15 or more letters visual acuity at 2 years. </p> </div> </div> </div> </section> <section id="CD005139-sec-0111"> <h6 class="title">(b) Loss of fewer than 15 letters of visual acuity</h6> <p>At one‐year follow‐up, the overall estimated effect (risk ratio) for loss of fewer than 15 letters of visual acuity was 1.00 (95% CI 0.98 to 1.02) when we compared participants treated with bevacizumab and those treated with ranibizumab (<a href="./references#CD005139-fig-0027" title="">Analysis 2.3</a>). Confidence intervals for all eight individual studies also crossed the line of equality. These results suggest no meaningful clinical or statistical difference between the two anti‐VEGF agents in terms of loss of fewer than 15 letters of visual acuity after one year of treatment. We graded the certainty of evidence for this outcome as high, with no reason to downgrade. </p> <p>At two‐year follow‐up, the relative treatment effect between the two drugs was almost identical to the relative effect at one year when researchers analyzed participants on the basis of their original randomization (RR 0.97, 95% CI 0.94 to 1.00) or those who remained in their originally randomized groups (RR 0.98, 95% CI 0.94 to 1.01; <a href="./references#CD005139-fig-0028" title="">Analysis 2.4</a>). We also graded the certainty of evidence for this outcome as high. </p> </section> <section id="CD005139-sec-0112"> <h6 class="title">(c) Loss of fewer than 30 letters of visual acuity</h6> <p>No participant in <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> lost 30 or more letters of visual acuity during the one‐year study period. In <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>, one participant in each group was reported to have lost fewer than 30 letters of visual acuity (RR 1.3, 95% CI 0.09 to 19.53). The other trials did not report this outcome, likely because of the low risk of losing 15 or more letters of BCVA.. </p> </section> <section id="CD005139-sec-0113"> <h6 class="title">(d) Prevention of blindness in the study eye (visual acuity better than 20/200)</h6> <p>Four trials reported the proportion of participants with visual acuity better than 20/200 as an outcome (<a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>), but six trials did not (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>). </p> <p>At one‐year follow‐up, the proportion of participants with visual acuity of the study eye better than 20/200 was neither clinically nor statistically significantly different when we compared participants treated with bevacizumab and those treated with ranibizumab (RR 0.98, 95% CI 0.96 to 1.01; <a href="./references#CD005139-fig-0029" title="">Analysis 2.5</a>). Results showed no statistically significant heterogeneity among studies (I² = 0%), and all confidence intervals for these four individual studies crossed the line of unity. We graded the certainty of evidence for this outcome as high, finding no reason to downgrade. </p> <p>At two years, results were consistent with one‐year outcomes, in that <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> investigators observed no significant difference in the proportion of participants with visual acuity of the study eye better than 20/200 between bevacizumab‐ and ranibizumab‐treated groups (RR 1.00, 95% CI 0.95 to 1.06; <a href="./references#CD005139-fig-0030" title="">Analysis 2.6</a>). When we analyzed only the 778 participants in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> who remained in their originally randomized groups, we found similar results (RR 1.01, 95% CI 0.95 to 1.06). Evidence shows moderate statistical heterogeneity between <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> for these analyses (I² &gt; 40%), possibly due to the precision of individual study effect estimates. We graded certainty of evidence for this outcome as high, finding no reason to downgrade. </p> </section> <section id="CD005139-sec-0114"> <h6 class="title">(e) Maintenance of visual acuity</h6> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>, <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>, <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>, <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>, <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>, <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>, <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>, and <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> did not report maintenance of visual acuity. In <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>, 10 of 15 (67%) participants maintained baseline visual acuity after one year of treatment with bevacizumab and 6 of 7 (86%) participants maintained baseline visual acuity after one year of treatment with ranibizumab (RR 0.78, 95% CI 0.49 to 1.24). We graded the certainty of evidence for this outcome as moderate, after downgrading for imprecision (‐1). </p> <p><a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a> reported different cut‐points for change in visual acuity at 18‐month follow‐up. In the bevacizumab group, 16 (32%) participants gained more than five letters, 30 (60%) did not change more than five letters, and four (8%) lost more than five letters of visual acuity. In the ranibizumab group, 18 (33%) participants gained more than five letters, 30 (56%) did not change more than five letters, and six (11%) lost more than five letters of visual acuity. </p> </section> <section id="CD005139-sec-0115"> <h6 class="title">(f) Mean change in visual acuity</h6> <p>At one year, the mean difference in mean change in visual acuity between bevacizumab and ranibizumab groups was less than one ETDRS letter (MD ‐0.5, 95% CI ‐1.5 to 0.4; <a href="./references#CD005139-fig-0031" title="">Analysis 2.7</a>). Confidence intervals for all nine individual studies crossed the line of no difference. The I² statistic was 0%. The <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> investigators reported only that they found no difference in mean BCVA between eyes treated with bevacizumab or ranibusumab as combined improvement of 4.1 lines (20 letters). </p> <p><a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> reported data for mean change from baseline in visual acuity at two years; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> reported data for only the 778 participants who remained in their originally randomized groups. The mean difference between bevacizumab and ranibizumab groups was less than two ETDRS letters (MD ‐1.2, 95% CI ‐2.8 to 0.5; <a href="./references#CD005139-fig-0032" title="">Analysis 2.8</a>). We graded the certainty of evidence for this outcome as high, with no reason to downgrade. </p> </section> </section> <section id="CD005139-sec-0116"> <h5 class="title">(2) Visual function</h5> <p>Only one of the ten trials that compared bevacizumab with ranibizumab reported visual function outcomes (<a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>). At one year, participants in the ranibizumab and bevacizumab groups were comparable with regard to mean letters of contrast sensitivity (adjusted MD 0.2 letters, that is, less than one 3‐letter segment on the Pelli‐Robson chart, 95% CI ‐0.5 to 0.9) and reading index (MD ‐5.53, 95% CI ‐14.59 to 3.54). Participants in the ranibizumab group had slightly better (8%) near LogMAR visual acuity than those in the bevacizumab group (adjusted geometric mean ratio 0.92, 95% CI 0.84 to 1.00; P = 0.058). </p> <p>At two‐year follow‐up, results for visual function outcomes were similar to those obtained at one year. Participants in the ranibizumab and bevacizumab groups were comparable with regard to mean letters of contrast sensitivity (adjusted MD 0.21, 95% CI ‐0.62 to 1.04) and reading index (MD ‐1.34, 95% CI ‐8.29 to 5.61). Participants in the ranibizumab group had slightly better (6%) near LogMAR visual acuity than those in the bevacizumab group (adjusted geometric mean ratio 0.94, 95% CI 0.85 to 1.04). We graded the certainty of evidence for these outcomes at one and two years as high, finding no reason to downgrade. </p> </section> <section id="CD005139-sec-0117"> <h5 class="title">(3) Morphologic outcomes</h5> <section id="CD005139-sec-0118"> <h6 class="title">(a) Mean change in size of CNV</h6> <p>One study reported mean change in size of CNV from baseline (<a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>). At one year, results showed no differences between bevacizumab (156 participants) and ranibizumab (144 participants) groups (MD 0.00 DAs, 95% CI ‐0.32 to 0.32). We graded the certainty of evidence for this outcome as high, upon finding no reason to downgrade. </p> </section> <section id="CD005139-sec-0119"> <h6 class="title">(b) Mean change in size of lesion</h6> <p>Two of the eight studies reported the outcome of change in total lesion size. We considered a difference of one or more DAs as a clinically meaningful difference. </p> <p>In <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>, the mean change in lesion size was similar in the bevacizumab (479 participants) and ranibizumab (509 participants) groups at one year (MD 0.20 optic DAs, 95% CI ‐0.09 to 0.49). Among the 778 participants who remained in their originally randomized groups through two years, participants in the bevacizumab groups (341 participants) showed larger increases in lesion size compared with those in the ranibizumab groups (360 participants) (MD 1.37 mm², 95% CI 0.39 to 2.36). </p> <p>In <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>, the median change in lesion size after one year of treatment was similar in the bevacizumab (median ‐1.79 DAs, IQR ‐5.18 to 0.00) and ranibizumab (median ‐1.92 DAs, IQR ‐4.81 to ‐0.01) groups. After two years, the median change in lesion size was ‐1.86 DAs (IQR ‐5.51 to 0.16) in the bevacizumab group and ‐0.96 DAs (IQR ‐4.29 to 0.39) in the ranibizumab group. </p> <p><a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>, <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>, <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>, <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>, <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>, and <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> did not report mean change in lesion size in DAs. <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> reported that "no significant difference was observed in terms of lesion size between the two groups (P = 0.55)." We graded the certainty of evidence for mean change in lesion size as moderate, upon downgrading for lack of analyzable data from two trials reporting this outcome (‐1). </p> </section> <section id="CD005139-sec-0120"> <h6 class="title">(c) Mean change in CRT</h6> <p>Nine of the ten trials reported on mean change in CRT at one year. Participants treated with bevacizumab showed less reduction in CRT compared with those treated with ranibizumab in six trials (MD ‐11.6 μm, 95% CI ‐21.6 to ‐1.7; <a href="./references#CD005139-fig-0033" title="">Analysis 2.9</a>). This difference is not considered to be clinically meaningful, as it falls within the typical range of measurement error. <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> reported a mean change of ‐50 μm in the bevacizumab group and ‐91 μm in the ranibizumab group at one year. Neither <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> nor <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> nor <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> investigators reported mean change in CRT by treatment group. <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> investigators stated that "differences were not significant between the groups (P = 0.81)." <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> investigators reported for the combined treatment groups that CRT changed from 401.5 μm at baseline to 310 μm after one year, and that "no significant difference was observed between both [sic] drugs." Similarly, <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> reported that "The mean CRT did not differ significantly between groups (p=0.088 after 12 months)." </p> <p>At two years, the finding of no or a trivial difference persisted only among study participants who remained in their originally randomized groups in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>. Participants in the bevacizumab groups showed only slightly less reduction in CRT compared with those in the ranibizumab groups (MD ‐12.4 μm, 95% CI ‐33.8 to ‐9.0; <a href="./references#CD005139-fig-0034" title="">Analysis 2.10</a>). We graded the certainty of evidence for this outcome at both one and two years as high, with no reason to downgrade. </p> </section> </section> <section id="CD005139-sec-0121"> <h5 class="title">(4) Quality of life outcomes</h5> <p><a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> evaluated quality of life among trial participants using the EQ‐5D. </p> <p>At one‐year follow‐up, the median (IQR) EQ‐5D summary score was the same for bevacizumab‐ and ranibizumab‐treated groups (median 0.85, IQR 0.73 to 1.00). The number of participants who reported "no health problems" for each of the five subscale domains was similar between groups (<a href="./references#CD005139-fig-0035" title="">Analysis 2.11</a>). </p> <p>At two‐year follow‐up, the median (IQR) EQ‐5D summary score was the same as at one‐year follow‐up (median 0.85, IQR 0.73 to 1.00) in bevacizumab‐ and ranibizumab‐treated groups. The number of participants who reported "no health problems" for each of the five subscale domains was similar in the two groups (<a href="./references#CD005139-fig-0036" title="">Analysis 2.12</a>). </p> <p>The remaining nine studies did not report quality of life outcomes (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>). We graded the certainty of evidence for quality of life as moderate, after downgrading for absence of data from other trials (‐1). </p> </section> <section id="CD005139-sec-0122"> <h5 class="title">(5) Economic outcomes</h5> <p>Three studies included economic‐related outcomes as prespecified secondary outcomes. <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> evaluated annual costs associated with each treatment group in USD. <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> evaluated cumulative resource use and costs for each treatment group in GBP. <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> prespecified medicoeconomic outcomes as secondary outcomes of interest; however, <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> investigators had published no results for economic outcomes by the time this review was prepared. </p> <p>In the first year of treatment in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>, the average annual cost of treatment per participant was USD 490 in the bevacizumab groups (USD 595 when treated monthly and USD 385 when treated as needed) compared with USD 18,590 (USD 23,400 when treated monthly and USD 13,800 when treated as needed) in the ranibizumab groups. For the 778 participants who remained in their originally randomized groups, the average cost of two years of treatment was USD 860 per participant in the bevacizumab groups (USD 1170 when treated monthly and USD 705 when treated as needed) and USD 31,805 per participant in the ranibizumab groups (USD 44,800 when treated monthly and USD 25,200 when treated as needed). </p> <p>In <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>, the average total cost of treatment per participant for the first year was GBP 1580 in the bevacizumab groups (GBP 1654 when treated monthly and GBP 1509 when treated as needed) compared with GBP 8035 in the ranibizumab groups (GBP 9656 when treated monthly and GBP 6398 when treated as needed). These values corresponded to approximately USD 2500 and USD 12,700 for the bevacizumab and ranibizumab groups, respectively (based on an average exchange rate of 1.58 for years 2010 to 2011). The mean difference was GBP 8001 (SE 113) when monthly treatment with ranibizumab versus bevacizumab was compared, and GBP 4889 (SE 184) when as‐needed treatment with ranibizumab versus bevacizumab was compared. <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> reported economic outcomes at two‐year follow‐up. </p> </section> <section id="CD005139-sec-0123"> <h5 class="title">(6) Adverse events</h5> <p>Although all ten trials provided information related to adverse events, data reported varied by study regarding the types and specificity of adverse events. </p> <p>At one year, investigators from four trials reported no serious ocular events (<a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>; <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a>; <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a>). Minor adverse events reported from three of these trials included subconjunctival hemorrhage, increased IOP, transient postinjection pain, and mild ocular inflammation; investigators did not report the numbers of participants who experienced these adverse events. No case of endophthalmitis or retinal detachment was reported from the four trials. In <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>, <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>, <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>, and <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>, less than 1% of participants had endophthalmitis, retinal detachment, retinal pigment epithelial tear, traumatic cataract, or uveitis (<a href="#CD005139-tbl-0008">Table 6</a>). <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> reported two eyes with subretinal bleeding, both treated with ranibizumab. <a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a> did not mention ocular adverse events. As a result of the small numbers of events, risk estimates for these adverse events are imprecise. We graded the certainty of evidence for ocular events as moderate, after downgrading for imprecision (‐1). </p> <div class="table" id="CD005139-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events up to 1 year: bevacizumab versus ranibizumab</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Serious ocular adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Studies reporting adverse events<sup>1</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number with event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number with event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 [0.40 to 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.05 [0.36 to 136.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal pigment epithelial tear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 [0.31 to 6.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 [0.05 to 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.14 [0.46 to 36.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Non‐ocular adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Studies reporting adverse events<sup>2</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Bevacizumab</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number with event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number with event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 1 serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298 (18%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 [0.99 to 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 [0.66 to 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 [0.22 to 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke or cerebral infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 [0.25 to 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient ischemic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 [0.43 to 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Venous thrombotic event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04 [0.61 to 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 [0.57 to 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 [0.99 to 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 [0.93 to 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Injury and procedural complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 [0.78 to 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoplasms (benign, malignant, unspecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 [0.61 to 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 [0.68 to 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgical or medical procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 [0.88 to 2.27]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.<br/> RR: risk ratio. </p> <p><sup>a</sup>Includes endophthalmitis and pseudo‐endophthalmitis. </p> <p><sup>1</sup><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> (n = 586 in bevacizumab group; n = 599 in ranibizumab group); <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> (n = 246 in bevacizumab group; n = 239 in ranibizumab group); <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> (n = 296 in bevacizumab group; n = 314 in ranibizumab group); <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> (n = 220 in bevacizumab group; n = 221 in ranibizumab group).<br/> <sup>2</sup>BRAMD 2016 (n = 161 in bevacizumab group; n = 166 in ranibizumab group); <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> (n = 586 in bevacizumab group; n = 599 in ranibizumab group); <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> (n = 246 in bevacizumab group; n = 239 in ranibizumab group); <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> (n = 296 in bevacizumab group; n = 314 in ranibizumab group); <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> (n = 220 in bevacizumab group; n = 221 in ranibizumab group); <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> (n = 154 in bevacizumab group; n = 163 in ranibizumab group). </p> </div> </div> <p><a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a> did not assess systemic adverse events. At one year, <a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> reported no serious systemic adverse events. <a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> reported a transient ischemic attack in one patient but did not specify the treatment assignment for participants. <a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> investigators reported three thromboembolitic events but did not report the anti‐VEGF agent given to those participants, nor whether cases were in the neovascular AMD or non‐neovascular AMD cohort. The remaining six trials reported that 18% of participants in the bevacizumab groups versus 16% in the ranibizumab groups experienced at least one serious adverse event (RR 1.15, 95% CI 0.99 to 1.34) (<a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a>). Mortality from any cause was approximately 2% in the bevacizumab and ranibizumab groups during the first year of follow‐up (RR 1.10, 95% CI 0.66 to 1.83). Less than 1% of participants experienced myocardial infarction, stroke or cerebral infarction, transient ischemic attack, or a venous thrombotic event (<a href="#CD005139-tbl-0008">Table 6</a>). Rates were comparable between bevacizumab and ranibizumab groups with respect to cardiac disorders (RR 0.84, 95% CI 0.57 to 1.23), neoplasms (RR 0.99, 95% CI 0.61 to 1.61), and nervous system disorders (RR 1.14, 95% CI 0.68 to 1.93). Investigators reported more gastrointestinal disorders (RR 1.76, 95% CI 0.99 to 3.14), infections (RR 1.42, 95% CI 0.93 to 2.17), injuries and procedural complications (RR 1.27, 95% CI 0.78 to 2.06), and surgical or medical procedures (RR 1.41, 95% CI 0.88 to 2.27) in the bevacizumab groups than in the ranibizumab groups at one year. We graded the certainty of evidence for systemic adverse events as moderate, after downgrading for imprecision (‐1). </p> <p>At two years, data for ocular and systemic adverse events were available for <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>. Less than 1% of participants were reported to have had endophthalmitis, retinal detachment, retinal pigment epithelial tear, traumatic cataract, or uveitis (<a href="#CD005139-tbl-0009">Table 7</a>). As a result of the small numbers of events, risk estimates for these adverse events are imprecise. In the bevacizumab groups, 36% of participants had at least one serious adverse event compared with 30% in the ranibizumab groups (RR 1.20, 95% CI 1.05 to 1.37). Mortality from any cause was 6% and 5% in the bevacizumab and ranibizumab groups, respectively (RR 1.12, 95% CI 0.76 to 1.65). In all, 2% or fewer participants experienced myocardial infarction, stroke or cerebral infarction, a venous thrombotic event, or a transient ischemic attack (<a href="#CD005139-tbl-0009">Table 7</a>). As with one‐year outcomes, investigators reported more gastrointestinal disorders (RR 2.74, 95% CI 1.49 to 5.02), infections (RR 1.37, 95% CI 0.96 to 1.95), and injuries and procedural complications (RR 1.33, 95% CI 0.86 to 2.05) in the bevacizumab groups than in the ranibizumab groups, and reported more cardiac disorders in the bevacizumab groups than in the ranibizumab groups at two years (RR 1.25, 95% CI 0.92 to 1.71). Rates were comparable between bevacizumab and ranibizumab groups with respect to neoplasms (RR 0.98, 95% CI 0.63 to 1.53), nervous system disorders (RR 1.06, 95% CI 0.70 to 1.60), and surgical or medical procedures (RR 0.91, 95% CI 0.44 to 1.84). We graded the certainty of evidence for ocular and systemic adverse events at two years as moderate, after downgrading for imprecision (‐1). </p> <div class="table" id="CD005139-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events up to 2 years: bevacizumab versus ranibizumab</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event (CATT trial)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab<br/> n = 586</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab<br/> n = 599</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 [0.53 to 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event (IVAN trial)<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab<br/> n = 296</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab<br/> n = 314</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 [0.07 to 16.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.18 [0.13 to 77.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 [0.01 to 8.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal pigment epithelial tear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 [0.04 to 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐ocular adverse event<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab<br/> n = 882</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab<br/> n = 913</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 1 serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314 (36%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271 (30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 [1.05 to 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 [0.76 to 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 [0.39 to 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke or cerebral infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 [0.37 to 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Venous thrombotic event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42 [0.93 to 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient ischemic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 [0.06 to 16.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 [0.92 to 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.74 [1.49 to 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 [0.96 to 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Injury and procedural complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 [0.86 to 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoplasms (benign, malignant, unspecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 [0.63 to 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 [0.70 to 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgical or medical procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 [0.44 to 1.84]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> <p>RR: risk ratio.</p> <p><sup>a</sup>Adverse events for endophthalmitis not reported in <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; data for <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> only.<br/> <sup>b</sup>Adverse events for traumatic cataract, uveitis, retinal detachment, retinal pigment epithelial tear, transient ischemic attack, and surgical or medical procedure not reported in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; data for <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> study only.<br/> <sup>c</sup>Adverse events experienced by 1185 participants in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and by 610 participants in <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>. </p> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005139-sec-0124" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005139-sec-0124"></div> <section id="CD005139-sec-0125"> <h3 class="title" id="CD005139-sec-0125">Summary of main results</h3> <p>Most of the 16 trials included in this systematic review were of good methodological quality. The six trials of anti‐vascular endothelial growth factor (VEGF) monotherapy versus control demonstrated the beneficial effect of anti‐VEGF therapy on visual acuity in the management of neovascular age‐related macular degeneration (AMD). Participants treated with any anti‐VEGF agent featured in these trials ‐ pegaptanib (one trial), ranibizumab (three trials), or bevacizumab (two trials) ‐ more often gained or maintained visual acuity at one year and less often lost visual acuity compared with participants who received no anti‐VEGF agent. Stability of visual acuity at one year was achieved more often in an anti‐VEGF treatment group than in a control group not treated with anti‐VEGF agents. The safety profile of anti‐VEGFs, as reported in the included studies, was acceptable. </p> <p>Functional outcomes (e.g. visual acuity) correlated with quality of life outcomes, when reported, and anatomic outcomes (e.g. lesion size, retinal thickness).across trials. Participants treated with pegaptanib showed a decrease in the size of the choroidal neovascular complex with less leakage observed on fluorescein angiography than in participants treated with sham injections. Bevacizumab‐ and ranibizumab‐treated participants experienced reductions in central retinal thickness (CRT) as measured by optical coherence tomography (OCT) compared with control participants. </p> <p>Investigators more often reported improvement in vision‐specific quality of life in anti‐VEGF‐treated groups than in control groups, as well as improved scores on the National Eye Institute‐Visual Functioning Questionnaire (NEI‐VFQ) scale with both pegaptanib and ranibizumab compared with control. Cost utility analysis, based on data from one trial and standardized utilities of degree of visual loss, compared ranibizumab with pegaptanib and revealed that ranibizumab was associated with better quality of life when compared with pegaptanib (<a href="./references#CD005139-bbs2-0088" title="BrownMM , BrownGC , BrownHC , PeetJ . A value‐based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology2008;115(6):1039‐45. ">Brown 2008</a>). Data on visual function (e.g. contrast sensitivity) and treatment costs were sparse in these trials. </p> <p>We found only one small trial that performed a head‐to‐head comparison of pegaptanib (n = 18) versus bevacizumab (n = 13), which we excluded because participants were followed for only six months (<a href="./references#CD005139-bbs2-0070" title="Schmid‐KubistaKE , KrebsI , Ansari‐ShahrezaeiS , HaasP , HagenS , BinderS . Comparing treatment of neovascular age‐related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono‐therapy ‐ a pilot study. Current Eye Research2011;36(10):958‐63. ">Schmid‐Kubista 2011</a>). Investigators reported improved best‐corrected visual acuity (BCVA) with bevacizumab compared to pegaptanib. Ten head‐to‐head trials compared bevacizumab versus ranibizumab. At one‐year and two‐year follow‐up, visual acuity outcomes were comparable for bevacizumab and ranibizumab, clinically and statistically, although confidence intervals for some outcomes reported by individual studies indicated some uncertainty regarding true effects. In terms of other measures of visual function, one trial showed better near LogMAR visual acuity among participants in the ranibizumab group than among those in the bevacizumab group at one‐year follow‐up; this effect had diminished at two‐year follow‐up. At one‐year and two‐year follow‐up, researchers noted no clinically meaningful differences in reduction of CRT between bevacizumab‐treated and ranibizumab‐treated participants. Participant responses to quality of life questionnaires were comparable between treatment groups. Researchers reported a small number of ocular adverse events for both bevacizumab and ranibizumab groups (&lt; 1%) across all trials. However, endophthalmitis rates were higher with injection of anti‐VEGF agents than with intravitreal surgery, except when estimates were based on numbers of injections given rather than on numbers of eyes treated. Individuals with AMD and their ophthalmologists must be aware of this small but serious risk. At both one‐year and two‐year follow‐up, fewer participants in the ranibizumab groups experienced any serious systemic adverse events compared with those in the bevacizumab groups. </p> </section> <section id="CD005139-sec-0126"> <h3 class="title" id="CD005139-sec-0126">Overall completeness and applicability of evidence</h3> <p>We conducted this review to investigate effects on vision and quality of life associated with intravitreous injections of anti‐VEGF agents for treatment of patients with neovascular AMD versus sham treatment or a different anti‐VEGF agent administered at comparable dosages and regimens. In this review, we included only randomized controlled trials (RCTs), each with a minimum follow‐up of one year. The primary outcome for this review was the proportion of participants who gained 15 or more letters of BCVA by one‐year follow‐up examination. Secondary outcomes included other visual acuity outcomes at one‐year and two‐year follow‐up, visual function outcomes, morphologic characteristics assessed by fluorescein angiography or OCT, ocular and systemic adverse outcomes, cost outcomes, and quality of life. We used multiple sources to identify relevant data for this review ‐ not only journal publications, but also conference abstracts, FDA documents, and descriptions in clinical trial registries, when available. When data were unclear or were missing, we contacted study investigators to request clarification or information. </p> <p>This review ultimately included representative and applicable outcomes data from 6347 participants enrolled in 16 trials conducted in various countries that included both men and women aged 50 years or older with subfoveal choroidal neovascularization (CNV) secondary to AMD. Approximately half of the included trials reported the type of neovascular lesion, and all lesion types (predominantly classic CNV, minimally classic CNV, and occult CNV only) were represented among these trials. All studies included at least one measure related to morphologic characteristics of study eyes, with fluorescein angiography used in 15 studies and OCT used in all but the earliest of these RCTs. </p> <p>The earliest RCTs of anti‐VEGF agents incorporated in this review individually and collectively established a new paradigm for management of neovascular AMD, particularly for lesions under or near the fovea, and validated administration of intravitreal anti‐VEGF therapy in affected individuals with clinical profiles similar to those of participants enrolled in these trials. Reported outcomes related to visual acuity gains, stability of visual acuity at one year, decreased risk of significant visual acuity loss, and low rates of ocular and systemic adverse events are mirrored in real‐life clinical encounters when anti‐VEGF agents are used to manage neovascular AMD in the retina specialist's office (<a href="./references#CD005139-bbs2-0090" title="CarneiroAM , MendoncaLS , FalcaoMS , FonsecaSL , BrandaoEM , Falcao‐ReisFM . Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clinical Ophthalmology2012;6:1149‐57. ">Carneiro 2012</a>; <a href="./references#CD005139-bbs2-0101" title="GilliesMC , WaltonRJ , ArnoldJJ , McAllisterIL , SimpsonJM , HunyorAP , et al. Comparison of outcomes from a phase 3 study of age‐related macular degeneration with a matched, observational cohort. Ophthalmology2014;121(3):676‐81. ">Gillies 2014</a>; <a href="./references#CD005139-bbs2-0107" title="HolzFG , BandelloF , GilliesM , MitchellP , OsborneA , SheidowT , et al. Safety of ranibizumab in routine clinical practice: 1‐year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. British Journal of Ophthalmology2013;97(9):1161‐7. ">Holz 2013</a>; <a href="./references#CD005139-bbs2-0120" title="RasmussenA , SanderB . Long‐term longitudinal study of patients treated with ranibizumab for neovascular age‐related macular degeneration. Current Opinion in Ophthalmology2014;25(3):158‐63. ">Rasmussen 2014</a>). As observed in the clinical trials incorporated into this review, morphologic changes in the CNV lesion complex, with regard to decreased size on fluorescein angiography, decreased leakage on fluorescein angiography, and decreased CRT on OCT, also have been observed to occur in clinical practice among individuals given intravitreous anti‐VEGF therapy for neovascular AMD (<a href="./references#CD005139-bbs2-0090" title="CarneiroAM , MendoncaLS , FalcaoMS , FonsecaSL , BrandaoEM , Falcao‐ReisFM . Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clinical Ophthalmology2012;6:1149‐57. ">Carneiro 2012</a>). </p> <p>With completion and reporting of ten head‐to‐head trials of bevacizumab versus ranibizumab, and the finding of little or no difference in outcomes between the two drugs, the primary consideration for the ophthalmologist and the individual with AMD has been the choice of anti‐VEGF agent. Issues include costs, availability, and quality control of the preparation of bevacizumab for intravitreal injection. Issues as yet unresolved include optimal frequency with which anti‐VEGF agents should be injected into affected eyes, length of calendar time over which anti‐VEGF agents must be injected to maintain the benefits seen with two‐year outcomes, and long‐term ocular and systemic effects of these treatments. These issues have been or will be addressed in other systematic reviews prepared by Cochrane reviewers and others. </p> </section> <section id="CD005139-sec-0127"> <h3 class="title" id="CD005139-sec-0127">Quality of the evidence</h3> <p>In addition to inclusion of only RCTs in this review, two review authors assessed potential sources of bias in these trials according to methods established by Cochrane. We assessed the certainty of evidence for most outcomes in this review as moderate to high on the basis of consistency of findings across trials and proper trial design. Parameters considered in risk of bias assessment included selection bias, performance bias, detection bias, attrition bias, and reporting bias; we graded each potential source of bias as low risk, unclear risk, or high risk. Overall, we found the included studies to be at low risk for most categories of bias. In most trials, few participants missed the primary outcome examination or were not treated per protocol assignment. In nine trials, proportions of participants lost to follow‐up at primary follow‐up visits were less than 15%, despite the age of participants and the death of some. Although not the best method that can be used to account for missing data, seven trials used the last observation carried forward method to impute missing data. We identified design publications, protocols, or clinical trial registration for 15 of the 16 included studies. We judged nine of these 15 trials to be free of reporting bias on the basis of consistency between study outcomes as defined in the protocols and clinical trial registers and reported in study publications to date. </p> <p>In retrospect, we should not have included <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> in this review because the "standard care" control arm included pegaptanib, which was approved for intravitreous injection by the Naational Health Service at the time the trial commenced. We elected to retain <a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> in the current updated review for consistency with earlier versions of this systematic review. </p> <p>We considered various other aspects of trial design, reporting, and financial support as potential sources of bias. Pharmaceutical companies that marketed the study drugs under investigation sponsored four of 16 trials ‐ one study of pegaptanib and three studies that compared ranibizumab with control. In addition, pharmaceutical company sponsors had important roles in design, analysis, and reporting of these trials, and some investigators reported that they had financial relationships with the company that manufactured the study drug. </p> </section> <section id="CD005139-sec-0128"> <h3 class="title" id="CD005139-sec-0128">Potential biases in the review process</h3> <p>For this review, we conducted broad electronic searches for studies and imposed no date or language restrictions to minimize potential biases in the study selection process. We followed standard Cochrane review methods. The outcomes evaluated in the review were those commonly specified for RCTs examining treatments for neovascular AMD. </p> </section> <section id="CD005139-sec-0129"> <h3 class="title" id="CD005139-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p>Whether assessed by systematic, comprehensive reviews, such as this one, or by more traditional, clinical reviews, anti‐VEGF compounds for treatment of patients with neovascular AMD appear to be efficacious and safe (<a href="./references#CD005139-bbs2-0109" title="IpMS , ScottIU , BrownGC , BrownMM , HoAC , HuangSS , et al. Anti‐vascular endothelial growth factor pharmacotherapy for age‐related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology2008;115(10):1837‐46. ">Ip 2008</a>; <a href="./references#CD005139-bbs2-0116" title="MitchellP . A systematic review of the efficacy and safety outcomes of anti‐VEGF agents used for treating neovascular age‐related macular degeneration: comparison of ranibizumab and bevacizumab. Current Medical Research and Opinion2011;27(7):1465‐75. ">Mitchell 2011</a>; <a href="./references#CD005139-bbs2-0125" title="SchmuckerC , EhlkenC , HansenLL , AntesG , AgostiniHT , LelgemannM . Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age‐related macular degeneration: a systematic review. Current Opinion in Ophthalmology2010;21(3):218‐26. ">Schmucker 2010</a>; <a href="./references#CD005139-bbs2-0126" title="SchmuckerC , EhlkenC , AgostiniHT , AntesG , RueckerG , LelgemannM , et al. A safety review and meta‐analyses of bevacizumab and ranibizumab: off‐label versus gold standard. PloS One2012;7(8):e42701. ">Schmucker 2012</a>). Beneficial effects of pegaptanib, ranibizumab, and bevacizumab are evident in terms of the proportion of participants with stabilization or small losses of BCVA. Ranibizumab and bevacizumab additionally resulted in a greater proportion of participants with improved BCVA after one and two years of injections. In independent studies and comprehensive reviews; effects on visual acuity have been consistent with morphologic changes in the size and composition of the CNV lesion complex, as well as with the observed change in CRT on OCT following treatment with these agents. In general, considerations of costs were limited in the trials included in this systematic review; additional analyses indicating a favorable cost/utility ratio for anti‐VEGF agents versus control or no treatment were cited in research using RCTs and observational data (<a href="./references#CD005139-bbs2-0025" title="CohenSY , Bremond‐GignacD , QuentelG , MimounG , CitterioT , Bisot‐LocardS , et al. Cost‐effectiveness sequential modeling of ranibizumab versus usual care in age‐related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology2008;246(11):1527‐34. ">Cohen 2008</a>; <a href="./references#CD005139-bbs2-0028" title="EarnshawSR , MorideY , RochonS . Cost‐effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age‐related macular degeneration in Canada. Clinical Therapeutics2007;29(9):2096‐106. ">Earnshaw 2007</a>; <a href="./references#CD005139-bbs2-0035" title="FletcherEC , LadeRJ , AdewoyinT , ChongNV . Computerized model of cost‐utility analysis for treatment of age‐related macular degeneration. Ophthalmology2008;115(12):2192‐8. ">Fletcher 2008</a>; <a href="./references#CD005139-bbs2-0043" title="Hernandez‐PastorLJ , OrtegaA , Garcia‐LayanaA , GiraldezJ . Cost‐effectiveness of ranibizumab compared with photodynamic treatment of neovascular age‐related macular degeneration. Clinical Therapeutics2008;30(12):2436‐51. ">Hernandez‐Pastor 2008</a>; <a href="./references#CD005139-bbs2-0046" title="JavittJC , ZlatevaGP , EarnshawSR , PleilAM , GrahamCN , BroganAJ , et al. Cost‐effectiveness model for neovascular age‐related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity. Value in Health2008;11(4):563‐74. ">Javitt 2008</a>; <a href="./references#CD005139-bbs2-0080" title="WolowaczSE , RoskellN , KellyS , MaciverFM , BrandCS . Cost effectiveness of pegaptanib for the treatment of age‐related macular degeneration in the UK. Pharmacoeconomics2007;25(10):863‐79. ">Wolowacz 2007</a>). Economic analyses have documented the lower cost of bevacizumab compared with ranibizumab in achieving the same benefits (<a href="./references#CD005139-bbs2-0066" title="RafteryJ , CleggA , JonesJ , TanSC , LoteryA . Ranibizumab (Lucentis®) versus bevacizumab (Avastin®): modelling cost effectiveness. British Journal of Ophthalmology2007;91(9):1244‐6. ">Raftery 2007</a>; <a href="./references#CD005139-bbs2-0130" title="SteinJD , Newman‐CaseyPA , MrinaliniT , LeePP , HuttonDW . Cost‐effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration. Ophthalmology2014;121(4):936‐45. ">Stein 2014</a>). A separate Cochrane review that specifically evaluated the systemic safety of bevacizumab versus ranibizumab also found no clinically or statistically significant differences between intravitreal injection of the two drugs after two years of follow‐up with respect to death or overall serious systemic adverse events (<a href="./references#CD005139-bbs2-0117" title="MojaL , LucenteforteE , KwagKH , BerteleV , CampomoriA , ChakravarthyU , et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2] ">Moja 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005139-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD005139-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD005139-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.1 Gain of 15 or more letters visual acuity at 1 year." data-id="CD005139-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.1 Gain of 15 or more letters visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.2 Gain of 15 or more letters visual acuity at 2 years." data-id="CD005139-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Ranibizumab versus control, outcome: 2.2 Gain of 15 or more letters visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.1 Gain of 15 or more letters visual acuity at 1 year." data-id="CD005139-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.1 Gain of 15 or more letters visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.2 Gain of 15 or more letters visual acuity at 2 years." data-id="CD005139-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Bevacizumab versus ranibizumab, outcome: 4.2 Gain of 15 or more letters visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 1 Gain of 15 or more letters visual acuity at 1 year." data-id="CD005139-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 1 Gain of 15 or more letters visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 2 Gain of 15 or more letters visual acuity at 2 years." data-id="CD005139-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 2 Gain of 15 or more letters visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 3 Loss of fewer than 15 letters visual acuity at 1 year." data-id="CD005139-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 3 Loss of fewer than 15 letters visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 4 Loss of fewer than 15 letters visual acuity at 2 years." data-id="CD005139-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 4 Loss of fewer than 15 letters visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 5 Loss of fewer than 30 letters visual acuity at 1 year." data-id="CD005139-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 5 Loss of fewer than 30 letters visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 6 Loss of fewer than 30 letters visual acuity at 2 years." data-id="CD005139-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 6 Loss of fewer than 30 letters visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 7 Visual acuity better than 20/200 at 1 year." data-id="CD005139-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 7 Visual acuity better than 20/200 at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 8 Visual acuity better than 20/200 at 2 years." data-id="CD005139-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 8 Visual acuity better than 20/200 at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 9 Maintenance of visual acuity at 1 year." data-id="CD005139-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 9 Maintenance of visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 10 Maintenance of visual acuity at 2 years." data-id="CD005139-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 10 Maintenance of visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 11 Mean change in visual acuity at 1 year (number of letters)." data-id="CD005139-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 11 Mean change in visual acuity at 1 year (number of letters). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 12 Mean change in visual acuity at 2 years (number of letters)." data-id="CD005139-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 12 Mean change in visual acuity at 2 years (number of letters). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 13 Reduction in size of CNV at 1 year (mean number of disc areas)." data-id="CD005139-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 13 Reduction in size of CNV at 1 year (mean number of disc areas). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 14 Reduction in size of lesion at 1 year (mean number of disc areas)." data-id="CD005139-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 14 Reduction in size of lesion at 1 year (mean number of disc areas). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 15 Reduction in size of lesion at 1 year (mean number of disc areas)." data-id="CD005139-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 15 Reduction in size of lesion at 1 year (mean number of disc areas). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 16 Reduction in size of lesion at 2 years (mean number of disc areas)." data-id="CD005139-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 16 Reduction in size of lesion at 2 years (mean number of disc areas). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 17 Mean change in quality of life scores at 1 year." data-id="CD005139-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 17 Mean change in quality of life scores at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anti‐VEGF treatment versus control, Outcome 18 Mean change in quality of life scores at 2 years." data-id="CD005139-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Anti‐VEGF treatment versus control, Outcome 18 Mean change in quality of life scores at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 1 Gain of 15 or more letters visual acuity at 1 year." data-id="CD005139-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 1 Gain of 15 or more letters visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 2 Gain of 15 or more letters visual acuity at 2 years." data-id="CD005139-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 2 Gain of 15 or more letters visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 3 Loss of fewer than 15 letters visual acuity at 1 year." data-id="CD005139-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 3 Loss of fewer than 15 letters visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 4 Loss of fewer than 15 letters visual acuity at 2 years." data-id="CD005139-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 4 Loss of fewer than 15 letters visual acuity at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 5 Visual acuity better than 20/200 at 1 year." data-id="CD005139-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 5 Visual acuity better than 20/200 at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 6 Visual acuity better than 20/200 at 2 years." data-id="CD005139-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 6 Visual acuity better than 20/200 at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 7 Mean change in visual acuity at 1 year (number of letters)." data-id="CD005139-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 7 Mean change in visual acuity at 1 year (number of letters). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 8 Mean change in visual acuity at 2 years (number of letters)." data-id="CD005139-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 8 Mean change in visual acuity at 2 years (number of letters). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 9 Reduction in central retinal thickness at 1 year." data-id="CD005139-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 9 Reduction in central retinal thickness at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 10 Reduction in central retinal thickness at 2 years." data-id="CD005139-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 10 Reduction in central retinal thickness at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 11 No problems in quality of life domain at 1 year." data-id="CD005139-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 11 No problems in quality of life domain at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 12 No problems in quality of life domain at 2 years." data-id="CD005139-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 12 No problems in quality of life domain at 2 years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005139-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/urn:x-wiley:14651858:media:CD005139:CD005139-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_t/tCD005139-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Bevacizumab versus ranibizumab, Outcome 13 Loss of fewer than 30 letters visual acuity at 1 year." data-id="CD005139-fig-0037" src="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Bevacizumab versus ranibizumab, Outcome 13 Loss of fewer than 30 letters visual acuity at 1 year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/media/CDSR/CD005139/image_n/nCD005139-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005139-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: anti‐VEGF treatment versus control</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anti‐VEGF treatment versus control for neovascular age‐related macular degeneration</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> people with neovascular age‐related macular degeneration </p> <p><b>Settings:</b> clinical centers </p> <p><b>Intervention:</b> intravitreal injections of anti‐VEGF agents (pegaptanib, ranibizumab, or bevacizumab) </p> <p><b>Control:</b> standard therapy at the time of the trial (sham injections, verteporfin photodynamic therapy with or without triamcinolone acetonide, or intravitreal injections of pegaptanib) </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Anti‐VEGF treatment</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gain of 15 or more letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b><br/> (99 to 322) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.19</b><br/> (2.32 to 7.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2667<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Loss of fewer than 15 letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>599 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>838 per 1000</b><br/> (760 to 928) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.40</b> </p> <p>(1.27 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2667<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year (number of letters)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change across control groups ranged from a <b>loss of 10 to 16</b> letters </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2508<br/> (4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Owing to substantial statistical heterogeneity between pegaptanib and ranibizumab subgroups, we did not combine data across subgroups </p> <p>Mean change in visual acuity in pegaptanib groups was on average <b>6.72 more letters gained</b> (95% CI 4.43 letters to 9.01 letters); <b>MD 6.72</b> (95% CI 4.43 to 9.01) </p> <p>Mean change in visual acuity in ranibizumab groups was on average <b>17.80 more letters gained</b> (95% CI 15.95 letters to 19.65 letters); <b>MD 17.80</b> (95% CI 15.95 to 19.65) </p> <p>Mean change from baseline in visual acuity was 7.0 letters in bevacizumab group and ‐9.4 letters in control group in 1 study. The second study reported that participants in bevacizumab group gained 8 letters on average and participants in control group lost 3 letters on average </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in central retinal thickness at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We were unable to find data on central retinal thickness in reports from the only trial comparing pegaptanib with control and from any of the 3 included trials comparing ranibizumab with control </p> <p>Mean change was ‐91 μm in bevacizumab group and ‐55 μm in control group in one study, and ‐113 μm in bevacizumab group and ‐72 μm in control group in the other study </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in vision‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change across control groups in vision‐related quality of life scores ranged from <b>‐3 to 2 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change across control groups in vision‐related quality of life scores ranged from <b>5 to 7 points</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 6.69</b> (3.38 to 9.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1134<br/> (2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Use of the NEI‐VFQ questionnaire with a 10‐point difference considered clinically meaningful </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious systemic adverse events at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>5 to 83 per 1000</b> for various systemic adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>0 to 55 per 1000</b> for various systemic adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of <b>RR 0.17</b> (0.01 to 4.24) to <b>2.08</b> (0.23 to 18.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2667<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious ocular adverse events at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>0 to 68 per 1000</b> for various ocular adverse events </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>3 to 118 per 1000</b> for various ocular adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of <b>RR 0.52</b> (0.03 to 8.25) to <b>2.71</b> (1.36 to 5.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2667<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is estimated by the proportion with the event in the control group. The <b>corresponding risk</b> (and its 95% CI) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> Anti‐VEGF: anti‐vascular endothelial growth factor; CI: confidence interval; MD: mean difference; NEI‐VFQ: National Eye Institute‐Visual Functioning Questionnaire; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence.<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded (‐1) owing to imprecision in the confidence interval.<br/> <sup>b</sup>Downgraded (‐1) owing to inconsistency in effect between types of anti‐VEGF agents.<br/> <sup>c</sup>Adverse events downgraded to moderate quality as not all eligible trials reported all types of adverse events, and numbers were small (&lt; 1%) for many specific adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: anti‐VEGF treatment versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005139-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: bevacizumab versus ranibizumab</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bevacizumab versus ranibizumab for neovascular age‐related macular degeneration</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Participant or population:</b> people with neovascular age‐related macular degeneration </p> <p><b>Settings:</b> clinical centers </p> <p><b>Intervention:</b> intravitreal injections of bevacizumab </p> <p><b>Comparison:</b> intravitreal injections of ranibizumab </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ranibizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gain of 15 or more letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>252 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>239 per 1000</b><br/> (204 to 282) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b><br/> (0.81 to 1.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3144<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Loss of fewer than 15 letters visual acuity at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>944 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>944 per 1000</b><br/> (926 to 963) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.00</b><br/> (0.98 to 1.02) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3144<br/> (8) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean change in visual acuity at 1 year (number of letters)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change across ranibizumab groups ranged from <b>gains of 3 to 8 letters</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in visual acuity in bevacizumab groups was on average <b>0.58 fewer letters gained</b> (95% CI 1.55 fewer letters to 0.40 more letters) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐0.6</b><br/> (‐1.6 to 0.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3190<br/> (9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction in central retinal thickness at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean reduction in central retinal thickness across ranibizumab groups ranged from <b>30 to 182 μm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean reduction in central retinal thickness in bevacizumab groups was on average <b>11.61 μm less</b> (95% CI 21.55 less to 1.66 less) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD ‐11.6</b><br/> (‐21.6 to ‐1.7) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2693<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Three additional trials reported no differences between groups for this outcome; however, these data were not reported in formats that could be included in meta‐analysis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No problems in quality of life domains at 1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>591 per 1000</b> to <b>861 per 1000</b> across 5 quality of life domains </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Range of <b>608 per 1000</b> to <b>828 per 1000</b> across<br/> 5 quality of life domains </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of <b>RR 0.96</b> (0.90 to 1.04) to <b>1.02</b><br/> (0.89 to 1.17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>548<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life domains included mobility, self‐care, usual activities, pain/discomfort, anxiety/depression </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious systemic adverse events at</b> <br/> <b>1 year<sup>b</sup> </b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>156 per 1000</b> with at least 1 serious systemic adverse event </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>179 per 1000</b><br/> (154 to 209) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b><br/> (0.99 to 1.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3365<br/> (6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious ocular adverse events at</b> <br/> <b>1 year</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>&lt; 5 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of <b>RR 0.51</b> (0.05 to 5.62) to <b>7.05</b> (0.36 to 136.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range 1670 to 2280<br/> (2 to 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Studies reported different ocular adverse events. One study reported only that there was no difference between treatment arms </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is estimated by the proportion with the event in the ranibizumab group. The <b>corresponding risk</b> (and its 95% CI) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; MD: mean difference; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group grades of evidence.<br/> <b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Quality of life and adverse event outcomes downgraded to moderate quality as not all eligible trials reported these outcomes, and numbers of some adverse events were small (&lt; 1%).<br/> <sup>b</sup>A Cochrane review on systemic safety of bevacizumab versus ranibizumab includes more complete data for this finding (<a href="./references#CD005139-bbs2-0117" title="MojaL , LucenteforteE , KwagKH , BerteleV , CampomoriA , ChakravarthyU , et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2] ">Moja 2014</a>). Please refer to <a href="./references#CD005139-bbs2-0117" title="MojaL , LucenteforteE , KwagKH , BerteleV , CampomoriA , ChakravarthyU , et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age‐related macular degeneration. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD011230.pub2] ">Moja 2014</a> for the most complete information on systemic safety for bevacizumab versus ranibizumab. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: bevacizumab versus ranibizumab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005139-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of study acronyms</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Acronym</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Details</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b><i>Included studies</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ABC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The Avastin<sup>®</sup> (Bevacizumab) in Choroidal Neovascularization Trial </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ANCHOR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐related Macular Degeneration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BRAMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison of Bevacizumab (Avastin<sup>®</sup>) and Ranibizumab (Lucentis<sup>®</sup>) in Exudative Age‐related Macular Degeneration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CATT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison of Age‐related Macular Degeneration Treatment Trials</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GEFAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>French Evaluation Group Avastin<sup>®</sup> Versus Lucentis<sup>®</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IVAN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A Randomized Controlled Trial of Alternative Treatments to Inhibit VEGF in Age‐related Choroidal Neovascularisation </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LUCAS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lucentis<sup>®</sup> Compared to Avastin<sup>®</sup> Study </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MANTA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A Randomized Observer and Subject Masked Trial Comparing the Visual Outcome After Treatment With Ranibizumab or Bevacizumab in Patients With Neovascular Age‐related Macular Degeneration Multicenter Anti‐VEGF Trial in Austria </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MARINA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minimally Classic/Occult Trial of the Anti‐VEGF Antibody Ranibizumab in the Treatment of Neovascular Age‐Related Macular Degeneration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PIER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A Phase IIIb, Multicenter, Randomized, Double‐Masked, Sham Injection‐Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects With Subfoveal Choroidal Neovascularization With or Without Classic CNV Secondary to Age‐related Macular Degeneration </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SAVE‐AMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of VEGF Inhibitors in Age‐Related Macular Degeneration</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VISION</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VEGF Inhibition Study in Ocular Neovascularization</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b><i>Ongoing study</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>VIBERA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevention of Vision Loss in Patients With Age‐Related Macular Degeneration by Intravitreal Injection of Bevacizumab and Ranibizumab </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of study acronyms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005139-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Treatment groups in included trials</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> <p><b>Treatment period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention 1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention 2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention 3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intervention 4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Pegaptanib vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> </p> <p>2 years; re‐randomized at end of first year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3 mg pegaptanib every 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0 mg pegaptanib every 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0 mg pegaptanib every 6 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham every 6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Ranibizumab vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> </p> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3 mg ranibizumab monthly plus sham verteporfin PDT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly plus sham verteporfin PDT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham intravitreal injection plus verteporfin PDT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a> </p> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3 mg ranibizumab monthly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham intravitreal injection monthly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a> </p> <p>2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.3 mg ranibizumab monthly for 3 months, then every 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 3 months, then every 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sham intravitreal injection monthly for 3 months, then every 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Bevacizumab vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0001" title="KeanePA , HeussenFM , OuyangY , MokwaN , WalshAC , TufailA , et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2012;53(3):1152‐61. PatelPJ , ChenFK , CruzL , RubinGS , TufailA . Contrast sensitivity outcomes in the ABC Trial: a randomized trial of bevacizumab for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2011;52(6):3089‐93. PatelPJ , HendersonL , SivaprasadS , BunceC , WormaldR , TufailA . The ABC trial ‐ a randomized double‐masked phase III study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularization secondary to age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4536. PatelPJ , RubinGS , ChenFK , Da‐CruzL , TufailA . Impact of anti‐vascular endothelial growth factor therapy on reading performance in age‐related macular degeneration: a randomized controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):4794. PatelPJ , TufailA , BunceC , daCruzL , DowlerJ , EganC , et al. A randomised, double‐masked phase III/IV study of the efficacy and safety of Avastin® (Bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age‐related macular degeneration: clinical trial design. Trials2008;9:56. TufailA , PatelPJ , EganC , HykinP , daCruzL , GregorZ , et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ2010;340:c2459. ">ABC 2010</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab given first 3 injections every 6 weeks, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard therapy (0.3 mg pegaptanib every 6 weeks, verteporfin PDT, or sham injection)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0012" title="MichelsSM , WeigertG , GeitzenauerW , SacuS , AlinaV , Schmidt‐ErfurthU . Intravitreal bevacizumab (Avastin®) therapy versus verteporfin therapy and intravitreal triamcinolone for neovascular age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1820. PragerF , MichelsS , SacuS , WeigertG , DunavölgyiR , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) monotherapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 12 months results of a prospective, randomized, controlled clinical trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 1168. SacuS , MichelsS , PragerF , WeigertG , DunavoelgyiR , GeitzenauerW , et al. Randomised clinical trial of intravitreal Avastin® vs photodynamic therapy and intravitreal triamcinolone: long‐term results. Eye2009;23(12):2223‐7. WeigertG , MichelsS , SacuS , VargaA , PragerF , GeitzenauerW , et al. Intravitreal bevacizumab (Avastin®) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age‐related macular degeneration: 6‐month results of a prospective, randomised, controlled clinical study. British Journal of Ophthalmology2008;92(3):356‐60. ">Sacu 2009</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0 mg bevacizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Verteporfin PDT plus same day 4 mg triamcinolone acetonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> </p> <p>2 years; re‐randomized at end of first year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 1 year; at 1 year, re‐randomization to ranibizumab monthly or variable dosing </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 1 year; at 1 year, re‐randomization to ranibizumab monthly or variable dosing </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab as needed after first injection for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab as needed after first injection for 2 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> </p> <p>2 years; ongoing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 3 months, then as needed in 3‐month cycles</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 3 months, then as needed in 3‐month cycles</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0003" title="BiswasP , SenguptaS , ChoudharyR , HomeS , PaulA , SinhaS . Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age‐related macular degeneration. Indian Journal of Ophthalmology2011;59(3):191‐6. ">Biswas 2011</a><br/> 18 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a><br/> 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab; maximum of 1 injection per month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab; maximum of 1 injection per month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab; treat and extend protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab; treat and extend protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a><br/> 1 year </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0013" title="EnseleitF , MichelsS , SudanoI , StahelM , ZweifelS , SchlagerO , et al. SAVE‐AMD: safety of VEGF inhibitors in age‐related macular degeneration. Ophthalmologica2017;238:205‐16. ">SAVE‐AMD 2017</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab at day 1 and at week 4, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab at day 1 and at week 4, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0014" title="SchollerA , Richter‐MuekschS , WeingesselB , Vecsei‐MarlovitsP‐V . Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD. Wiener Klinische Wochenschrift (Central European Journal of Medicine)2014;126:355‐9. ">Scholler 2014</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 mg bevacizumab for 3 months, at 30‐day intervals, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 mg ranibizumab for 3 months, at 30‐day intervals, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0015" title="DonahueSP , RecchiaF , SternbergPJr . Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2010;150(2):287. MessoriA , FaddaV , TrippoliS . Randomized study of bevacizumab vs ranibizumab for age‐related macular degeneration: inappropriate conclusions. American Journal of Ophthalmology2010;149(5):867. SubramanianML , AbediG , NessS , AhmedE , FenbergM , DalyMK , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: 1‐year outcomes of a prospective, double‐masked randomised clinical trial. Eye2010;24(11):1708‐15. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Bevacizumab vs ranibizumab for age‐related macular degeneration: early results of a prospective double‐masked, randomized clinical trial. American Journal of Ophthalmology2009;148(6):875‐82. SubramanianML , NessS , AbediG , AhmedE , DalyM , FeinbergE , et al. Reply. American Journal of Ophthalmology2010;149(5):867. ">Subramanian 2010</a> </p> <p>1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 mL bevacizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05 mL ranibizumab monthly for 3 months, then as needed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>PDT: photodynamic therapy.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Treatment groups in included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005139-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events up to 1 year: pegaptanib versus control</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg pegaptanib<br/> n = 295</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.0 mg pegaptanib<br/> n = 301</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.0 mg pegaptanib<br/> n = 296</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses pegaptanib<br/> n = 892</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 298</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any eye disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.84 [0.91 to 16.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.37 [0.50 to 140.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.68 [0.20 to 66.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.68 [0.20 to 66.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.67 [0.08 to 34.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitreous hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.04 to 24.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.04 to 24.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated intraocular pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.04 to 24.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Papilledema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11 [0.00 to 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg pegaptanib<br/> n = 295</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1.0 mg pegaptanib<br/> n = 301</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3.0 mg pegaptanib<br/> n = 296</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses pegaptanib<br/> n = 892</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 298</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 1 serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64 (22%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>169 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 [0.93 to 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.60 [0.31 to 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoplasms (benign, malignant, unspecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.72 [0.37 to 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Injury and procedural complications, such as fractures (also includes traumatic cataracts)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.01 [0.92 to 9.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.19 [0.52 to 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infections and infestations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34 [0.51 to 3.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.17 [0.39 to 3.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory, thoracic, mediastinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 [0.33 to 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Musculoskeletal and connective tissue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50 [0.33 to 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Renal and urinary disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 [0.20 to 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vascular disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.78 [0.20 to 3.00]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval.</p> <p>RR: risk ratio.</p> <p><sup>a</sup>Most frequent serious adverse events experienced by 1190 participants in the <a href="./references#CD005139-bbs2-0016" title="ChakravarthyU . Efficacy and safety of pegaptanib in age‐related macular degeneration: three‐year results of the V.I.S.I.O.N. trials. The Macula Society. 2006:116. D'AmicoDF . Macugen® in neovascular age‐related macular degeneration: exploratory subgroup analyses. American Academy of Ophthalmology. 2005:261. D'AmicoDJ . VEGF Inhibition Study in Ocular Neovascularization (VISION): second year efficacy data. Investigative Ophthalmology and Visual Science2005;46:ARVO E‐abstract 2309. D'AmicoDJ , BirdAC . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): safety evaluation from the pivotal Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐Abstract 2363. EyetechPharmaceuticals , Inc , Pfizer . Inc . Pegaptanib sodium injection in the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). FDA . Macugen® (pegaptanib sodium injection) for the treatment of neovascular age‐related macular degeneration. www.fda.gov/ohrms/dockets/ac/04/briefing/2004‐4053b1.htm (accessed 20 December 2011). GragoudasES . VEGF Inhibition Study in Ocular Neovascularization‐1 (VISION‐1): efficacy results from phase II/III Macugen® (pegaptanib sodium) clinical trials. Investigative Ophthalmology and Visual Science2004;45:ARVO E‐abstract 2364. GragoudasES , AdamisAP , CunninghamETJr , FeinsodM , GuyerDR . Pegaptanib for neovascular age‐related macular degeneration. New England Journal of Medicine2004;351(27):2805‐16. JacksonTL , DanisRP , GoldbaumM , SlakterJS , ShustermanEM , OeshaughnessyDJ , et al. Retinal vascular abnormalities in neovascular age‐related macular degeneration. Retina2014;34(3):568‐75. KuppermannBD . The V.I.S.I.O.N. Study: results with two years of Macugen® and outcomes of earlier treatment in early disease. American Academy of Ophthalmology. 2005:178. LarsenM , SanderB , VillumsenJE , HaamannPH , laCourM , Lund‐AndersenH , et al. Treatment of neovascular age‐related macular degeneration with intravitreal vascular endothelial growth factor inhibitor ‐ secondary publication. Ugeskrift for Laeger2005;167(35):3301‐5. LeysA , ZlatevaG , ShahSN , PatelM . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Eye2008;22(6):792‐8. Macugen AMD Study Group, ApteRS , ModiM , MasonsonH , PatelM , WhitfieldL , et al. Pegaptanib 1‐year systemic safety results from a safety‐pharmacokinetic trial in patients with neovascular age‐related macular degeneration. Ophthalmology2007;114(9):1702‐12. MarcusDM . Four‐year safety of pegaptanib sodium in neovascular age‐related macular degeneration (AMD): results of the V.I.S.I.O.N. trial. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐ Abstract 5069. MielerW . Safety evaluation of second year treatment of age‐related macular degeneration with pegaptanib sodium (Macugen®): VEGF Inhibition Study in Ocular Neovascularization (VISION). Investigative Ophthalmology and Visual Science2005;46:ARVO E‐Abstract 1380. MillsE , Heels‐AnsdellD , KellyS , GuyattG . A randomized trial of pegaptanib sodium for age‐related macular degeneration used an innovative design to explore disease‐modifying effects. Journal of Clinical Epidemiology2007;60(5):456‐60. PatelM , MonesJ , LeysA , ZlatevaG , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the V.I.S.I.O.N. trial. European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RakicJM , BlaiseP , FoidartJM , GragoudasES , AdamisAP , FeinsodM . Pegaptanib and age‐related macular degeneration. New England Journal of Medicine2005;352(16):1720‐1. SingermanLI . Two‐year systemic safety of pegaptanib in patients with neovascular age‐related macular degeneration: results of the V.I.S.I.O.N. trials. The Macula Society. 2006:120. SingermanLJ , MasonsonH , PatelM , AdamisAP , BuggageR , CunninghamE , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: third‐year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. British Journal of Ophthalmology2008;92(12):1606‐11. SjolieAK , MortensenKK , HansenMH . Antiangiogenesis therapy of age‐related macular degeneration. Ugeskrift for Laeger2005;167(35):3267. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, ChakravarthyU , AdamisAP , CunninghamETJr , GoldbaumM , GuyerDR , et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age‐related macular degeneration. Ophthalmology2006; Vol. 113, issue 9:1508. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'AmicoDJ , MasonsonHN , PatelM , AdamisAP , CunninghamET , et al. Pegaptanib sodium for neovascular age‐related macular degeneration: two‐year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006;113(6):1001. ZlatevaG , PatelM , ShahSN . Quality of life in patients with age‐related macular degeneration: results from the VISION study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐Abstract 2152. ">VISION 2004</a> study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse events up to 1 year: pegaptanib versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005139-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events up to 1 year: ranibizumab versus control</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg ranibizumab<br/> n = 196</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.5 mg ranibizumab<br/> n = 201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses ranibizumab<br/> n = 397</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 206</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.60 [0.13 to 53.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 [0.03 to 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.48 [0.83 to 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52 [0.07 to 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitreous hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 [0.06 to 38.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.56 [0.06 to 38.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated intraocular pressure (≥ 30 mmHg increase)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22 [0.99 to 4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ocular inflammation (trace to 4+)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.71 [1.36 to 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg ranibizumab<br/> n = 196</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.5 mg ranibizumab<br/> n = 201</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses ranibizumab<br/> n = 397</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 206</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 [0.25 to 6.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.08 [0.23 to 18.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke or cerebral infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 [0.09 to 11.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ischemic cardiomyopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 [0.01 to 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment‐emergent hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.67 [0.36 to 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐ocular hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.90 [0.78 to 4.62]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval.</p> <p>RR: risk ratio.</p> <p><sup>a</sup>Adverse events experienced by 420 participants in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> and by 183 participants in <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>. Adverse events at 1‐year follow‐up not reported in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Adverse events up to 1 year: ranibizumab versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005139-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events up to 2 years: ranibizumab versus control</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg ranibizumab<br/> n = 434</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.5 mg ranibizumab<br/> n = 440</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses ranibizumab<br/> n = 874</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 441</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.59 [0.50 to 148.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 [0.07 to 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>141 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 [0.94 to 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.50 [0.03 to 8.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitreous hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.01 [0.19 to 5.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (&lt;1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.58 [0.43 to 132.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated intraocular pressure (≥ 30 mmHg increase)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106 (18%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.81 [2.63 to 8.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ocular inflammation (1+ to 4+)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.91 [1.89 to 8.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐ocular adverse event<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.3 mg ranibizumab<br/> n = 434</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0.5 mg ranibizumab<br/> n = 440</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>All doses ranibizumab<br/> n = 874</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control<br/> n = 441</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> All doses vs control</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 [0.41 to 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.08 [0.44 to 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke or cerebral infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21 [0.43 to 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ischemic cardiomyopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17 [0.01 to 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment‐emergent hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 (14%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 [0.73 to 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐ocular hemorrhage</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.64 [1.05 to 2.55]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI: confidence interval.</p> <p>RR: risk ratio.</p> <p><sup>a</sup>Adverse events experienced by 420 participants in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a>; 713 participants in <a href="./references#CD005139-bbs2-0010" title="BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BoyerDS , AntoszykAN , AwhCC , BhisitkulRB , ShapiroH , AcharyaNR , MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(2):246‐52. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. ChangTS , BresslerNM , FineJT , DolanCM , WardJ . Self‐reported perception of driving function following ranibizumab treatment in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1830. ChangTS , BresslerNM , FineJT , DolanCM , WardJ , KlesertTR , et al. Improved vision‐related function after ranibizumab treatment of neovascular age‐related macular degeneration: results of a randomized clinical trial. Archives of Ophthalmology2007;125(11):1460‐9. ChangTS , FineJT , AlexanderS , BresslerN . Ranibizumab (Lucentis®) self‐reported vision specific quality of life through 12 months in age‐related macular degeneration patients with minimally classic or occult‐with‐no‐classic choroidal neovascularization in a phase III randomized clinical trial. The Macula Society. 2006:106. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. ChangTS , FineJT , DolanCM , MarceauC , BresslerNM . Ranibizumab (Lucentis®) vision‐specific quality of life through 24 months in neovascular AMD subjects in MARINA: a phase III clinical trial. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ShapiroH , SinghAA . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year efficacy results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2959. HoA , ShapiroH , AcharyaN . Ranibizumab for neovascular age‐related macular degeneration: one‐year subanalysis of the MARINA study. The Macula Society. 2006:108. HolekampNM , AcharyaN , ShapiroH . Two‐year FA/OCT results of MARINA study of ranibizumab (Lucentis®) in neovascular AMD. American Academy of Ophthalmology. 2006:194. HurleySF , MatthewsJP , GuymerRH . Cost‐effectiveness of ranibizumab for neovascular age‐related macular degeneration. Cost Effectiveness and Resource Allocation2008;6:12. KaiserPK , BlodiBA , ShapiroH , AcharyaNR , MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age‐related macular degeneration. Ophthalmology2007;114(10):1868‐75. KokameGT . Anatomic outcomes from the MARINA study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration. The Macula Society. 2006:110. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). MillerJW , ShapiroH , AcharyaN . Randomized, controlled phase III study of ranibizumab (Lucentis®) for minimally classic or occult neovascular age‐related macular degeneration: two‐year safety results of the MARINA study. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 3539. ReichelE , ShapiroH , AcharyaN . Subgroup analyses of two‐year results of MARINA study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:194. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , BrownDM , HeierJS , BoyerDS , KaiserPK , ChungCY , et al. Ranibizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1419‐31. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. Schmidt‐ErfurthU , WilliamsGA , MARINA Study Group. Two‐year efficacy and safety results from the MARINA study. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). SunerIJ , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: 24 month results from MARINA. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 1808. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , Glaeser AlexanderS , ElledgeKA , HinerC , HurtenbachCH , et al. Ranibizumab (Lucentis®) in subjects with minimally classic or occult CNV (MARINA): reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2206. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YuEB , BresslerNM , FineJT , WardJF , DolanCM , KlesertT , et al. Relationship between patient‐reported visual function and visual acuity in subjects with neovascular AMD. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1174. ">MARINA 2006</a>; and 182 participants in <a href="./references#CD005139-bbs2-0011" title="AbrahamP , YueH , ShamsN . PIER: year 1 results of a phase IIIb study of ranibizumab efficacy and safety in choroidal neovascularization due to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). AbrahamP , YueH , WilsonL . Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 2. American Journal of Ophthalmology2010;150(3):315‐24. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BenzMS , BrownDM , ShapiroH , TuomiL . Ranibizumab for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 347. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BrownDM , ChungCY , TuomiL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): optical coherence tomography (OCT) vs. visual acuity (VA) changes in PIER study. The Macula Society. 2008:78. BrownDM , TuomiL , ShapiroH , PIER Study Group. Anatomical measures as predictors of visual outcomes in ranibizumab‐treated eyes with neovascular age‐related macular degeneration. Retina2013;33(1):23‐34. BrownDM , YueH , ShamsN . Ranibizumab (Lucentis®) in neovascular age‐related macular degeneration (AMD): subgroup analysis of year 1 PIER efficacy data. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4540. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HoAC , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): two‐year angiographic results of PIER study. The Macula Society. 2008:164. HoAC , YueH , WilsonL . Ranibizumab in wet age‐related macular degeneration (AMD): crossover/rollover patient results in PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 368. KaiserPK , YueH , ShamsN . Subgroup analyses of one‐year results of the PIER study of ranibizumab in neovascular AMD. American Academy of Ophthalmology. 2006:195. LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 5571. MichelsM , ShapiroH , WilsonL . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 2‐year angiographic results of PIER study. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2882. MielerWF . PIER: Year 1 FA/OCT results in a study of ranibizumab (Lucentis™) for CNV due to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). RegilloCD , BresslerNM , FineJT , DolanCM , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in subjects with or without classic CNV due to AMD: phase III clinical trial of ranibizumab (Lucentis™). European VitreoRetinal Society 2006. Poster Session. www.evrs.eu/2006‐evrs‐congress‐cannes/poster‐session‐amdanti‐angiogenesis (accessed 13 March 2013). RegilloCD , BrownDM , AbrahamP , YueH , IanchulevT , SchneiderS , et al. Randomized, double‐masked, sham‐controlled trial of ranibizumab for neovascular age‐related macular degeneration: PIER study year 1. American Journal of Ophthalmology2008;145(2):239‐48. RegilloCD , ChungCY , WilsonL , PIER Study Group. Ranibizumab in neovascular age‐related macular degeneration (AMD): crossover/rollover treatment effects in PIER study. The Macula Society. 2008:166. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐Abstract 2883. ">PIER 2008</a>.<br/> <sup>b</sup>Adverse events for elevated intraocular pressure not reported in <a href="./references#CD005139-bbs2-0002" title="AlexanderSG , BlodiBA , WebsterMKW , ElledgeJA , HinerCJ , ArmstrongJ , et al. Ranibizumab (Lucentis®) in subjects with predominantly classic CNV: reading center evaluation of angiographic eligibility characteristics and baseline fluorescein angiographic data. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2207. BarbazettoI , SarojN , ShapiroH , WongP , FreundKB . Dosing regimen and the frequency of macular hemorrhages in neovascular age‐related macular degeneration treated with ranibizumab. Retina2010;30(9):1376‐85. BarbazettoIA , SarojN , ShapiroH , WongP , HoAC , FreundKB . Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. American Journal of Ophthalmology2010;149(6):939‐46. BresslerNM , BoyerDS , WilliamsDF , ButlerS , FrancomSF , BrownB , et al. Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials. Retina2012;32(9):1821‐8. BresslerNM , ChangTS , FineJT , DolanCM , WardJ , Anti‐VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age‐Related Macular Degeneration (ANCHOR) Research Group. Improved vision‐related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Archives of Ophthalmology2009;127(1):13‐21. BresslerNM , ChangTS , SuñerIJ , FineJT , DolanCM , WardJ , et al. Vision‐related function after ranibizumab treatment by better‐ or worse‐seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology2010;117(4):747‐56. BresslerNM , ChangTS , VarmaR , SunerI , LeeP , DolanCM , et al. Driving ability reported by neovascular age‐related macular degeneration patients after treatment with ranibizumab. Ophthalmology2013;120(1):160‐8. BresslerNM , DolanCM , FineJ , MarceauC , ChangTS . Vision‐specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT. European VitreoRetinal Society 2006. Symposium II: Anti‐Angiogenesis (Part 2). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). BrownDM , KaiserPK , MichelsM , SoubraneG , HeierJS , KimR , et al. Ranibizumab versus verteporfin for neovascular age‐related macular degeneration. New England Journal of Medicine2006;355(14):1432‐44. BrownDM , MichelsM , KaiserPK , HeierJS , SyJP , IanchulevT , et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age‐related macular degeneration: two‐year results of the ANCHOR study. Ophthalmology2009;116(1):57‐65. BrownDM , ShapiroH , SchneiderS . Subgroup analysis of first‐year results of ANCHOR: a phase III, double‐masked, randomized comparison of ranibizumab and verteporfin photodynamic therapy for predominantly classic choroidal neovascularization related to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 2963. ChangTS , FineJT , BresslerN . Self‐reported vision‐specific quality of life at 1 year in patients with neovascular age‐related macular degeneration in 2 phase III randomized clinical trials of ranibizumab (Lucentis®). Investigative Ophthalmology and Visual Science2006;47:ARVO E‐abstract 5252. CiullaTA , ShapiroH , SchneiderS . Ranibizumab (Lucentis®) for neovascular age‐related macular degeneration (AMD): 1‐year visual acuity (VA) results for fellow eyes with neovascular AMD in MARINA and ANCHOR. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4573. CunninghamET , FeinerL , ChungC , TuomiL , EhrlichJS . Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age‐related macular degeneration. Ophthalmology2011;118(12):2447‐52. HeierJS , ChungC , SchneiderS . Time course of visual acuity changes with ranibizumab (Lucentis®) in the 2‐year ANCHOR study of patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 2872. KaiserPK , BrownDM , ZhangK , HudsonHL , HolzFG , ShapiroH , et al. Ranibizumab for predominantly classic neovascular age‐related macular degeneration: subgroup analysis of first‐year ANCHOR results. American Journal of Ophthalmology2007;144(6):850‐7. KorobelnikJF . Consistency of effect of ranibizumab at 2 doses on contrast sensitivity in 3 phase III and IIIB studies of patients with CNV secondary to AMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LanzettaP . Ranibizumab and patient‐reported outcomes: VFQ‐25 data from the ANCHOR and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5571. LanzettaP , MARINA and ANCHOR Study Groups. Combined safety of intravitreal ranibizumab in two phase III studies of CNV secondary to ARMD. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). LoewensteinA , MARINA and ANCHOR Study Groups. Combined efficacy of intravitreal ranibizumab in two phase III studies of choroidal neovascularization secondary to age‐related macular degeneration. European VitreoRetinal Society 2006. Symposium I: Anti‐Angiogenesis (Part 1). www.evrs.eu/2006‐evrs‐congress‐cannes (accessed 13 March 2013). McDonaldHR , SchneiderS , SyJP . One‐year results of ANCHOR: a phase III, multicenter, randomized, double‐masked comparison of ranibizumab and verteporfin photodynamic therapy in treatment of predominantly classic choroidal neovascularization secondary to age‐related macular degeneration. The Macula Society. 2006:114. RofaghaS , BhisitkulRB , BoyerDS , SaddaSR , ZhangK . Seven‐year outcomes in ranibizumab‐treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN‐UP). Ophthalmology2013;120(11):2292‐9. RosenfeldPJ , ShapiroH , ShamsN , SchneiderS , DepperschmidtEE , MARINA and ANCHOR Study Groups. Baseline and treatment characteristics of patients losing vision at year 1 of the MARINA and ANCHOR trials. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4576. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology2011;118(3):523‐30. RosenfeldPJ , ShapiroH , TuomiL , WebsterM , ElledgeJ , BlodiB . Lesion characteristics in ranibizumab (Lucentis®) treated patients with a visual acuity (VA) gain or loss in the MARINA and ANCHOR trials for wet age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 329. SaddaSR , ShapiroH , SchneiderS . Anatomic outcomes at 2 years in the ANCHOR study comparing ranibizumab (Lucentis®) and verteporfin photodynamic therapy (PDT) in predominantly classic neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 4561. SaddaSR , StollerG , BoyerDS , BlodiBA , ShapiroH , IanchulevT . Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age‐related macular degeneration in the 2‐year anchor study. Retina2010;30(9):1390‐9. SchwartzSG , BresslerN , FineJT , DolanCM , YuEM , WardJF , et al. Patient‐reported visual function over 24 months in predominantly classic neovascular AMD: results from ANCHOR, a phase III trial of ranibizumab and verteporfin PDT. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐abstract 1822. SutterFK , Kurz‐LevinMM . Towards an optimized treatment scheme of ranibizumab in patients with subfoveal choroidal neovascularization secondary to age‐related macular degeneration: subanalysis of clinical trial data and clinical routine use. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2884. WebsterMK , BlodiBA , ElledgeJA , DanisRP . Angiographic results of the ANCHOR study of ranibizumab in neovascular age‐related macular degeneration: reading center evaluation of angiographic data. Investigative Ophthalmology and Visual Science2007; Vol. 48:ARVO E‐Abstract 4583. WeinbergDV , ShapiroH , EhrlichJS . Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Ophthalmology2013;120(6):1278‐82. WinPH , BresslerNM , ChangTS , FineJT , DolanCM , WardJ . Self‐reported perception of driving function after ranibizumab therapy in patients with neovascular age‐related macular degeneration (AMD). Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 5578. WolfS . Visual acuity gain with ranibizumab therapy: two‐year data from the MARINA, ANCHOR, and PIER trials in patients with neovascular AMD. Investigative Ophthalmology and Visual Science2008;49:ARVO E‐abstract 2883. WolfS , HolzFG , KorobelnikJF , LanzettaP , MitchellP , PrünteC , et al. Outcomes following three‐line vision loss during treatment of neovascular age‐related macular degeneration: subgroup analyses from MARINA and ANCHOR. British Journal of Ophthalmology2011;95(12):1713‐8. YangYC . Two year contrast sensitivity results from the ANCHOR study comparing intravitreal ranibizumab 0.3mg and 0.5mg with verteporfin PDT for predominantly classic CNV lesions secondary to age‐related macular degeneration. Investigative Ophthalmology and Visual Science2007;48:ARVO E‐Abstract 4545. ">ANCHOR 2006</a> at 2‐year follow‐up (n = 297 in 0.3 mg ranibizumab group, n = 300 in 0.5 mg ranibizumab group, and n = 298 in 0.3 mg control group). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Adverse events up to 2 years: ranibizumab versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005139-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events up to 1 year: bevacizumab versus ranibizumab</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Serious ocular adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Studies reporting adverse events<sup>1</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Bevacizumab</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number with event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number with event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1059</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.68 [0.40 to 7.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>832</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.05 [0.36 to 136.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal pigment epithelial tear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 [0.31 to 6.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 [0.05 to 5.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.14 [0.46 to 36.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Non‐ocular adverse event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Studies reporting adverse events<sup>2</sup> </b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Bevacizumab</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Ranibizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number with event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number with event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total participants</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 1 serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>298 (18%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>265 (16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.15 [0.99 to 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 [0.66 to 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51 [0.22 to 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke or cerebral infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1502</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.65 [0.25 to 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient ischemic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.53 [0.43 to 5.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Venous thrombotic event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.04 [0.61 to 6.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 [0.57 to 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.76 [0.99 to 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.42 [0.93 to 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Injury and procedural complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.27 [0.78 to 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoplasms (benign, malignant, unspecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99 [0.61 to 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a>; <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 [0.68 to 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgical or medical procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD005139-bbs2-0004" title="SchauwvliegheAME , DijkmanG , HooymansJM , VerbraakFD , HoyngCB , DijkgraafMGW , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. The BRAMD study. PLOS ONE2016;11(5):e0153052. SchauwvliegheASME , DijkmanG , HooymansJMM , VerbraakFD , DijkgraafMG , PetoT , et al. Comparing the effectiveness of bevacizumab to ranibizumab in patients with exudative age‐related macular degeneration. Investigative Ophthalmology and Visual Science2014;55(13):870. ">BRAMD 2016</a><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a>; <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a>; <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41 [0.88 to 2.27]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI: confidence interval.<br/> RR: risk ratio. </p> <p><sup>a</sup>Includes endophthalmitis and pseudo‐endophthalmitis. </p> <p><sup>1</sup><a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> (n = 586 in bevacizumab group; n = 599 in ranibizumab group); <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> (n = 246 in bevacizumab group; n = 239 in ranibizumab group); <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> (n = 296 in bevacizumab group; n = 314 in ranibizumab group); <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> (n = 220 in bevacizumab group; n = 221 in ranibizumab group).<br/> <sup>2</sup>BRAMD 2016 (n = 161 in bevacizumab group; n = 166 in ranibizumab group); <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> (n = 586 in bevacizumab group; n = 599 in ranibizumab group); <a href="./references#CD005139-bbs2-0006" title="KodjikianL , SouiedEH , MimounG , Mauget‐FaysseM , Behar‐CohenF , DecullierE , et al. Ranibizumab versus bevacizumab for neovascular age‐related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology2013;120(11):2300‐9. ">GEFAL 2013</a> (n = 246 in bevacizumab group; n = 239 in ranibizumab group); <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> (n = 296 in bevacizumab group; n = 314 in ranibizumab group); <a href="./references#CD005139-bbs2-0008" title="BergK , HadzalicE , GjertsenI , ForsaaV , BergerLH , KingeB , et al. Ranibizumab or bevacizumab for neovascular age‐related macular degeneration according to the Lucentis Compared to Avastin Study treat‐and‐extend protocol: two‐year results. Ophthalmology2016;123(1):51‐9. BergK , PedersenTR , SandvikL , BragadottirR . Comparison of ranibizumab and bevacizumab for neovascular age‐related macular degeneration according to LUCAS treat‐and extend protocol. Ophthalmology2015;122(1):146‐52. ">LUCAS 2015</a> (n = 220 in bevacizumab group; n = 221 in ranibizumab group); <a href="./references#CD005139-bbs2-0009" title="KrebsI , SchmettererL , BoltzA , ToldR , Vécsei‐MarlovitsV , EggerS , et al. A randomised double‐masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age‐related macular degeneration. British Journal of Ophthalmology2013;97(3):266‐71. ">MANTA 2013</a> (n = 154 in bevacizumab group; n = 163 in ranibizumab group). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Adverse events up to 1 year: bevacizumab versus ranibizumab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD005139-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events up to 2 years: bevacizumab versus ranibizumab</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event (CATT trial)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab<br/> n = 586</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab<br/> n = 599</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Endophthalmitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.79 [0.53 to 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ocular adverse event (IVAN trial)<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab<br/> n = 296</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab<br/> n = 314</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Traumatic cataract</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 [0.07 to 16.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe uveitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.18 [0.13 to 77.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal detachment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 [0.01 to 8.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retinal pigment epithelial tear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35 [0.04 to 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐ocular adverse event<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bevacizumab<br/> n = 882</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Ranibizumab<br/> n = 913</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR [95% CI]<br/> Bevacizumab vs ranibizumab</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least 1 serious adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>314 (36%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>271 (30%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20 [1.05 to 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.12 [0.76 to 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 [0.39 to 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stroke or cerebral infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 [0.37 to 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Venous thrombotic event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42 [0.93 to 6.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Transient ischemic attack</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 (&lt; 1%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.04 [0.06 to 16.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25 [0.92 to 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.74 [1.49 to 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66 (7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.37 [0.96 to 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Injury and procedural complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33 [0.86 to 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neoplasms (benign, malignant, unspecified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.98 [0.63 to 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervous system disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06 [0.70 to 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Surgical or medical procedure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 [0.44 to 1.84]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval.</p> <p>RR: risk ratio.</p> <p><sup>a</sup>Adverse events for endophthalmitis not reported in <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>; data for <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> only.<br/> <sup>b</sup>Adverse events for traumatic cataract, uveitis, retinal detachment, retinal pigment epithelial tear, transient ischemic attack, and surgical or medical procedure not reported in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a>; data for <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a> study only.<br/> <sup>c</sup>Adverse events experienced by 1185 participants in <a href="./references#CD005139-bbs2-0005" title="Comparison of Age‐Related Macular Degeneration Treatment Trials. www.med.upenn.edu/cpob/studies/documents/CATTEligibilityCriteria.pdf (accessed 20 December 2011). AltaweelMM , DanielE , MartinDF , MittraRA , GrunwaldJE , LaiMM , et al. Outcomes of eyes with lesions composed of &gt;50% blood in the comparison of age‐related macular degeneration treatments trials (CATT). Ophthalmology2015;122(2):391‐8. CATT Research Group, MaguireMG , MartinDF , YingGS , JaffeGJ , DanielE , GrunwaldJE . Five‐year outcomes with anti‐vascular endothelial growth factor treatment of neovascular age‐related macular degeneration: the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(8):1751‐61. CATT Research Group, MartinDF , MaguireMG , YingGS , GrunwaldJE , FineSL , JaffeGJ . Ranibizumab and bevacizumab for neovascular age‐related macular degeneration. New England Journal of Medicine2011;364(20):1897‐908. CiullaTA , YingGS , MaguireMG , MartinDF , JaffeGJ , GrunwaldJE , et al. Influence of the vitreomacular interface on treatment outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(6):1203‐11. DanielE , ShafferJ , YingGS , GrunwaldJE , MartinDF , JaffeGJ , et al. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2016;123(3):609‐16. DanielE , TothCA , GrunwaldJE , JaffeGJ , MartinDF , FineSL , et al. Risk of scar in the Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2014; Vol. 121, issue 3:656‐66. GrunwaldJE , DanielE , HuangJ , YingGS , MaguireMG , TothCA , et al. Risk of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2014;121(1):150‐61. GrunwaldJE , DanielE , YingGS , PistilliM , MaguireMG , AlexanderJ , et al. Photographic assessment of baseline fundus morphologic features in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2012;119(8):1634‐41. GrunwaldJE , PistilliM , DanielE , YingGS , FineSL , MartinDF , MaguireMG . Size and growth of geographic atrophy in the Comparison of Age‐related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):1649. GrunwaldJE , PistilliM , DanielE , YingGS , PanW , JaffeGJ , et al. Incidence and growth of geographic atrophy during 5 years of Comparison of Age‐related Macular Degeneration Treatments Trials. Ophthalmology2017;124(1):97‐104. GrunwaldJE , PistilliM , YingGS , MaguireMG , DanielE , MartinDF , et al. Growth of geographic atrophy in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(4):809‐16. HagstromSA , YingGS , PauerGJ , Sturgill‐ShortGM , HuangJ , CallananDG , et al. Pharmacogenetics for genes associated with age‐related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2013; Vol. 120, issue 3:593‐9. HuangJ , YingGS , MaguireMG , StoneRA , MartinDF . Impact of change in retinal thickness on refractive error in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2014;55(13):657. JaffeGJ , MartinDF , TothCA , DanielE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(9):1860‐70. MaguireMG . Comparing treatments for age‐related macular degeneration: safety, effectiveness and cost. LDI Issue Brief2012; Vol. 17, issue 8:1‐4. MaguireMG , DanielE , ShahAR , GrunwaldJE , HagstromSA , AveryRL , et al. Incidence of choroidal neovascularization in the fellow eye in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2013;120(10):2035‐41. MartinDF , MaguireMG , FineSL , YingGS , JaffeGJ , GrunwaldJE , et al. Ranibizumab and bevacizumab for treatment of neovascular age‐related macular degeneration: two‐year results. Ophthalmology2012;119(7):1388‐98. MeredithTA , McCannelCA , BarrC , DoftBH , PeskinE , MaguireMG , et al. Postinjection endophthalmitis in the Comparison of Age‐Related Macular Degeneration Treatments Trials (CATT). Ophthalmology2015;122(4):817‐21. PistilliM , YingGS , JaffeGJ , TothCA , MartinDF . Resolution of retinal fluid on optical coherence tomography in the Comparison of AMD Treatments Trials (CATT). Investigative Ophthalmology and Visual Science2015;56(7):1657. ShahN , MaguireMG , MartinDF , ShafferJ , YingGS , GrunwaldJE , et al. Angiographic cystoid macular edema and outcomes in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):858‐64. SharmaS , TothCA , DanielE , GrunwaldJE , MaguireMG , YingGS , et al. Macular morphology and visual acuity in the second year of the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2016;123(4):865‐75. WilloughbyAS , YingGS , TothCA , MaguireMG , BurnsRE , GrunwaldJE , et al. Subretinal hyperreflective material in the Comparison of Age‐Related Macular Degeneration Treatments Trials. Ophthalmology2015;122(9):1846‐53. YingGS , HuangJ , MaguireMG , JaffeGJ , GrunwaldJE , TothC , et al. Baseline predictors for one‐year visual outcomes with ranibizumab or bevacizumab for neovascular age‐related macular degeneration. Ophthalmology2013;120(1):122‐9. YingGS , MaguireMG , DanielE , FerrisFL , JaffeGJ , GrunwaldJE , et al. Association of baseline characteristics and early vision response with 2‐year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology2015;122(12):2523‐31. ">CATT 2011</a> and by 610 participants in <a href="./references#CD005139-bbs2-0007" title="A randomised controlled trial of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation. www.ivan‐trial.co.uk/Default.aspx (accessed 4 April 2014). Erratum: Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial (Ophthalmology (2012) 119 (1399‐1411)). Ophthalmology2012;119(8):1508. ChakravarthyU , HardingSP , RogersCA , DownesS , LoteryAJ , DakinHA , et al. A randomised controlled trial to assess the clinical effectiveness and cost‐effectiveness of alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation (IVAN). Health Technology Assessment2015;19(78):1‐298. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , CullifordLA , on behalf of the IVAN study investigators. Alternative treatments to inhibit VEGF in age‐related choroidal neovascularisation: 2‐year findings of the IVAN randomised controlled trial. Lancet2013;382(9900):1258‐67. ChakravarthyU , HardingSP , RogersCA , DownesSM , LoteryAJ , WordsworthS , et al. Ranibizumab versus bevacizumab to treat neovascular age‐related macular degeneration: one‐year findings from the IVAN randomized trial. Ophthalmology2012;119(7):1399‐411. FossAJ , ScottLJ , RogersCA , ReevesBC , GhanchiF , GibsonJ , et al. Changes in intraocular pressure in study and fellow eyes in the IVAN trial. British Journal of Ophthalmology.2016;100(12):1662‐7. LoteryAJ , GibsonJ , CreeAJ , DownesSM , HardingSP , RogersCA , et al. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age‐related macular degeneration in the IVAN study. Ophthalmology2013;120(12):2637‐43. ">IVAN 2013</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Adverse events up to 2 years: bevacizumab versus ranibizumab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/full#CD005139-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005139-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF treatment versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Gain of 15 or more letters visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.19 [2.32, 7.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Pegaptanib vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.83 [1.23, 6.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Ranibizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.92 [1.59, 9.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Bevacizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.80 [2.44, 24.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Gain of 15 or more letters visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.77 [3.38, 9.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Loss of fewer than 15 letters visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.27, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Pegaptanib vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.11, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Ranibizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [1.41, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Bevacizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.09, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Loss of fewer than 15 letters visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.32, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Loss of fewer than 30 letters visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.06, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Pegaptanib vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.08, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Ranibizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.11, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Bevacizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Loss of fewer than 30 letters visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.15, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Visual acuity better than 20/200 at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.34, 1.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Pegaptanib vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [1.15, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Ranibizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.41, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Visual acuity better than 20/200 at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.52, 1.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Maintenance of visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.31, 3.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Pegaptanib vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.19, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Ranibizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.53 [1.95, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Bevacizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.2 [1.03, 4.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Maintenance of visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mean change in visual acuity at 1 year (number of letters) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Pegaptanib vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.72 [4.43, 9.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Ranibizumab vs control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.80 [15.95, 19.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mean change in visual acuity at 2 years (number of letters) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1322</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>20.11 [18.08, 22.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Reduction in size of CNV at 1 year (mean number of disc areas) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Reduction in size of lesion at 1 year (mean number of disc areas) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Reduction in size of lesion at 1 year (mean number of disc areas) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.34 [1.88, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Reduction in size of lesion at 2 years (mean number of disc areas) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Mean change in quality of life scores at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Overall vision‐related quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.69 [3.38, 9.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Near vision activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.45 [0.28, 16.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Distance vision activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.65 [3.20, 16.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Dependency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.82 [6.86, 12.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 Driving ability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.85 [6.34, 13.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [0.54, 5.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.7 Role difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.99 [0.76, 13.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.8 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.42 [5.75, 11.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.9 General vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.20 [5.90, 10.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.10 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.03 [5.36, 10.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.11 Color vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [‐0.02, 5.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.12 Peripheral vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.20 [0.37, 10.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.13 Ocular pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.78 [‐3.67, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Mean change in quality of life scores at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Overall vision‐related quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.63 [3.31, 13.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Near vision activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.52 [3.49, 19.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Distance vision activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.86 [3.82, 17.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 Dependency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.06 [3.29, 18.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 Driving ability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.53 [9.51, 17.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.6 General health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [‐0.18, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.7 Role difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.44 [1.34, 17.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.8 Mental health</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.07 [3.98, 16.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.9 General vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.61 [5.49, 13.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.10 Social functioning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.12 [1.77, 14.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.11 Color vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.70 [2.89, 8.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.12 Peripheral vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.79 [1.48, 12.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.13 Ocular pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐3.13, 0.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anti‐VEGF treatment versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005139-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bevacizumab versus ranibizumab</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Gain of 15 or more letters visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.81, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Gain of 15 or more letters visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Participants in groups as randomized at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.64, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Participants remaining in same groups after re‐randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.64, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Loss of fewer than 15 letters visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.98, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Loss of fewer than 15 letters visual acuity at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Participants in groups as randomized at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.94, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Participants remaining in same groups after re‐randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.94, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Visual acuity better than 20/200 at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.96, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Visual acuity better than 20/200 at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Participants in groups as randomized at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.95, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Participants remaining in same groups after re‐randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mean change in visual acuity at 1 year (number of letters) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐1.49, 0.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mean change in visual acuity at 2 years (number of letters) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.15 [‐2.82, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Reduction in central retinal thickness at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.61 [‐21.55, ‐1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Reduction in central retinal thickness at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.40 [‐33.83, 9.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 No problems in quality of life domain at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Mobility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Self‐care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Usual activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 Pain/discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.5 Anxiety/depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 No problems in quality of life domain at 2 years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Mobility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Self‐care</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Usual activities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Pain/discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.5 Anxiety/depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Loss of fewer than 30 letters visual acuity at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bevacizumab versus ranibizumab</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005139.pub4/references#CD005139-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005139.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD005139-note-0016">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD005139-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005139-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005139-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD005139-note-0001">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005139\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005139\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005139\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005139\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005139\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Ko3zGe0H&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005139.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005139.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005139.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005139.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005139.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726042621"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005139.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726042625"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005139.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e89f8e8929379',t:'MTc0MDcyNjA0My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 